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When presented with certain unfavorable environmental conditions, C. trachomatis reticulate 
bodies (RBs) enter into a viable, yet noncultivable state called persistence. Two hallmarks of 
persistent chlamydiae are swollen, aberrantly shaped RBs, as viewed by transmission electron 
microscopy and a decrease in infectious progeny. Several models of chlamydial persistence have 
been described, including interferon-γ (IFN-γ), IFN-α, IFN-β, and tumor necrosis factor-α-
exposure and nutrient deprivation. Previously, we established an in vitro co-infection model of 
two of the most common sexually transmitted pathogens in the United States, C. trachomatis and 
Herpes Simplex Virus-2 (HSV). Data from this tissue culture model indicate that: i) viral co-
infection stimulates the formation of persistent chlamydiae and ii) productive HSV replication is 
not required for persistence induction. Further studies indicate that, co-infection-induced 
persistence is not mediated by: i) any known anti-chlamydial cytokine; ii) activation of inducible 
nitric oxide synthase or indoleamine 2, 3-dioxygenase; iii) inhibition of vesicular trafficking or 
sphingomyelin transport to the inclusion or; iv) amino acid, iron or glucose deprivation. These 
data demonstrate that co-infection-induced persistence is mediated by a previously undescribed, 
novel mechanism. During long-term co-infection with UV-inactivated HSV-2, chlamydiae 
recover following an initial suppression of chlamydial infectivity. These data indicate that HSV-
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induced persistence, like other persistence models, is reversible. Co-incubation of fixed, HSV-2-
infected inducer cells with viable, C. trachomatis infected responder cells suppresses production 
of infectious chlamydial progeny and stimulates the formation of swollen, aberrantly shaped 
RBs. Antibody neutralization of HSV glycoprotein D (gD), which prevents viral attachment to 
one of four known HSV co-receptors on the host cell surface, also prevents co-infection-induced 
persistence, suggesting that HSV gD interaction with host cell surface receptors can provide the 
necessary stimulus to alter C. trachomatis development. Finally, exposure of C. trachomatis 
infected cells to soluble, recombinant HSV-2 gD:Fc fusion proteins decreases production of 
infectious EBs to a similar degree observed in co-infected cultures. Thus, we hypothesize that 
interaction of HSV gD with the host cell surface triggers a novel host anti-chlamydial pathway 
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Sexually transmitted diseases (STDs) continue to represent a health crisis of monumental 
proportions. The World Health Organization estimates that 340 million cases of curable STDs 
occur annually, worldwide, with 19 million infections occurring in the United States (US) alone 
(CDC, 2006; Weinstock et al., 2004). Even more alarming is the report that up to one half of all 
new STDs each year affect people between the ages of 15-24 (CDC, 2006; Weinstock et al., 
2004). Two of the most common STD agents in the US are Herpes Simplex Virus (HSV) and 
Chlamydia trachomatis. The Centers for Disease Control and Prevention reports that there are 
between 200,000-500,000 primary genital HSV infections each year, with an estimated 40-60 
million people currently suffering from recurrent HSV infections. C. trachomatis infections are 
the most commonly reported bacterial STD in the US, with 4 million new cases each year. These 
staggering statistics not only describe a major health concern in the US but also indicate a 
substantial economic burden. The direct medical costs of treating STDs in 2006 were 
approximately 14.7 billion dollars. Ten billion dollars were spent on treating chlamydial 
infections alone in 2002 (CDC, 2006; Weinstock et al., 2004). 
Co-infections with multiple STD agents further increase the difficulties of treating STDs. 
A recent study demonstrated that 20% of men and 42% of women with confirmed Neisseria 
gonorrhoeae infection tested positive for C. trachomatis. The prevalence of N. gonorrhoeae and 
C. trachomatis co-infection is substantial enough that treatment guidelines  recommend dual 
treatment of both pathogens when there is a diagnosis of gonorrhea (Lyss, 2003). Co-infection is 
a valid concern as the presence of multiple infectious agents has the ability to affect disease 
pathology and prevalence.  For example, an active HSV-2 infection increases the risk for Human 
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Immunodeficiency Virus (HIV) infection by three-fold (Freeman et al., 2007). C. trachomatis 
infection is also considered a co-factor for the transmission of HIV (Peipert, 2003). 
 
Herpes Simplex Virus 
Herpes Simplex Virus Types 1 and 2 (HSV-1 and HSV-2) belong to the 
Alphaherpesvirinae subfamily of the viral family, Herpesviridae. HSV-2 is the primary cause of 
genital herpes infection. HSV-1 is predominantly associated with oral infections; however, it is a 
common agent of genital herpes infections as well (Whitley, 2001). Primary HSV-2 infections 
usually occur on the mucous membranes and skin surrounding the genitals. Herpes infection of 
epithelial cells causes a characteristic vesicular lesion due to the cytopathic effects of the virus 
on the host cell and the host’s inflammatory response to infection. After primary infection of 
epithelial cells, HSV infects sensory nerve endings in the surrounding tissue. The viral 
nucleocapsids are transported by retrograde axonal flow to the dorsal root ganglion where they 
establish a latent infection. Latent infections can be reactivated by numerous stimuli, such as 
emotional or physical stress, fever, tissue damage, and immune suppression. Upon reactivation, 
virions travel through the infected neurons to the site of primary infection and once again infect 
the epithelial cells in that area. Skin lesions usually occur during recurrent herpes infections; 
however, evidence suggests that virions can be shed in the absence of noticeable symptoms 
(Whitley, 2001; Mertz et al., 1992). Latent HSV-2 infections are reactivated at least five times 
each year and some studies suggest that subtle reactivation may be almost continuous (Mertz et 
al., 1992; Corey et al., 1983). Active herpes infections can be suppressed with drugs targeting 
the viral protein tyrosine kinase (TK). However, the latency-associated transcripts are the only 
viral genes transcribed in latently infected neurons (Jones, 2003). Because TK is not expressed, 
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antiviral drugs cannot eliminate the infection once latency is established (Roizman, 2001). 
Although most genital HSV infections are clinically mild, HSV-2 can also cause serious diseases 
such as keratitis, meningitis, and disseminated neonatal HSV infection (Roizman, 2001).  
Structurally, Herpes Simplex Viruses have a double stranded DNA genome, contained in 
an icosahedral capsid. The nucleocapsid is encircled by an unstructured tegument that contains 
several active viral proteins including virion host shut off protein (vhs), viral protein 16 (VP16), 
and VP22. The tegument is surrounded by the viral envelope composed of a lipid bilayer 
containing numerous viral glycoproteins (Roizman, 2001).  
Infection of a host cell by HSV is initiated by a series of consecutive interactions between 
envelope glycoproteins and the host cell membrane (Fig. 1.1A). First, glycoproteins B (gB) and 
gC bind to the host cell receptor, heparan sulfate. The initial binding event is followed by 
interaction of gD with one of several co-receptors - herpes viral entry mediator (HVEM), Nectin-
1, Nectin-2, or 3-O-sulfated heparan sulfate (Spear, 2004). The co-receptor used during infection 
is dependant on cell type as well as on the strain of HSV. HVEM is primarily expressed on T and 
B lymphocytes, epithelial cells and fibroblasts and can be used by both HSV-1 and HSV-2 for 
entry into the host cell (Kwon et al., 2006; Spear, 2004; Hsu et al., 1997; Marsters et al., 1997; 
Montgomery et al., 1996). Both nectin 1 and 2 are expressed on epithelial and neuronal cells. 
Nectin-1 can efficiently be used as a co-receptor by both HSV-1 and HSV-2. Nectin-2 also 
serves as a co-receptor for both types of HSV; however, Nectin-2 is used as a co-receptor by 
HSV-2 at significantly higher efficiency than by HSV-1(Spear, 2004). Lastly, 3-O-sulfated 
heparan sulfate is expressed on numerous cell types and is primarily used as a co-receptor by 
HSV-1 (Shukla et al., 1999). 
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Interestingly, HSV co-receptors also serve as host cell signaling molecules. HVEM is a 
member of the tumor necrosis factor receptor family (Mauri et al., 1998). When complexed to its 
natural ligand, LIGHT, HVEM stimulates cellular transduction pathways involved in the 
activation of T-cells (Granger and Rickert, 2003; Hsu et al., 1997). Nectin-1 and Nectin-2 are 
members of the Immunoglobulin superfamily and are involved in the formation of cell junctional 
complexes (Cocchi et al., 1998). When stimulated, nectins interact with cell signaling molecules, 
Cdc42 and Rac small G proteins, through their cytoplasmic tails to coordinate cytoskeletal 
rearrangements (Nakanishi and Takai, 2004). Additionally, Hoppe, et. al., have demonstrated 
that Rac1 and Cdc42 are activated following infection of epithelial cell lines with HSV-1 (Hoppe 
et al., 2006).  
 Once gD interacts with the appropriate host co-receptor, a complex of gH/L promotes 
fusion of the viral envelope and the host cell plasma membrane following attachment to the host 
cell. Once inside the host cell, viral tegument proteins are released. One such protein, VP22, 
functions as a microtubule-associated protein and induces reorganization of microtubules in the 
host cell cytoplasm (Elliott, 1998).  Another virion protein, the HSV-2 virion host shut off 
protein (VHS), immediately suppresses host transcription by inducing degradation of host 
mRNAs (Roizman, 2001; Kwong, 1989).  VP16 is a virion protein that is transported to the 
nucleus and is involved in activation of both viral and host gene transcription (Roizman, 2001).  
After entry (Fig. 1.1B), viral capsids interact with the molecular motor dynein and are 
transported along microtubules to the nucleus where capsids dock with nuclear pore complexes 
and translocation of the viral genome occurs (Ojala, 2000).  Transcription of the viral genome 
occurs in three consecutive stages. First, VP16 aids in initiating transcription of the immediate 
early, or α genes. The gene products of the α genes then stimulate the transcription of the β 
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genes. At this point in viral replication, viral DNA synthesis occurs. Lastly the γ genes, which 
include many of the tegument proteins and envelope glycoproteins, are transcribed. Following 
transcription, viral proteins are synthesized using host cell machinery. New virions are then 
assembled in the nucleus, bud through viral glycoprotein enriched areas of the nuclear envelope, 
and exit the host cell through vesicular transport (Roizman, 2001). 
 
Figure 1.1 Replication Cycle of HSV.  A. Attachment and entry of HSV virions into the host 




The bacterial family Chlamydiaceae contains several human pathogens including, C. 
pneumoniae, C. psittaci, and C. trachomatis. C. muridarum and C. suis are non-human animal 
pathogens, infecting mice and swine respectively (Mpiga and Ravaoarinoro, 2006). C. 
pneumoniae is a causative agent of community acquired pneumonia in humans, which has been 
associated with cardiovascular plaque formation and Alzheimer’s disease (Hogan et al., 2004). It 
is estimated that 90% of all adults are infected with C. pneumoniae during their lives and that 
10% of all community acquired pneumonia and 5% of bronchitis and sinusitis cases are due to C. 
pneumoniae (Koehler et al., 1997; Summersgill et al., 1995). C. psittaci is a zooanotic pathogen 
that causes a respiratory disease in humans called psiticosis. Psiticosis is often observed in 
poultry farm workers and owners of exotic birds (Mpiga and Ravaoarinoro, 2006; Everett et al., 
1999).  
 C. trachomatis is separated into two biovars, the Lymphogranuloma Venereum (LGV) 
biovar and the trachoma biovar, both of which are broken into several serovars. There are four 
LGV serovars, L1, L2, L2a, and L3 and 14 trachoma serovars, designated as serovars A-K, Ba, 
Da, and Ia. C. trachomatis serovars A-C are the etiological agents of trachoma, the world’s 
leading cause of preventable blindness. It is estimated that 162 million people suffer from ocular 
infections by serovars A-C and that 6 million people are rendered completely blind because of 
these bacteria (Mpiga and Ravaoarinoro, 2006; Mabey and Fraser-Hurt, 2003). C. trachomatis 
serovars D-K represent the world’s most reported bacterial sexually transmitted disease agents 
and cause urethritis or cervicitis. Approximately 85-90% of chlamydial infections are 
asymptomatic and chronic, allowing the bacteria to ascend the genital tract, which can result in 
endometritis, salpingitis, and pelvic inflammatory disease. The silent nature of chlamydial 
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infections leads to prolonged inflammation, causing fibrosis and scarring in the tissues of the 
genital tract. Eventually, the damage sustained by the host response to C. trachomatis infections 
promotes the development of more severe disease sequelae including ectopic pregnancy, 
infertility and reactive arthritis. Additionally, 30-50% of infants born to chlamydiae-infected 
mothers will develop chlamydial conjunctivitis and nasopharyngeal infections (Peipert, 2003). C. 
trachomatis LGV infections cause a more invasive sexually transmitted disease. Following 
infection, the bacteria travel from the genital tract to the inguinal and femoral lymph nodes. Once 
the lymph nodes are infected, necrotic abscesses develop and result in draining fistulas 
(Schachter, 1999). Acute chlamydial infections can be successfully treated with cyclins 
(doxycycline and tetracycline), quinolones (ofloxacin and levofloxacin), and macrolides 
(erythromycin and azithromyacin) (Mpiga and Ravaoarinoro, 2006). 
 
The Chlamydial Developmental Cycle  
All chlamydiae are Gram-negative obligate intracellular bacteria and share a unique 
biphasic developmental cycle (Fig 1.2). Extracellularly, chlamydiae exist as small (0.3µm), 
infectious, metabolically inert forms of the bacteria termed elementary bodies (EBs).  EBs are 
round, structurally rigid, and osmotically stable and contain a highly compacted bacterial 
nucleoid. Chlamydiae have an interesting bacterial cell wall that contains little or no 
peptidoglycan.  Therefore, the rigidity of EBs is maintained by crosslinking between outer 
membrane proteins. EBs attach to the apical surface of columnar epithelial cells and enter via 
receptor mediated endocytosis (Abdelrahman and Belland, 2005; Wyrick, 2000). Several surface 
exposed bacterial proteins present on EBs have been purposed to be involved in chlamydial 
attachment to the host cell, including: the major outer membrane protein (MOMP), heat shock 
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protein 70, outer membrane protein A, outer membrane complex protein B, members of the 
polymorphic membrane protein family, and heparan sulfate-like glycosaminoglycans.  Likewise, 
several chlamydial receptor candidates are present on the surface of host cells including the 
heperan sulfate receptor and the estrogen receptor (Dautry-Varsat et al., 2004; Fields and 
Hackstadt, 2002; Bavoil et al., 2000; Wyrick, 2000). Once inside the host cell, chlamydiae-
containing vesicles escape lysosomal fusion and are transported to the perinuclear region. Here 
they differentiate within a modified vacuole, called an inclusion, into the larger (1µm), non-
infectious form of the bacterium, called the reticulate body (RB).  Reticulate bodies are 
metabolically active and will undergo 8-12 rounds of replication within the inclusion. Following 
replication, RBs condense to form EBs that are released and can infect new host cells. The 
infectious cycle takes anywhere from 30-72 hours depending upon the chlamydial 
species/serovar (Wyrick, 2000). In addition to growth in the normal developmental cycle, 
chlamydiae have evolved a mechanism to sustain viability during adverse conditions. When 
developing chlamydiae are exposed to certain environmental insults, they deviate from the 
normal developmental cycle into a state called persistence (Hogan et al., 2004). 
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 Figure 1.2 The Chlamydia trachomatis developmental cycle. 
 
Chlamydial Persistence 
Persistent chlamydiae are traditionally defined as a viable but non-cultivatable form of 
chlamydiae (Beatty et al., 1994d). It appears that chlamydiae use persistence as a general stress 
response to maintain viability until growth conditions improve, therefore, resulting in a 
prolonged existence within the host cell (Mpiga and Ravaoarinoro, 2006; Harper et al., 2000). 
Persistent chlamydial forms appear as swollen, diffuse, and aberrantly shaped RBs upon 
examination by transmission electron microscopy (TEM). While in the persistent state, RBs 
continue to enlarge and accumulate chromosomes, but they fail to divide, resulting in the 
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persistent morphology. The abnormal RBs do not differentiate into EBs, thus, causing a decrease 
in progeny EB infectivity (Beatty et al., 1994d; Beatty et al., 1993; Byrne et al., 1986; Johnson 
and Hobson, 1977; Matsumoto and Manire, 1970). Several models of persistence have been 
examined in culture including: antibiotic exposure, monocyte infection, nutritional deficiencies, 
and cytokine exposure (Gerard et al., 2001; Darville et al., 2000; Raulston, 1997; Beatty et al., 
1994d).  
Antibiotic-induced persistence has been most extensively examined in chlamydiae-
infected cultures exposed to Penicillin G, which inhibits bacterial cell wall synthesis (Nicholson 
et al., 2003). Although the presence of peptidoglycan in the chlamydial cell wall remains 
unproven, C. trachomatis does have the genes required to produce it (McCoy et al., 2003; 
Stephens et al., 1998). In fact, recent studies report that chlamydiae possess functional enzymes 
to synthesize meso-diaminopimelate, a key component of peptidoglycan (McCoy et al., 2006). It 
has been suggested that peptidoglycan is produced in RBs and aids in cell division (McCoy and 
Maurelli, 2006). Therefore, it is possible that by interfering with cell wall synthesis, Penicillin G 
is able to induce persistence. When antibiotics are removed from the culture medium, RBs 
resume normal development and production of infectious progeny is restored (Matsumoto and 
Manire, 1970). Additionally, other antibiotics, including erythromycin and ampicillin have been 
shown to induce persistence under certain experimental conditions (Wolf et al., 2000; Clark et 
al., 1982).  
Deficiencies in amino acids, glucose, or iron have all been shown to induce chlamydial 
persistence. Growth of C. trachomatis serovar E under iron-limiting conditions produces 
inclusions that contain numerous membrane blebs and RBs with loose, wavy outer membranes 
(Raulston, 1997). Likewise, removal of glucose or amino acids from the culture medium leads to 
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the formation of abnormally shaped RBs and a loss of chlamydial infectivity (Harper et al., 
2000; Coles et al., 1993). In each case, replacement of the deficient/depleted nutrients allows the 
chlamydiae to recover infectivity (Harper et al., 2000; Raulston, 1997; Coles et al., 1993).  
Cytokine exposure, especially interferon- γ (IFN-γ), often induces chlamydial persistence 
by stimulating an indirect depletion of nutrients. In human cells, IFN-γ-exposure increases host 
cell indoleamine 2, 3-dioxygenase (IDO) expression, leading to depletion of host cellular 
tryptophan. Without this essential amino acid, developing chlamydiae enter into persistence and 
cease productive replication (Beatty et al., 1994d).  In murine cells, IFN-γ-exposure increases 
synthesis/activity of the p47 GTPase, Iigp1. Iigp1 inhibits chlamydial development by restricting 
vesicular trafficking to developing inclusions (Nelson, 2005). Other cytokines [tumor necrosis 
factor-α (TNF-α), interleukin-1α (IL-1α) and IL-1β] can synergize with IFN-γ to enhance its 
negative effect on chlamydial development at lower concentrations (Carlin and Weller, 1995; 
Summersgill et al., 1995; Shemer-Avni et al., 1988).  Lymphotoxin-α (LT- α), IFN-α, IFN-β, 
and TNF-α also interfere with chlamydial development by induction of a host anti-chlamydial 
pathway involving inducible nitric oxide synthase (iNOS) and/or induction of iron restriction-
mediated persistence (Hogan et al., 2004; Matsushima et al., 1999). When iNOS is up-regulated, 
the host cell produces nitric oxide (NO) that kills developing chlamydiae. Interferon-γ-induced 
persistence is also reversible with the addition of exogenous tryptophan to the culture medium 
(Beatty et al., 1994d). In the case of IFN-α, both tryptophan and iron must be added to the 
medium for full recovery of chlamydial infectivity (Ishihara et al., 2005).  
Gerard et. al. (2001) demonstrated that C. trachomatis serovar K enters persistence 
spontaneously, in the absence of any exogenous inducer when infecting human monocytes. 
Interestingly, neither the addition of tryptophan nor antibodies to IFN-γ or TNF-α allowed 
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recovery of chlamydial infectivity, suggesting a cytokine-independent mechanism of persistence 
induction (Airenne et al., 1999; Koehler et al., 1997). C. trachomatis serovar E has also been 
shown to enter spontaneous persistence when cultured in non-permissive synovial cells (Hanada 
et al., 2003).  
A number of experimental parameters have been used as indicators of chlamydial 
persistence; these include: altered inclusion size, abnormal RB morphology, decreased 
production of progeny EBs, and recovery of infectivity following the removal of the persistence 
inducer (Hogan et al., 2004; Darville et al., 2000; Beatty et al., 1994d). Chlamydial MOMP 
expression is often decreased during persistence while expression of the chlamydial pro-
inflammatory antigen, heat shock protein 60 (HSP60), is stable or increased (Hogan et al., 2004; 
Beatty et al., 1994a; Beatty et al., 1993). Because DNA synthesis continues in persistence, 
accumulation of chlamydial DNA in persistently-infected cultures is not significantly different 
from that in productively infected cultures (Hogan et al., 2004; Gerard et al., 2001). Continued 
expression of unprocessed 16S rRNA transcripts is also a key marker of persistence. Processing 
of 16S rRNA transcripts occurs almost immediately following transcription; thus, isolation of 
unprocessed transcriptsin the absence of infectivity demonstrates viability of the organisms 
(Gerard et al., 1997). 
While many characteristics of chlamydial persistence are reiterated among the various in 
vitro models, some markers of persistence vary depending on the experimental conditions used. 
For instance, expression of the cell separation genes, ftsK and ftsW, is reduced in C. trachomatis 
serovar K-infected monocytes as well as in IFN-γ-exposed C. pneumoniae (Byrne et al., 2001; 
Gerard et al., 2001).  Conversely, Stevens et al. demonstrated that in penicillin-exposed, C. 
trachomatis serovar D infected cells, ftsW remains unchanged while ftsK is elevated (Nicholson, 
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2002). The timing of persistence induction also varies among persistence models. The addition 
of IFN-γ to chlamydiae-infected cultures must be performed prior to or early during infection for 
the maximal effects to be observed (Nelson et al., 2005). However, Penicillin G can be added at 
24hr post infection and still induce abnormal chlamydial development (Nicholson, 2002). 
Though recovery of infectious progeny following the removal of the persistence inducing agent 
or replenishment of deficient nutrients is a key feature of most persistence models (Gerard et al., 
2001; Darville et al., 2000; Raulston, 1997; Beatty et al., 1994d), recovery was not demonstrated 
in spontaneously persistent cultures even after the addition of tryptophan (Airenne et al., 1999; 
Koehler et al., 1997). The differences between persistence models serve as a reminder that 
experimental conditions, persistence inducer, chlamydial species/serovar, and choice of host cell 
employed in a study all play a role in the development of persistence. Taken together these 
observations indicate that although the outcome of persistence may appear similar in various 
models, the underlying mechanisms could be very different.  
Although most known information about chlamydial persistence has been revealed by 
cell cultue, in vivo persistence is a tangible scenario. Improper or inadequate antibiotic therapies 
could allow persistence to occur in vivo (Mpiga and Ravaoarinoro, 2006).  Natural fluctuations in 
iron levels in the female genital tract could cause chlamydiae to experience iron limitations 
(Raulston, 1997). Release of IFN-γ by the immune system is a part of the host response to 
intracellular pathogens, including C. trachomatis (Morrison et al., 2000; Rank and Sanders, 
1992; Ramsey et al., 1988).  In fact, evidence from several studies strongly suggests that 
chlamydiae do become persistent in vivo (Gerard et al., 2002; Gerard et al., 2001; Dean et al., 
2000; Fortenberry et al., 1999; Patton et al., 1994). An investigation of recurrent genital 
chlamydial infections indicated that several study participants were infected with the same 
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serovar and genotype of C. trachomatis 3-10 times in a 2-5 year time span despite appropriate 
antibiotic treatment. Based upon the principle that anti-chlamydial immunity is genotype 
specific, these results indicate that the women in this study were persistently-infected rather than 
becoming re-infected with a different strain of C. trachomatis (Dean et al., 2000).  The presence 
of atypical RBs has been demonstrated by electron microscopy examination of fibroblasts 
isolated from patients suffering from reactive arthritis (Nanagara et al., 1995). Unprocessed 
chlamydial 16S rRNA transcripts have been amplified from snyovial tissue of arthritis patients 
(Gerard et al., 1997). A recent in vitro study demonstrated that persistent chlamydiae become 
refractory to killing by azithromycin (Wyrick and Knight, 2004). Finally, abnormal RBs similar 
to the persistent forms observed in culture have been visualized in urethral and cervical tissues 
from C. trachomatis infected patients despite treatment with azithromycin (Bragina et al., 2001). 
Taken together, these observations argue that in vivo chlamydial persistence is a relevant medical 
concern.  Furthermore, increased release of inflammatory mediators, like Hsp-60, from 
persistently-infected cells in vivo may enhance disease pathology (Darville et al., 2000). 
 
HSV and Chlamydia trachomatis Co-infection 
There is evidence that HSV and C. trachomatis co-infections exist in vivo. Serologic 
investigations indicate that HSV-2 positive individuals are likely to be C. trachomatis positive as 
well (Silins et al., 2002; Paroli et al., 1990). Several studies have documented seropositivity rates 
of >50% for both pathogens, implying that some of the individuals had been exposed to both 
HSV-2 and C. trachomatis (Wagner et al., 1994; Duncan et al., 1992). Although IgG 
seropositivity does not prove coexisting infection, there is a high probability that some of the 
individuals were infected simultaneously with both pathogens.  In addition to serological studies, 
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direct examination of cervical biopsy samples by PCR indicated that approximately 10% of 
women tested positive for C. trachomatis, HSV, and Human Papilloma Virus (Finan et al., 
2006). Furthermore, both C. trachomatis and HSV have been isolated simultaneously in samples 
from women stricken by upper genital tract diseases (Paavonen et al., 1985; Tait et al., 1985). In 
fact, co-infections of C. trachomatis and HSV are so prevalent that a dual vaccine for both 
pathogens has been proposed (Macmillan et al., 2007). Although co-infections of C. trachomatis 
and HSV exist, the implications of these dual infections on disease pathology and pathogen/host 
interactions have not been investigated.  
In vitro models of HSV-2/C. trachomatis co-infections have also been established. 
Transmission electron microscopy (TEM) analyses of Vero cells co-infected with C. trachomatis 
serovar L2 and HSV-2 revealed swollen inclusions with few RBs or EBs (Pontefract et al., 
1989).  Chiarini et al. reported that the number of cells positive for chlamydiae by 
immunofluorescence was reduced when HeLa cells were co-infected with HSV-2/C. trachomatis 
serovar D (Chiarini et al., 1996). The number of chlamydial inclusions and infectious EBs was 
also reduced in HSV-2 pre-infected HT1376 human bladder cells (Superti et al., 2001). Although 
these observations indicate that HSV-2 co-infection alters chlamydial development, these studies 
did not examine the co-infection process in detail.  
A tissue culture model of HSV-2 and C. trachomatis serovar E co-infection was recently 
established in our laboratory. Findings from this model demonstrate that HSV co-infection 
decreases production of infectious chlamydial progeny, suggesting that viral co-infection drives 
developing chlamydiae to enter a persistent state. TEM analyses also show that numerous 
membrane blebs and vesicles are present in inclusions and RBs become swollen and aberrantly 
shapen during co-infection (Deka et al., 2006). Furthermore, co-infection with either UV-
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inactivated, replication incompetent virus or with replication-competent HSV-2 in the presence 
of cyclohexamide reduced chlamydial infectivity (Deka et al., 2007). These data demonstrate 
that productive viral replication is not required for the induction of chlamydial persistence and 
suggest that HSV attachment and entry can provide the necessary stimulus to alter C. 
trachomatis development. 
The experiments in this study will allow us to begin to unravel the mechanism by which 
HSV-2 causes C. trachomatis to enter persistence. The first objective in this study is to 
characterize co-infection-induced persistence by examining several known molecular markers of 
persistence. These include: i) chlamydial genome accumulation; ii) expression profiles of several 
persistence influenced genes (ftsK, ftsW, and gro-EL1); iii) accumulation of chlamydial Hsp60 
and MOMP proteins; and iv) recovery of chlamydial infectivity following induction of 
persistence. The second aim in this study is to determine whether the mechanism of HSV-2-
induced persistence is one of the previously characterized persistence inducers or if it is 
stimulated by novel anti-chlamydial pathway. The last aim of this study involves differentiating 
between the events of viral attachment and entry so that the role that these events (specifically 
HSV-2 attachment) play in triggering chlamydial persistence during co-infection can be 
determined. Examination of the cellular pathways that are stimulated by HSV-2 attachment and 
entry during co-infection will further illuminate the mechanisms that C. trachomatis uses to 
occupy its specific niche within the host cell as well as the host cell mechanisms that have co-
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 Epidemiologic and clinical studies have shown that double infection with herpes simplex 
virus, type 2 (HSV-2) and Chlamydia trachomatis occurs in vivo. We hypothesized that co-
infection would alter replication of these agents. To test this hypothesis, HeLa cells were infected 
with C. trachomatis serovar E, followed 24 hours (h) later by HSV-2 strain 333. Transmission 
electron microscopic (TEM) analyses indicated that, by 10 hours post-HSV addition, reticulate 
bodies (RBs) in co-infected cells were swollen, aberrantly shaped, and electron-lucent.  In 
infectious titer assays, HSV-2 co-infection abrogated production of infectious chlamydial 
progeny. Western blot analyses indicated that accumulation of chlamydial major outer membrane 
protein (MOMP) was decreased by HSV co-infection while accumulation of chlamydial heat-
shock protein 60-1 (HSP60-1) was increased. Polymerase chain reaction (PCR) experiments 
indicated that chlamydial genome copy number was unaltered by HSV-2 super-infection. Semi-
quantitative, reverse transcriptase-PCR (RT-PCR) experiments demonstrated that levels of 
chlamydial groEL, ftsK, ftsW, dnaA, and unprocessed 16S rRNA transcripts were not changed by 
HSV-2 super-infection. These data indicate that HSV-2 super-infection drives chlamydia into a 
viable but non-cultivable state, which is the hallmark of persistence. Because chlamydial HSP60-
1 has been associated with immunopathology in vivo, these results also suggest that disease 




Sexually transmitted diseases (STD) have reached epidemic proportions worldwide. This 
year in the United States (US) there will be approximately 19 million new cases of STDs 
(Weinstock, 2004). The most commonly reported STD agents in the US include Chlamydia 
trachomatis serovars D-K with 4,000,000 new cases/year and herpes simplex virus (primarily 
HSV-2) with 200,000-500,000 new cases/year (Butler, 1997). Because both organisms establish 
asymptomatic or latent infections, these numbers underestimate the infectious burden. 
The Chlamydia are a genus of Gram negative, obligate intracellular bacteria. Multiple 
and persistent chlamydial infections are strongly associated with increased pathology in vivo 
(Beatty et al., 1994c). Genital chlamydial infections are associated with serious complications; 
these include pelvic inflammatory disease, tubal factor infertility, and ectopic pregnancy in 
females and epididymitis and reactive arthritis in men (Darville, 2000). Extracellularly, 
chlamydiae exist as elementary bodies (EBs). Infection begins by contact of infectious EBs with 
the epithelial cell apical surface, followed by receptor-mediated endocytosis. Upon uptake, each 
EB is incorporated into an endocytic vesicle. Multiple EB-containing endocytic vesicles fuse to 
form an expanding, membrane-bound vacuole termed an inclusion. The small, spherical, 
metabolically-inactive EBs (0.2µm diameter) then transform into larger (0.8µm), metabolically-
active, non-infectious, reticulate bodies (RBs). RBs use host metabolites and energy to 
synthesize macromolecules, grow, and divide by binary fission. The RBs then mature into 
infectious EBs and exit the host cell (Wyrick, 2000). 
Chlamydiae can establish persistent infection of host cells in vitro under specific 
environmental conditions. These include IFN-γ, TNF-α and penicillin G exposure as well as 
amino acid or iron deprivation and monocyte infection (Beatty et al., 1994c; Raulston, 1997; 
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Darville, 2000; Gerard et al., 2001), all of which can occur in vivo as well. The persistent state is 
characterized by inclusion enlargement, the presence of swollen, diffuse RBs and decreased EB 
production (Matsumoto and Manire, 1970; Johnson and Hopson, 1977; Byrne et al., 1986; 
Beatty et al., 1993; Beatty et al., 1994a). Persistent chlamydiae can remain in a viable but less 
metabolically active, non-replicative state for weeks or months. Chlamydial MOMP expression 
is often decreased during persistence while expression of the chlamydial pro-inflammatory 
antigen, heat shock protein 60 (HSP60) is stable or increased (Cevenini et al., 1988; Beatty et al., 
1993; Beatty et al., 1994b). Persistent chlamydial forms shed MOMP and lipopolysaccharide 
(LPS) into membrane blebs that find their way to the host cell surface and are released (Karimi et 
al., 1989; Wyrick et al., 1994; Wyrick et al., 1997; Wyrick et al., 1999). Although C. 
trachomatis persistence in vivo has been difficult to demonstrate, recent studies suggest that C. 
trachomatis establishes persistent infections in humans (Patton et al., 1994; Fortenberry et al., 
1999; Dean et al., 2000; Gerard et al., 2001; Gerard et al., 2002). Increased release of 
inflammatory mediators from persistently-infected cells in vivo may enhance disease pathology 
(Darville, 2000). 
The Herpesviridae are a family of enveloped DNA viruses. Primary human HSV-2 
genital infections usually occur on genital skin or mucous membranes, where an intense 
inflammatory response is observed. The virus may then establish latency in the sacral ganglia. 
HSV-2-infected individuals experience an average of 5 reactivations/year throughout their lives, 
during which lesions and virions are present (Corey et al., 1983). HSV-2 may also cause several 
serious diseases including keratitis, meningitis, and disseminated herpes infection. At a single 
cell level, the HSV-2 replication cycle takes from 12 to 24 hours and is initiated by viral 
attachment to one of several host cell receptors. Once viral DNA enters the nucleus, the viral 
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genes are expressed in a specific temporal order. New virions are then assembled, enveloped, 
and released (Roizman and Knipe, 2001). 
A number of studies have established that co-and super-infections with HSV-2 and C. 
trachomatis occur in the human population. HSV-2 and C. trachomatis have been 
simultaneously isolated from the genital tract of women suffering from endometritis and 
salpingitis (Paavonen et al., 1985) as well as cystitis (Tait et al., 1985). Several large serologic 
studies indicate that HSV-2 positive individuals are likely to be C. trachomatis positive as well 
(Paroli et al., 1990; Vetter, et al., 1990; Silins et al., 2002). Also, seropositivity rates of >50% 
for both HSV-2 and C. trachomatis have been reported, suggesting that some study participants 
had been exposed to both (Duncan et al., 1992; Wagner et al., 1994). Although IgG 
seropositivity cannot establish concurrent infection, it is likely that both organisms were present 
simultaneously in some individuals. 
Cell culture models of HSV/chlamydial co-infection have been established. Pontefract et 
al. observed that inclusions in Vero cells co-infected with C. trachomatis serovar L2 and HSV-2 
were swollen and contained few RBs or EBs (Pontefract et al., 1989). Chiarini and colleagues 
reported that in HSV-2/C. trachomatis serovar D co-infected HeLa cervical epithelial cells, the 
number of cells positive for chlamydiae by immunofluorescence (IFA) was reduced (Chiarini et 
al., 1996). HSV-2 pre-infection of HT-1376 human bladder cells also reduced both inclusion 
number and production of infectious C. trachomatis EBs (Superti et al., 2001). These data 
suggested that HSV-2 co-infection might alter the chlamydial developmental cycle in a manner 
similar to that observed during persistent infections. Because no previous study directly 
addressed this possibility, we established a cell culture HSV-2/C. trachomatis serovar E co-
infection system and evaluated this hypothesis using multiple experimental indicators of 
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chlamydial persistence. These data demonstrate that HSV-2 co-infection alters the chlamydial 
developmental cycle similarly to other inducers of chlamydial persistence and illuminate 
potential mechanisms by which co-infection could enhance pathology. 
 
Results 
HeLa cells can be co-infected with C. trachomatis serovar E and HSV-2.  
HeLa monolayers were either mock, singly, or co-infected (Fig. 2.1A). At 20 h post-HSV 
infection, HeLa cells were immunostained (Fig. 2.1B). Both C. trachomatis and HSV-2 singly-
infected cells stained only with antibodies specific for either agent; control, mock-infected cells 
did not stain with either antibody. IFA using C. trachomatis MOMP-specific antibodies 
demonstrated that chlamydial inclusions were present in more than 60% of C. trachomatis 
infected or co-infected cells. HSV-2 ICP5 and ICP8 antibody staining showed that at least 90% 
of the HSV singly-infected and co-infected cells were HSV-2-infected (Fig. 2.1B). Similar 
results have been obtained in multiple experiments and demonstrate that co-infection did occur 
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Figure 2.1. HSV-2 co-infection increases C. trachomatis inclusion size. (A) HeLa cells were 
plated and divided into 4 groups: Mock (uninfected negative control), Ct-25 (infected only with 
C. trachomatis), HSV (infected only with HSV-2) and Ct-25/HSV (infected first with C. 
trachomatis and 24 hours later with HSV-2). Each group was mock-infected with 2SPG
C. trachomatis serovar E at 80% infectivity at T
 alone or 
re 
 
-25 and with HSV-2 at 10 PFU/cell or cultu
medium at T-1 as indicated. All cells were incubated at 35oC from T-25 until the end of the 
experiment. Following a 1 h attachment/entry period, all cells were refed with fresh culture 
medium following both C. trachomatis (T-25) and HSV-2 (T0) and mock (T-25 and/or T0)
infection. Samples for IFA (immunofluorescence assay), TEM (transmission electron 
microscopy), plaque assays, EB (elementary body) titer, and Western blot experiments were 
collected at various times after T0. (B) Mock, HSV-2, C. trachomatis and co-infected cells were 
fixed and stained using FITC conjugated anti-C. trachomatis major outer membrane protein 
(Anti-C. trach.) or using antibodies against HSV-2 (Anti-HSV-2) as described in the methods. 
Photomicrographs are 320X magnification. (C) Average relative inclusion size was determined 
from fluorescence photomicrographs. Images were coded and analyzed in double blind fashion 
as described. Means were compared using a 2-sample t-test for independent samples. Data are 
presented as average relative inclusion size ± the SEM. The Ct-25 and Ct-25/HSV inclusion size 
values are significantly different (p < 0.05)* 
 36 
 
HSV-2 super-infection increases chlamydial inclusion size. 
 Because inclusion enlargement has been observed in several in vitro models of 
chlamydial persistence (Matsumoto and Manire, 1970; Johnson and Hobson, 1977; Byrne et al., 
1986; Beatty et al., 1993; Raulston, 1997), image analysis was used to determine the average 
inclusion size in singly and co-infected cells at 20 hours post-HSV infection (Fig. 2.1C). 
Comparison of inclusion size indicated that inclusions were 28% larger in co-infected compared 
to singly-infected cells (448.6 ± 27 vs 624.9 ± 49). Statistical analysis indicated that average 
inclusion areas in these two samples were significantly different (p< 0.05). 
 
Super-infection with HSV-2 induces morphological changes in C. trachomatis.  
 Persistent forms of C. trachomatis have a characteristic electron microscopic appearance 
(Matsumoto and Manire, 1970; Johnson and Hobson, 1977; Byrne et al., 1986; Beatty et al., 
1993; Raulston, 1997). Thus, chlamydial morphology in singly and co-infected cells was 
compared by TEM (Fig. 2.2). At 30 hours post-chlamydial infection chlamydial inclusions in C. 
trachomatis singly-infected cells contained morphologically normal reticulate bodies (RB, black 
arrow, Fig. 2.2A); by 45 hours post infection (hpi) these inclusions contained chlamydiae 
progressing through the standard developmental cycle with normally sized RBs (Fig. 2.2B, black 
arrow) as well as intermediate and elementary bodies (IBs and EBs, black arrow with star). The 
C. trachomatis singly-infected control cells in Figure 2.2A and B are labeled 5h and 20h (post-
HSV infection) for ease of comparison to the appropriate co-infected samples. In co-infected 
cells, the RBs appeared slightly swollen as early as 5 h post-HSV-2 infection (Fig. 2.2D, black 
arrow). At 10 h (Fig. 2.2E), 15 h (Fig. 2.2F) and 20 h (Fig. 2.2G and H) post-HSV-2 infection, the 
inclusions contained enlarged, irregular, and diffuse RBs (Fig. 2.2E-H, black arrows). At 20 h 
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after viral infection very few IBs and no EBs were observed in co-infected cells (Fig. 2.2G and 
H). Increased accumulation of membrane blebs was also apparent in co-infected cells at both 15 h 
(Fig. 2.2F, black boxes) and 20 h (Fig. 2.2G and H, black boxes) post-virus infection. HSV-2 
virions were visible within nearly all co-infected cells containing aberrant chlamydial forms, 
beginning at 10 h post-HSV-2 infection (Fig. 2.2E, F, G and I, black circles). Neither chlamydial 
inclusions nor HSV-2 virions were visible in mock-infected cells (Fig. 2.2C). Similar data were 
obtained in multiple experiments and indicated that HSV-2 super-infection induced readily 




Figure 2.2. HSV-2 co-infection induces a “persistent-like” chlamydial morphology. HeLa cells 
were mock-infected (Mock, panel C), C. trachomatis infected (Ct-25, panels A and B) and C. 
trachomatis/HSV-2 co-infected (Ct-25/HSV, panels D-I) as described in Figure 2.1A. At 5 (panels 
A and D), 10 (panel E), 15 (panel F), or 20 h (panels B, C, G-I) post-HSV infection, cells were 
pre-fixed with glutaraldehyde-paraformaldehyde, processed, and then subjected to high contrast 
transmission electron microscopy. Panels A through H are at 12,101 X magnification. Panel I is at 
29,388 X magnification. 
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HSV-2 super-infection abolishes production of infectious chlamydial EBs.  
Previous studies have demonstrated that chlamydial persistent forms are non-infectious 
(Johnson and Hobson, 1977; Beatty et al., 1993). The dearth of EBs in co-infected cells observed 
by TEM suggested that HSV-2 co-infection interfered with RB maturation to EB. Therefore, 
subpassage was used to determine whether infectious chlamydiae were produced by co-infected 
cells (Table 2.1). Neither mock nor HSV-2 singly-infected cells produced detectable infectious 
EBs, whereas C. trachomatis singly-infected cells produced abundant EBs. Co-infected cells 
produced few, or no, infectious EBs, demonstrating that production of infectious chlamydial 





Experiment 1c  Experiment 2c
Mock < 5d < 5d 
HSV < 5d < 5d 
Ct-25 5,869 18,000 
Ct-25/HSV < 5d 120 
 
Table 2.1. Co-infected cells do not produce infectious chlamydial EBs. aInclusion counts from 
triplicate wells were averaged and used to calculate # inclusion forming units (IFU)/106 cells.  
bHeLa cells were mock-infected (Mock), C. trachomatis infected (Ct-25), HSV-2-infected (HSV) 
and C. trachomatis/HSV-2 co-infected (Ct-25/HSV) as described in Figure 2.1A.  
cResults from two independent co-infection experiments are shown. 
dBecause the lowest dilution of cell lysate tested was 1/5, inclusion counts of “0” cannot be used 
to calculate the exact number of IFU present in undiluted cell lysates and only indicate that the 






 Co-infection alters neither chlamydial nor HSV-2 genome copy number.   
 One characteristic of persistent chlamydiae is that they do not divide but continue to 
replicate their DNA (Gerard et al., 2001).  Total DNA from co-infected and singly-infected cells 
(Fig. 2-3) was subjected to PCR using primers specific for the human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene, the chlamydial 16S rRNA gene and the HSV-2 G2 
glycoprotein gene.  All amplimers were the expected size (Fig. 2.3A) and the identity of each 
was confirmed by DNA sequencing (data not shown). The quantity of chlamydia DNA specific 
product is similar in both co-infected and C. trachomatis singly-infected samples (Fig. 2.3A, 
lanes 4 and 5). Likewise, the amount of HSV-2 specific amplimer appears unchanged by C. 
trachomatis co-infection (Fig. 2.3A, lanes 3 and 5). Amplification was never observed in 
negative (no template) controls (Fig. 2.3A, lane 1). GAPDH amplification products were 
observed in all samples at similar amounts (data not shown). HSV and chlamydia-specific 
products were observed only in the appropriate samples, confirming amplification specificity.  
The experiment shown in Figure 2.3A was repeated 3 times; 6 log dilution series of known DNA 
template controls were also amplified and used to generate amplification standard curves. All 
experimental samples quantified fell within the linear range of the PCR amplification as 
determined from the appropriate, co-amplified, standard curve. Chlamydial 16S rRNA and HSV 
G2 amplimer quantities were then normalized to host genome copy number as ascertained by 
PCR with human GAPDH specific primers and plotted in Figure 2.3B.  Statistical analyses 
indicated that there was no difference in either chlamydial or HSV genome copy number in co-














































































Figure 2.3.  Co-infection alters neither chlamydial nor HSV-2 genome copy number. (A) HeLa 
cells were mock-infected (Mock), C. trachomatis infected (Ct-25), HSV-2-infected (HSV) and C. 
trachomatis/HSV-2 co-infected (Ct-25/HSV) as described in Figure 2.1A. Total DNA was 
purified as described and subjected to PCR analyses using host genome (GAPDH), chlamydial 
genome (16S rRNA gene), and HSV-2 genome (G2 glycoprotein gene) specific DNA 
oligonucleotides.  Chlamydial 16S rRNA (107 bp) and HSV-2 G2 (72 bp) amplimers were 
electrophoresed as described; representative photographs are shown.  The position of DNA size 
markers are shown to the left of each gel image in base pairs (bp). (B) Specific DNA amplimers 
were quantified as described.  Chlamydial (black bars) and HSV (grey bars) amplimer quantities 
were normalized to host genome copy number as ascertained by PCR with human GAPDH 
specific primers (data not shown).  The values plotted are averages of three independent 
experiments; the value obtained for each independent experiment is the average obtained from 
three biological replicates.  The average integrated intensity for each amplimer was plotted ± 
SEM versus sample identity (X-axis).   
 
 
Co-infection does not alter accumulation of chlamydial dnaA, ftsW, ftsK, groEL-1, or 
unprocessed 16S rRNA transcripts.   
 Several investigators have demonstrated that expression of one or both of the chlamydial 
cell division genes, ftsK and ftsW, changes after persistence induction.  In contrast, expression of 
the DNA replication gene dnaA, remains unchanged (Byrne et al., 2001; Gerard et al., 2001; 
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Nicholson and Stephens, 2002).  Also, by definition, persistent chlamydiae are viable but non-
infectious.  As a result, transcription of unprocessed 16S rRNA continues during persistence and, 
thus, would be expected to remain unchanged compared to actively dividing, viable chlamydiae. 
Co-infected and singly-infected cell cDNAs (Fig. 2.4) were subjected to RT-PCR using primers 
specific for the chlamydial dnaA, ftsW, ftsK, groEL-1 and unprocessed 16S rRNA transcripts.  
All amplimers were the expected size (Fig. 2.4A) and the identity of each was confirmed by 
DNA sequencing (data not shown). The quantity of each specific product was similar in both co-
infected and C. trachomatis singly-infected samples (Fig. 2.4A, lanes 4 and 5). Amplification 
was not observed in negative (no template) controls (Fig. 2.4A, lane 1) or in RT(-) controls (data 
not shown). Specific amplimers were observed only in C. trachomatis singly and co-infected 
cells, confirming amplification specificity.  Amplimers were quantified, compared to 
amplification standard curves, and then normalized to relative chlamydial genome copy number 
from that same sample as ascertained by PCR in Figure 2.3.  Statistical analyses indicated that 
there was no significant difference in accumulation of any of the chlamydial transcripts in co-










































































































Figure 2.4.  Co-infection does not alter accumulation of chlamydial dnaA, ftsW, ftsK, groEL-1, or 
unprocessed 16S rRNA transcripts. (A) HeLa cells were mock-infected (Mock), C. trachomatis 
infected (Ct-25), HSV-2-infected (HSV), and C. trachomatis/HSV-2 co-infected (Ct-25/HSV) as 
described in Figure 2.1A. Total cellular RNA was collected from each group of cells at 20 h 
post-HSV-2 infection and subjected to RT-PCR analyses using transcript specific 
oligonucleotide probes.  Chlamydial dnaA (501 bp), ftsW (274 bp), ftsK (351 bp), groEL-1 (223 
bp), and 16 rRNA primary transcript (466 bp) amplimers were electrophoresed and 
photographed; representative photographs are shown.  The position of DNA size markers are 
shown to the left of each gel image in base pairs (bp). (B) Specific DNA amplimers were 
quantified as described.  Amplimer quantities were normalized to chlamydial genome copy 
number (Fig. 2.3B).  The values plotted are averages of three independent experiments; the value 
obtained for each independent experiment is the average obtained from three biological 
replicates.  The average integrated intensities for dnaA (white bars), ftsW (grey bars), ftsK (black 
bars), groEL-1 (vertically striped bars) and 16S rRNA primary transcript (diagonally striped 
bars) were plotted versus sample identity (X-axis).  Mock and HSV singly-infected reactions 
were negative for these amplimers; therefore, only data for chlamydiae singly-infected and co-
infected cells are shown. 
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HSV-2 super-infection reduces accumulation of chlamydial MOMP and increases accumulation 
of HSP60.  
Accumulation of chlamydial MOMP is often decreased when RBs enter a persistent state; 
in contrast, HSP60-1 levels are usually stable or increased (Cevenini et al., 1988; Beatty, et al., 
1993; Beatty et al., 1994b). To determine whether HSV-2 super-infection altered MOMP or 
HSP60-1 accumulation, Western blot analyses were performed at 0, 5, 10, 15, and 20 h post-HSV 
infection. Single bands of the correct size for MOMP (40 kD) and HSP60-1 (60kD), were 
observed in C. trachomatis singly-infected and co-infected cell lysates but not in mock or in 
HSV-singly-infected cell lysates (Fig. 2.5A). The HSV-2 ICP-8 and ICP-5 proteins were observed 
in only HSV singly and co-infected samples (Fig. 2.5A).  Bands were quantified, normalized to 
focal adhesion kinase (FAK-a host cellular control protein) and plotted in Figure 2.5B.  Statistical 
analyses have demonstrated that FAK accumulation does not change over the course of the 
experiment (data not shown). MOMP accumulation was clearly decreased at 5, 10, 15, and 20 h 
post-HSV infection in co-infected cells.  In contrast, HSP60-1 accumulation was increased in co-
infected cells, particularly at 10 h post-HSV infection. Accumulation of the HSV-2 proteins ICP8 
and ICP5 was either unchanged or diminished by chlamydial co-infection (Fig. 2.5B).  Similar 
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Figure 2.5.  Chlamydial major outer membrane protein (MOMP) accumulation is reduced in co-
infected cells. (A) HeLa cells were mock-infected (Mock), C. trachomatis infected (Ct-25), HSV-
2-infected (HSV), and C. trachomatis/HSV-2 co-infected (Ct-25/HSV) as described in Figure 
2.1A. Cell lysates were collected from each group of cells at 0, 5, 10, 15, and 20 h post-HSV-2 
infection and Western blotted using anti-C. trachomatis MOMP, anti-C. trachomatis HSP60-1, 
anti-HSV-2 ICP-5, anti-HSV-2 ICP-8, or anti-human FAK sera.  Three independent experiments 
were performed; a representative autoradiogram is shown. (B) MOMP, HSP60-1, ICP-5, and 
ICP-8 proteins present in cell lysates from the experiment in panel A were quantified by 
phosphorimage analysis.  The integrated intensities were normalized to the internal control 




C. trachomatis co-infection does not significantly alter HSV-2 progeny virion release or viral 
ultrastructure.  
To determine whether chlamydial pre-infection altered subsequent viral replication, 
HSV-2 production/release from singly and co-infected cells was quantified using plaque assays 
(Fig. 2.6A). Mock-infected and C. trachomatis singly-infected cells produced no virions (Fig. 
2.6A). While co-infected cells appeared to release a greater quantity of HSV-2 progeny virions at 
the later time intervals (22-30 h post viral infection), at no time was there greater than 10% 
difference between the two groups. These data suggested that co-infection of HSV-infected 
HeLa cells with chlamydiae did not significantly affect HSV-2 replication kinetics or release of 
infectious HSV-2 progeny virions. 
It was possible that co-infection might have decreased HSV-2 virion production and 
increased release such that the supernatant virus levels would have appeared unaffected. 
Therefore, cell pellets and culture supernatants were collected at 20 h post-virus infection and 
used for virus titer assays. Total PFUs (plaque forming units) produced in each culture was 
determined by adding the cell-associated and supernatant virus titers; the data obtained from four 
independent experiments are plotted in Figure 2.6B. Again, the total amount of virus obtained 
from co-infected cells tended to be slightly higher than that obtained from HSV singly-infected 
cells; however, the difference was not statistically significant. These data indicated that 
chlamydial co-infection had little, if any, effect on HSV-2 replication. 
Viral morphology was also studied by TEM. In HSV-2 singly and co-infected cells viral 
capsids could be observed as early as 10 h post-infection (Fig. 2.2E). By 20 h post-infection, 
arrays of capsids were readily apparent in the nucleus of HSV-2 singly-infected and co-infected 
cells (Fig. 2.2I). Comparison of viral particles in singly and co-infected cells indicated that virion 
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morphology was unaltered by chlamydial co-infection (data not shown). Considered together, 
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Figure 2.6. Chlamydial pre-infection does not significantly effect HSV-2 replication or release. 
(A) HeLa cells were mock-infected (Mock), HSV-2-infected (HSV), C. trachomatis infected and 
C. trachomatis/HSV-2 co-infected (Ct-25/HSV) as described (Fig. 2.1A). Supernatants (sup) were 
collected from each group of cells 2, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30 hours post-HSV-2 
infection. Plaque assays were performed as described. Plaques were counted and the number of 
PFU per ml supernatant at the end of each time interval was calculated. These values were 
plotted in panel A.  C. trachomatis singly-infected supernatants were identical to the mock 
values and are not shown. (B) HeLa cells were infected as described (Fig. 2.1A). Culture 
supernatants and cell pellets were collected from each group of cells at 20 h post-HSV-2 
infection. Plaque assays were performed and the total number of PFU per culture was calculated 
by adding the values obtained for cell associated and supernatant virus. Average PFU/culture 
from 4 independent experiments ± the SEM were plotted on the histogram in panel B. 
 
Discussion  
While previous studies (Pontefract et al., 1989; Chiarini et al., 1996; Superti et al., 2001) 
suggested that HSV-2 co-infection alters the chlamydial developmental cycle, none of the 
previous studies determined whether a persistent chlamydial phenotype was induced. A number 
of experimental parameters have been used as “markers” of chlamydial persistence. These 
include: altered inclusion size, abnormal RB morphology, decreased progeny EB infectivity, 
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decreased MOMP and stable/increased HSP60 accumulation, unchanged DNA copy number, and 
decreased ftsK and/or ftsW expression (Beatty et al., 1994c; Darville, 2000; Hogan et al., 2004). 
However, down-regulation of ftsK and ftsW tend to be variable in the persistent state.  For 
example, accumulation of ftsK and ftsW RNA is reduced in C. trachomatis serovar K infected 
monocytes as well as in IFN-γ exposed C. pneumoniae (Byrne et al., 2001; Gerard et al., 2001).  
In contrast, Nicholson and Stephens demonstrated that in penicillin-exposed, C. trachomatis 
serovar D infected cells, ftsW remains unchanged while ftsK is elevated (Nicholson and Stephens, 
2002).  Finally, in C. pneumoniae continuous infection, ftsK expression is unchanged (Hogan et 
al., 2003).  It is likely that many “markers” of persistence vary according to the inducer, host cell, 
chlamydial species, and timing used (Hogan et al., 2004), which increases the importance of 
examining as many of the different markers as is feasible.  
Because most of the previously mentioned markers were observed during HSV co-
infection, it seems likely that HSV super-infection of C. trachomatis infected HeLa cells induces 
development of a persistent chlamydial state. By definition, persistent chlamydiae are viable but 
non-infectious.  As a result, transcription of unprocessed 16S rRNA continues during persistence 
and, thus, would be expected to remain unchanged compared to that in actively dividing, viable 
chlamydiae. The observation that accumulation of unprocessed 16S rRNA is unaltered but 
chlamydial infectivity is abrogated, thus, indicated that HSV co-infection renders the chlamydae 
viable but non-infectious, the hallmark of the persistent state. Because co-infected cells quickly 
die in culture (approximately 30 h post-HSV addition), this is not long-term persistence in the 
classical sense. However, because it is similar in many respects, we shall continue to refer to 
HSV-induced, chlamydial developmental changes as persistence. 
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An alternate interpretation of the observation that co-infection reduces chlamydial 
infectivity and MOMP expression is that HSV super-infection simply delays the chlamydial 
developmental cycle.  If HSV causes a chlamydial developmental cycle delay, one would expect 
chlamydial DNA replication to be slowed or halted. In contrast, persistent chlamydiae continue to 
replicate their chromosome (Gerard et al., 2001). Thus, the observation that chlamydial genome 
copy number was similar in co-infected and singly-infected cells strongly supports the conclusion 
that HSV super-infection of C. trachomatis infected HeLa cells induces development of 
chlamydial persistence rather than simply delaying the chlamydial developmental cycle. 
Additionally, delayed chlamydial development would not be expected to induce the alterations in 
EB morphology observed in co-infected cells. 
There are a number of mechanisms by which HSV-2 super-infection could induce 
chlamydial persistence. One simple explanation is that HSV-2-induced cell death aborts the 
chlamydial developmental cycle. Chlamydial morphologic alterations are observed as early as 5 
h post-HSV infection, much earlier than HSV-induced cell death usually occurs (Roizman and 
Knipe, 2001). Trypan blue staining experiments indicate that >99% of co-infected HeLa cells are 
viable at 20 h post-HSV infection (R.V. Schoborg, unpublished data). Also, TEM analysis of co-
infected cells at 20 hours post-HSV infection does not reveal any ultrastructural alterations 
associated with cell death. These observations argue that cell death is not inducing this effect.  
Amino acid starvation is a well-studied inducer of C. trachomatis persistence (Beatty et 
al., 1994c; Darville, 2000), suggesting that HSV-2 might “out-compete” the chlamydiae for 
cellular amino acid pools. However, persistent-like chlamydial morphological changes are 
observed at 5 and 10 h post-HSV addition, well before the bulk of HSV-2 protein synthesis 
occurs. Additionally, the HSV-2 VHS (virion host shut off) and ICP27 proteins act early in the 
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replication cycle to diminish host gene expression (Roizman and Knipe, 2001). Thus, at early 
times post-HSV infection, it seems likely that amino acids would be more readily available to 
support both HSV-2 and chlamydial replication. These observations reduce the likelihood that 
HSV-induced chlamydial persistence is simply an effect of amino acid depletion. 
A more interesting possibility is that a specific viral protein(s) could induce chlamydial 
persistence. If so, this protein is most likely a virion component or an early gene product because 
the effect is evident by 5 hours post-HSV infection. The HSV-2 VHS and ICP27 proteins are 
known to profoundly influence host cell gene expression. VHS is a virion component that 
suppresses host transcription beginning immediately after entry (Kwong et al., 1988). ICP27 is a 
viral inhibitor of host cell mRNA splicing/transport that is expressed early in the replication 
cycle (Smith et al., 1992; Sandri-Goldin and Mendoza, 1992; Hardy and Sandri-Goldin, 1994). 
Although either protein could induce chlamydial persistence, it is not likely to be due to their 
effects on host gene expression because cyclohexamide-exposure is known to enhance 
chlamydial development (Ripa and Mardh, 1977). 
A previously published study suggested that pre-infection of host cells with C. 
trachomatis increases HSV-2 replication by up to 40%, as quantified by IFA (Chiarini et al., 
1996). In contrast, we did not observe any difference in staining intensity or frequency in co-
infected compared to HSV singly-infected cells. Also, plaque assays show no significant 
difference in total virus production from singly and co-infected cells. Because any major effect 
of co-infection on viral replication would be readily visible as an increase or decrease in viral 





Induction of chlamydial persistence by HSV-2 co-infection has significant implications 
for pathogenesis. The presence of membrane blebs similar to those observed in chlamydia/HSV 
co-infected cells has been associated with release of chlamydial LPS from persistently-infected 
cells (Karimi et al., 1989; Wyrick et al., 1994; Wyrick et al., 1999). Because complications of 
chlamydial infection are thought to be due, at least in part, to release of inflammatory mediators 
from infected cells, any stimulus that increases release of these compounds might enhance 
disease pathology. Thus, it is possible that co-infection will result in increased release of 
inflammatory molecules and more severe immunopathology compared to that in an individual 
infected with either agent alone. 
Co-infection in vivo could also influence transmission or immunity to either organism.  
Both C. trachomatis and HSV-2 have been shown to modulate immune cell function. For 
example, HSV infection suppresses dendritic cell function (Pollara et al., 2003). C. trachomatis 
infection increases IL-11 production, which may suppress local immune responses and aid in 
establishment of infection (Dessus-Babus et al., 2000). It is easy to envision how an organism 
that manipulates the local immune response in the genital tract might also suppress or alter the 
host response to other pathogens that are present at the same time. Also, super- or co-infection 
could increase genital tract susceptibility or increase shedding of either organism by induction of 
inflammatory lesions in a manner analogous to that proposed in co-infections with HIV 
(Cameron et al., 1989; Plummer et al., 1991; Laga et al., 1993; McClelland et al., 2001; 
McClelland et al., 2002). Determination of the effect of co-infection on disease severity and 
transmission is dependent upon determination of the exact mechanism by which HSV interferes 
with the chlamydial developmental cycle and development of an animal co-infection model, 





Chlamydia, HSV-2, and host cells.  
A human urogenital isolate of C. trachomatis E/UW-5/CX was originally obtained from 
S.P. Wang and C. C Kuo (University of Washington, Seattle, WA). The same standardized 
inoculum of C. trachomatis serovar E elementary bodies, propagated in McCoy cells, was used 
for all experiments (Wyrick et al., 1996). Herpes simplex type 2 strain 333 stock was prepared in 
monolayers of CV-1 simian kidney cells using standard techniques (Duff and Rapp, 1971). 
 
Co-Infection experimental design.  
HeLa cells, a cervical adenocarcinoma epithelial cell line (ATCC #CCL2), were used for 
all infection experiments. They were propagated in MEM with Earle’s salts containing L-
glutamine, 10% fetal calf serum (Atlanta Biologicals), and 1 µg/ml gentamycin at 37oC in an 
atmosphere of 5% C02. HeLa cells were divided into four groups, 1 x 106 cells per 60 mm 
culture dish, for mock infection, chlamydial infection, HSV-2 infection, and both C. trachomat
and HSV-2 double infection (Figure 2.1A). Host cells were infected with a titer of crude EB 
stock (200 µl) calculated to infect 80% of the HeLa cells and with HSV-2 at a multiplicity of 
infection (MOI) of 10 PFU/cell; mock-infected cells were treated similarly except they were 
exposed to 200 µl of either 2SPG (0.2 M sucrose, 6mM NaH
is 
ral infection). 
2PO4, 15mM Na2HPO4, 5mM L-







Microscopy and image analysis.  
For fluorescence analyses, infected cells were fixed and permeabilized as described 
(Saltarelli et al., 1994). A pool of FITC-conjugated monoclonal antibodies generated against C. 
trachomatis MOMP (SYVA MicroTrak, Wampole Laboratories) was used to visualize 
chlamydial inclusions. Monoclonal antibodies against HSV-2 ICP5 (the major capsid protein; 
Virusys Corp.) and ICP8 (the viral DNA binding protein; Virusys Corp.) were combined, diluted 
1/200 in PBT buffer (1X PBS, 1% BSA, 0.05% Tween 20) and used to immunostain for HSV-2 
for 1 h at 37oC. After washing, HSV-2 antigens were visualized by staining with a Texas Red-
conjugated secondary anti-murine IgG (Jackson Immuno Research) diluted 1/100 in PBT buffer 
for 1 h at 37oC. Stained monolayers were washed, mounted, and photographed at 320X using a 
Zeiss Axiovert S100 inverted microscope and Axiocam camera. FITC-labeled cells were 
photographed at an exposure of 8 s using a FITC-band pass filter (excitation 470 nm and 
emission 540 nm); Texas Red-labeled cells were photographed at an exposure of 2 s using a 
Rhodamine-long pass filter (excitation 546 nm and emission 590 nm). 
Selected photomicrographs were subjected to image analysis using the Quantity One 
software package (Version 4.2.1, Biorad). The relative area of each fluorescent focus was 
determined using the software volume analysis function. Ten random fields (40-50 
inclusions/field) from each experimental group (mock, HSV-2-infected, C. trachomatis infected 
and co-infected cells) were analyzed blind and the average inclusion size for each set was 
determined. 
Duplicate samples of infected HeLa cells were processed at 5, 10, 15, and 20 h for high 
contrast transmission electron microscopy as described (Wyrick et al., 1994). Counterstained 
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gold thin sections were examined using a Tecnai 10 (FEI) transmission electron microscope 
operating at 60-80 kV. 
 
Chlamydial titrations by subpassage.  
At 20 hours post-HSV-2 infection, monolayers were scraped into 1 ml cold growth 
medium, pelleted, and resuspended in 1 ml fresh medium. Infected host cells were lysed by 
freeze/thaw and sonication and centrifuged (500 X g for 5 min) to pellet cell debris. Supernatants 
were centrifuged twice (8000 X g for 30 min). Control experiments demonstrated that >95% of 
the “contaminating” HSV-2 was removed by discarding supernatants from the two high speed 
centrifugation steps, while >75% of the input chlamydial EBs were recovered in the pellet (data 
not shown). Final EB pellets were resuspended in 200µl 2SPG, diluted (1/5 to 1/200) and used to 
infect HeLa cells plated on glass coverslips in triplicate. After infection, the HeLa monolayers 
were refed with medium containing 1µg/ml cyclohexamide and 400µM phosphonoformate 
(Cheng et al., 1981). Neither drug interferes with chlamydial inclusion development while 
completely abrogating productive replication of HSV-2 (data not shown). HeLa monolayers were 
incubated at 35oC for 48 h, fixed, and stained with SYVA stain as described above. The number 
of inclusions in 10 random microscopic fields per sample was determined using a Zeiss Axiovert 
S100 Microscope at 320X. Triplicate coverslips were counted and the counts averaged. The 
number of inclusion forming units (IFU) in the undiluted inoculum was then calculated and 
expressed as IFU/106 cells. 
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RNA and DNA isolation.  
 Total DNA and RNA were simultaneously isolated from the same plate of cells without 
manipulation of the cells before the lysis step using modifications to the RNeasy Mini (Qiagen) 
and QIAmp DNA Blood Mini (Qiagen) kits. After aspiration of the culture medium, 750 μl of 
RLT (lysis) buffer (RNeasy Mini Kit) was immediately added to each monolayer.  The plates 
were scraped and the lysate passed 10 times through a 20-gauge needle using a 1cc syringe.  Six 
hundred μl of cell lysate was used for total RNA isolation and DNase treatment using the Qiagen 
RNase-free DNase Kit following the manufacturer’s protocol.  One-hundred fifty μl of each cell 
lysate was diluted with 50 μl of 1XPBS and used for total DNA isolation as per the kit 
instructions.  Control experiments with known quantities of RNA and DNA demonstrated that 
this modification did not alter recovery efficiency or quality of isolated host cellular, chlamydial 
or HSV nucleic acids (data not shown).  Total RNA and DNA preparations were quantified using 
optical density (OD) at 260 and 280 nm; all samples had OD260/280 ratios > 1.9.  The 
concentration and integrity of each RNA sample was further confirmed by formaldehyde-agarose 
gel electrophoresis and ethidium bromide (EtBr) staining (data not shown). 
 
Reverse transcription, PCR and RT-PCR.   
One μg of total RNA was subjected to reverse transcription using SuperScript II RNase H 
minus reverse transcriptase (RT; Invitrogen) and random hexamer primers (Pharmacia) as per the 
manufacturer’s suggested protocol.  Each reaction also contained 20U of Super RNase Inhibitor 
(Ambion). Duplicate reactions containing ddH2O substituted for RT (RT – reactions) were 
performed in parallel.  PCR was performed using total cellular DNA or cDNA for RT+ and RT- 
reactions as appropriate.  Experimental template DNAs were used at dilutions ranging from 1/10 
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to 1/1000 (in ddH2O) such that each reaction was in the linear amplification range.   
Amplification was performed with MasterTaq (Eppendorf) under the manufacturer’s 
recommended reaction conditions. Human GAPDH, chlamydial dnaA and HSVG2 reactions 
were run without MasterTaq enhancer (Eppendorf); all other reactions contained enhancer at 1X 
concentration.  Published primer sets included chlamydial dnaA, ftsK, ftsW (Gerard et al., 2001), 
chlamydial 16S rRNA primary transcript (Gerard et al., 1997), and HSV-2 glycoprotein gene 2 
(HSV G2, Filen et al., 2004).  We designed specific primers for chlamydial CT-110/groEL-1 
(forward: 5′-GAG TTA AGA CTT TAG CTG AAG CTG T-3′, reverse: 5′-GTA GCT GTT GTA 
GTT CCG TCT CCA-3′), chlamydial 16S rRNA (forward: 5′-GGA CGG AAG TCT GAC 
GAA-3′, reverse: 5′-TCA AATCCA GCG GGT ATT-3′) and human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH- forward: 5′-GTC CAC CAC TGA CAC GTT G-3′, reverse: 
5′-GGG AAA CTG TGG CGT GAT-3′).  Most PCR reactions were heated to 94°C for 1 min and 
then cycled under the following conditions 30 times: 94°C, 1 min; 58°C, 1 min; 72°C, 1 min.  
Human GAPDH reactions were performed under identical conditions but were cycled 35 times; 
chlamydial dnaA PCR reactions were performed for 30 cycles but annealed at 54°C.  After PCR, 
all reactions were electrophoresed on 1.5% agarose/TBE gels.  Gels were stained with EtBr and 
visualized using a BioRad Chemi Doc XRS Image Capture System.  Amplimers were quantified 
on the image analysis system using Quantity One V4.5.0 software (BioRad).  
 
SDS-PAGE and western blotting.  
At various times post-HSV-2 infection, monolayers were lysed in 1 ml 1X PBS + 0.1% 
SDS + 0.1% Nonidet NP-40. Equal cell equivalents of each lysate (2x104 cells) were 
electrophoresed; gels were then Coomassie stained, fixed, and dried. Densitometric analysis 
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indicated that the variation in protein concentrations between samples was <5%. Total protein 
concentrations for each set of lysates were also determined using the Micro-BCA method 
(Pierce), which confirmed the results obtained by Coomassie stains (data not shown). For 
determination of relative protein accumulation, 1 x104 cell equivalents of each lysate were 
electrophoresed on 4-12% NuPage precast gels using the MES-SDS buffer system (Invitrogen). 
Gels were electrophoresed at 150V for 25 min and blotted to PVDF membranes (Pall, Inc.) for 1 
hour at 200mA. Blots were blocked in 1X PBS + 0.1% Tween 20 + 5% nonfat dried milk 
(BLOTTO) for 1 h at 25oC. Replicate blocked blots were incubated with a 1/1000 to 1/5000 
dilutions the following primary antibodies in BLOTTO: polyclonal goat anti-MOMP (OEM 
Concepts); polyclonal, monospecific rabbit anti-HSP60-1 (a kind gift from J. Raulston); 
polyclonal rabbit anti-human FAKC20 (SantaCruz Biologicals) or monoclonal antibodies against 
HSV-2 ICP5 or ICP8 (Virusys Corp.).  Blots were incubated for 1 h, washed 5 times in 1X PBS 
+ 0.1% Tween 20 (PBS-T), and reprobed with peroxidase-conjugated rabbit anti-goat, rabbit 
anti-mouse, or goat anti-rabbit secondary antibodies (Cappel) at 1/20,000 dilution. After 5 
additional washes, blots were subjected to chemiluminescent detection using SuperSignalWest 
Pico reagent (Pierce). Specific bands were quantified using an FX phosphorimager and Quantity 
One V2.5.0 software (BioRad). 
 
HSV-2 plaque assay.  
At various times post-HSV-2 infection, culture supernatants or frozen/thawed cell pellets 
were centrifuged at 4000 X g for 5 min and 4oC to remove cell debris. Plaque assays were 
carried out on the resulting supernatants as described (Duff and Rapp, 1971). Duplicate, infected 
cultures were incubated for 72 h at 37oC, fixed, stained, and counted in a blind fashion. Average 
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plaque counts from each set of duplicate plates were used to calculate the PFU/ml present in the 
original supernatant. 
 
Statistical analyses.  
Statistical analyses were performed using MiniTab (Version 9). Comparison of means 
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 Epidemiological studies have demonstrated that co-infections of herpes simplex virus 
type 2 (HSV-2) and Chlamydia trachomatis occur in vivo. Data from a tissue culture model of C. 
trachomatis/HSV-2 co-infection indicate that viral co-infection stimulates the formation of 
persistent chlamydiae. Transmission electron microscopic (TEM) analyses demonstrated that in 
both HeLa and HEC-1B cells co-infection caused developing chlamydiae to exhibit swollen, 
aberrantly shaped reticulate bodies (RBs), characteristically observed in persistence. 
Additionally, HSV-2 co-infection suppressed production of infectious chlamydial elementary 
bodies (EBs) in both host cell types. Co-infection with HSV type 1 (HSV-1) produced similar 
morphologic alterations and abrogated infectious EB production. These data indicate that virus-
induced chlamydial persistence was neither host cell nor virus strain specific. Purification of 
crude HSV-2 stocks demonstrated that viral particles were required for co-infection-induced 
chlamydial persistence to occur.  Finally, co-infection with either UV-inactivated, replication 
incompetent virus or with replication-competent HSV-2 in the presence of cyclohexamide 
reduced chlamydial infectivity without altering chlamydial genomic DNA accumulation. These 
data demonstrate that productive viral replication is not required for the induction of chlamydial 
persistence and suggest that HSV attachment and entry can provide the necessary stimulus to 




 Treatment of sexually transmitted diseases and their sequelae cost the United States 
billions of dollars each year.  Approximately 19 million people in the US were infected with a 
STD in 2000. Nearly half of those individuals were between the ages of 15 and 24 (Weinstock et 
al., 2004). Given the fact that several STD agents can establish chronic or latent infections, 
clinical management of STDs remains a challenge of epidemic proportions. Two of the most 
common sexually transmitted disease agents are Herpes Simplex Virus Type 2 (HSV-2) causing 
200,000-500,000 new infections annually and Chlamydia trachomatis serovars D-K causing 4 
million new infections annually (Weinstock et al., 2004; Butler, 1997).  
 Herpes Simplex Virus Type 1 (HSV-1) and HSV-2 are enveloped DNA viruses of the 
viral family Herpesviridae. Upon infection, herpes simplex viruses bind to the host cell receptor 
heparin sulfate. The initial binding event is followed by interaction of viral envelope 
glycoproteins with one of four known co-receptors that facilitate viral entry (Spear, 2004). Once 
inside the host cell, viral tegument proteins are released into the host cell and the capsid is 
transported to the nucleus, where viral genome replication occurs. The viral genome is 
transcribed and viral proteins are synthesized using host cell machinery.  New virions are then 
assembled and exit the host cell (Roizman, 2001).   
  Herpes Simplex Virus Type-2 is the primary cause of genital herpes infection. HSV-2 
infection usually occurs on the mucous membranes and skin surrounding the genitals causing a 
characteristic lesion. After primary infection, HSV-2 can establish a latent, life-long infection in 
the neurons of the sacral ganglia. On average, latent HSV-2 infections are reactivated five times 
each year. Upon reactivation, the virus travels through the neurons to the site of initial infection 
where it can be shed from skin lesions (Corey et al., 1983).  Although most genital HSV 
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infections are clinically mild, HSV-2 can also be responsible for serious diseases such as keratitis 
and meningitis (Roizman, 2001). 
 Chlamydia trachomatis is a Gram-negative, obligate intracellular bacterium that has a 
biphasic developmental cycle.  During the infectious phase of the cycle, chlamydiae exist as 
small, infectious, metabolically inert, elementary bodies (EBs).  The EBs attach and enter a host 
cell, where they differentiate within an inclusion into the non-infectious, vegetative form of the 
bacterium called the reticulate body (RB).  Once the RBs have completed several rounds of 
replication, they condense to form EBs.  The EBs are then released and can infect new host cells 
(Wyrick, 2000).  Genital chlamydial infections are often chronic and asymptomatic leading to 
severe complications including pelvic inflammatory disease, ectopic pregnancy, and infertility 
(Darville, 2000). 
  When developing chlamydiae are exposed to certain environmental factors, they deviate 
from the normal developmental cycle into a state called persistence (Hogan et al., 2004).  While 
in a persistent state, chlamydiae form large, abnormally shaped RBs. Although they remain 
viable, persistent chlamydiae are no longer infectious. Some of the most well studied inducers of 
chlamydial persistence include Interferon-γ (IFN- γ) exposure, amino acid and iron deficiencies, 
and exposure to penicillin G (Gerard et al., 2001; Darville, 2000; Raulston, 1997; Beatty et al., 
1994a).  
 Several studies have shown that C. trachomatis and HSV-2 co-infections occur in vivo. 
Both pathogens have been simultaneously isolated from women afflicted with endometritis, 
salpingitis, and cystitis (Paavonen et al., 1985; Tait et al., 1985).  Serologic investigations 
indicate that HSV-2 positive individuals are likely to be C. trachomatis positive as well (Silins et 
al., 2002; Paroli et al., 1990). Several studies have documented seropositivity rates of >50% for 
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both pathogens, implying that some of the individuals had been exposed to both HSV-2 and C. 
trachomatis (Wagner et al., 1994; Duncan et al., 1992). Although IgG seropositivity does not 
prove coexisting infection, there is a high probability that some of the individuals were infected 
simultaneously with both pathogens.   
 In vitro models of HSV-2/C. trachomatis co-infections have also been established. 
Transmission electron microscopy (TEM) analyses of Vero cells co-infected with C. trachomatis 
serovar L2 and HSV-2 revealed swollen inclusions with few RBs or EBs (Pontefract et al., 
1989).  Chiarini et al. reported that the number of cells positive for chlamydiae by 
immunofluorescence was reduced when HeLa cells were co-infected with HSV-2/C. trachomatis 
serovar D (Chiarini et al., 1996). The number of chlamydial inclusions and infectious EBs were 
also reduced in HSV-2 pre-infected HT1376 human bladder cells (Superti et al., 2001). Although 
these observations indicate that HSV-2 co-infection alters chlamydial development, these studies 
did not examine the co-infection process in detail.  
    Previously, we developed a tissue culture model of C. trachomatis and HSV-2 co-
infection. Data from these studies indicate that during C. trachomatis serovar E and HSV-2 co-
infection, chlamydiae become persistent.  Such data include abnormal ultrastructure and 
decreased production of infectious EBs.  Although less infectious, chlamydiae within HSV-2 co-
infected cells remain viable as demonstrated by continued accumulation of precursor 16S rRNA 
and chlamydial genomes (Deka et al., 2006).  However, the mechanism by which HSV-2 induces 
chlamydial persistence is currently unknown.  As a first step in defining how viral-induced 
persistence occurs, we have determined whether productive viral replication is necessary for 
induction of chlamydial persistence.  The present study will allow us to begin to unravel the 




HSV-2 induction of chlamydial persistence is not host cell type specific.  
Previous studies have shown that host cell interaction with chlamydiae can be a 
determining factor in the induction of chlamydial persistence. For example, IFN-γ induction of 
chlamydial persistence has been shown to occur in several host cell types, including HeLa cells 
(Hogan et al., 2003). However, developing chlamydiae within HEC-1B cells are resistant to IFN-
γ because these host cells do not produce indoleamine 2,3-dioxgenase in response to IFN-γ 
(Wyrick and Knight, 2004; Kane and Byrne, 1998). To be certain that induction of chlamydial 
persistence during HSV-2 co-infection is not a specific property of HeLa cells, HEC-1B cells 
were also used as host cells for co-infection. Duplicate monolayers of HeLa and HEC-1B cells 
were either mock, singly, or co-infected. Cells were collected 20 hours post-HSV-2 infection and 
processed for either TEM or chlamydial EB titration. Electron micrographs demonstrated that 
chlamydiae within both HeLa and HEC-1B co-infected cells exhibited abnormal RB morphology 
characteristic of persistence (Figure 3.1, B and E). EBs were absent from chlamydial inclusions 
within HSV-2 co-infected HeLa and HEC-1B cells (Figure 3.1, B and E). In contrast, in both C. 
trachomatis singly-infected cell types, RBs appeared normal and EBs were present (Figure 3.1, 
A and D). Furthermore, chlamydial EB titer assays indicated a significant decrease in the 
production of infectious EBs during HSV-2 co-infection in both host cell types (Figure 3.2, A 
and C) when compared to chlamydia singly-infected controls. Interestingly, singly-infected 
HEC-1B cells consistently produced higher titers of chlamydiae than did HeLa cells. These data 
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2µm12,500X
Figure 3.1: HSV co-infection induces persistent chlamydial morphology. Cultures of HeLa 
(Panels A, B, C, and F) or HEC-1B (Panels D and E) cells were C. trachomatis infected or co-
infected with C. trachomatis and HSV-2 strain 333 (Panels A, B, D, E, and F) or HSV-1 strain 
KOS (Panel C) at 10 MOI (Panels A, B, C, D, and E) or 1 MOI (Panel F). Cells were harvested 
for TEM analyses. Black arrows on electron micrographs indicate EBs and white arrows indicate 
RBs. 
 
HSV induction of chlamydial persistence is not virus specific.  
Although HSV-2 is the primary agent of genital herpes infection, Herpes Simplex Virus 
Type 1 (HSV-1) infections also account for many genital infections in vivo (Whitley, 2001). 
Therefore, the effect of HSV-1 co-infection on C. trachomatis development was examined. HeLa 
cell monolayers were co-infected with C. trachomatis serovar E and HSV-1 strain KOS as 
described. C. trachomatis singly-infected cells contained abundant EBs and RBs of normal 
morphology (Figure 3.1A). However, in HSV-1 co-infected cells, RBs were enlarged and 
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misshapen and few or no EBs were observed (Figure 3.1C). Chlamydial infectivity was also 
significantly reduced by HSV-1 co-infection compared to that in C. trachomatis singly-infected 
controls (Figure 3.2B). These data were indistinguishable from the results observed with HSV-2 
in HeLa cells (Fig 3.1B and Fig 3.2A), thus indicating that both HSV-2 and HSV-1 co-infection 




































































































































































































































































































Figure 3.2: HSV co-infection decreases chlamydial infectivity. Cultures of HeLa or HEC-1B 
cells were mock, C. trachomatis, or HSV singly-infected and C. trachomatis/HSV co-infected.  
Cells were harvested for EB titration assays. A. HeLa cells were co-infected with HSV-2 strain 
333 at 10 MOI. B. HeLa cells were co-infected with HSV-1 strain KOS at 10 MOI.  C. HEC-1B 
cells were co-infected with HSV-2 strain 333 at 10 MOI. D. HeLa cells were co-infected with 
HSV-2 strain 333 at, 0.1, 1, or 10 MOI.  EB titers are expressed as IFU/ml sample ± SEM; n=3. 
Asterisks (*) indicate titers that are significantly different (by t-test) compared to those from C. 





HSV-2 induction of chlamydial persistence is viral dose dependent.  
In order to ensure that every chlamydiae-infected cell was also infected with HSV-2, co-
infections were originally conducted using a viral MOI of 10 PFU/cell. To examine whether 
chlamydial persistence could be induced with lower concentrations of virus, co-infection 
experiments were performed using various MOIs of HSV-2. Triplicate HeLa cell monolayers 
were either mock, singly, or co-infected with C. trachomatis and HSV-2 at 10, 1, or 0.1 MOI. 
The cells were collected at 20 h post-HSV-2 infection and processed for TEM and chlamydial 
titration. Inclusions in C. trachomatis singly-infected cells contained normal developing EBs and 
RBs similar to those shown in Figure 3.1A.  In cells co-infected with C. trachomatis and HSV-2 
at 1 MOI, chlamydiae exhibited morphological characteristics of persistence (Figure 3.1F).  
Subpassage experiments revealed that HSV-2 co-infection at 10, 1, and 0.1 MOI significantly 
suppressed production of infectious EBs compared to that in C. trachomatis singly-infected cells 
(Figure 3.2D). Furthermore, the degree to which EB production was reduced correlated directly 
to increased viral MOI.  
 
Purification of HSV-2 does not diminish its capacity to induce chlamydial persistence during co-
Infection.  
It is well known that cellular host factors, especially the cytokines IFN-γ, IFN-α, TNF-α, 
can induce or enhance chlamydial persistence (Hogan et al., 2004).  Because the viral inocula 
used in this study were crude stocks, it is possible that these cytokines might be present in the 
HSV-2 stocks and could be responsible for the observed alterations in chlamydial development 
during co-infection. To test this possibility, crude lysates from either HSV-2 or mock-infected 
cells were subjected to centrifugal purification; the resultant purified components were used in 
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co-infection experiments with C. trachomatis. Four separate viral stocks were prepared: HSV-2 
crude, mock crude, purified HSV-2, and purified mock.  Luminex assays for IFN-γ, IFN-α, TNF-
α, and IL-6 were performed on both crude and purified stocks to determine; 1) whether these 
cytokines were present and 2) whether these cytokines were removed by this purification 
method. Although IL-6 has not been associated with chlamydial persistence, HSV infection is 
known to induce this cytokine, thus it serves as a positive control (Kanangat S, 1996 ). Of the 
four cytokines examined, only IL-6 was detected in viral stocks.  The HSV-2 crude and mock 
crude stocks contained IL-6 at 1,121 pg/ml and 2,835 pg/ml, respectively. IL-6 concentrations 
were reduced at least 43-fold by centrifugal purification (purified HSV-2, 26 pg/ml and purified 
mock, 38 pg/ml). These data demonstrate that the purification method used efficiently removed 
cytokines from the stocks and that IFN-γ, IFN-α, TNF-α cytokines known to alter chlamydial 
development were not present in any of the viral inocula used in this study.    
Co-infection with crude and purified viral stocks was performed as described. Data from 
chlamydial titer assays indicated that only HSV-2 crude and purified HSV-2 stocks significantly 
decreased infectious EB yield during co-infection (Figure 3.3). Neither the mock crude nor 
purified mock stock controls reduced chlamydial infectivity in “co-infected” cells compared to 
C. trachomatis singly-infected cells (Figure 3.3). These data indicate that co-infection-induced 
chlamydial persistence is not mediated by IFN-γ, IFN-α, or TNF-α present in viral stocks and 

































































































Figure 3.3: Purified HSV-2 co-infection decreases chlamydial infectivity. Cultures of HeLa cells 
were infected with C. trachomatis, or co-infected with chlamydia and HSV-2 crude stock, 
purified stock, mock crude stock, or mock purified stock at 10 MOI or the equivalent volume of 
mock stock. Cells were harvested for EB titration analyses. EB titers are expressed as IFU/ml 
sample ± SEM; n=3. Asterisks (*) indicate titers that are significantly different (by t-test) 
compared to those from C. trachomatis singly-infected cells (p<0.05). The data shown are 
representative of three independent experiments.  
 
Cyclohexamide exposure does not abrogate HSV-induced C. trachomatis persistence. 
Productive replication of HSV-2 within a host cell is dependant on host cell enzymes and 
machinery (Roizman, 2001). Cyclohexamide is a well known inhibitor of eukaryotic protein 
synthesis. By preventing host cell protein synthesis, cyclohexamide inhibits synthesis of viral 
proteins and prevents productive replication of HSV-2 (Vasquez, 1979; Swanstrom et al., 1975). 
In contrast, cyclohexamide actually enhances C. trachomatis development (Ripa KT, 1977). 
Therefore, cyclohexamide exposure was used to investigate whether productive viral replication 
is required to induce chlamydial persistence during co-infection with HSV-2. Monolayers of 
HeLa cells were either mock or chlamydiae infected, exposed to cyclohexamide, and HSV-2-
infected as described in the methods. Control experiments indicated that productive viral 
replication and viral protein synthesis was inhibited by >95% under these exposure conditions, as 
 75 
 
ascertained by plaque assays and S35-methionine incorporation (data not shown).  Co-infected 
cells exposed to either diluent (ddH2O) or cyclohexamide contained chlamydiae of abnormal 
morphology (Figure 3.4, B and E) in electron micrographs. Chlamydial inclusions in singly-
infected cells contained normal RBs and developing EBs regardless of cyclohexamide exposure 
(Figure 3.4, A and D).  As previously observed, the quantity of infectious EBs recovered from 
co-infected cells was significantly lower than that recovered from singly-infected cells (Figure 
3.4C). Cyclohexamide exposure during co-infection did not reverse this result (Figure 3.4F).  
D. Ct-25 + Cx E. Ct-25/HSV-2 + Cx
2µm12,500X
















































































































Figure 3.4: Co-infection with HSV-2 in the presence of cyclohexamide induces chlamydial 
persistence.  Cultures of HeLa cells were infected with C. trachomatis. At 23 hours post-
chlamydial infection the cells were refed with medium containing either diluent (ddH2O) (Panels 
A, B, and C) or1 µg/ml cyclohexamide (Panels D, E, and F) for 1 h. The cells were then infected 
with HSV-2 inoculum containing cyclohexamide or ddH2O. The cells remained under 
cyclohexamide exposure until they were harvested for TEM and EB titration analyses. EBs on 
electron micrographs are indicated by black arrows; RBs by white arrows.  EB titers are 
expressed as IFU/ml sample ± SEM; n=3. Asterisks (*) indicate titers that are significantly 
different (by t-test) compared to those from C. trachomatis singly-infected cells (p<0.05). The 





Co-infection with replication incompetent HSV-2 induces chlamydial persistence.  
Although cyclohexamide greatly reduces productive viral replication, it does not 
completely block replication (Sanfilippo, 2004; Vasquez, 1979; Swanstrom et al., 1975).  
Previous studies have demonstrated that UV-inactivation of HSV-2 renders the virus completely 
replication incompetent (Moxley, 2002). Replication incompetent HSV-2 (HSV-2UV) was 
generated using ultraviolet irradiation. A UV dose of 2.5 J/cm2 sufficiently inactivated the virus 
so that no infectious HSV-2 virions were detectable in plaque assays (data not shown). However, 
UV irradiation did not affect PCR amplification of HSV-2 DNA (data not shown).  
Duplicate HeLa cell monolayers were either mock, singly, or co-infected with C. 
trachomatis and HSV-2 or HSV-2UV. Infections with HSV-2UV were performed using a volume 
of stock equivalent to 10 MOI of replication-competent HSV-2. Infected cell monolayers were 
collected and assayed for chlamydial titer, TEM, and PCR analyses at 0 and 20 h post-HSV 
infection. Supernatants were also collected from each sample for plaque assay analyses of viral 
replication. Infectious viral particles were only recovered from cultures infected with replication-
competent HSV-2 (data not shown). Electron micrographs from chlamydia singly-infected cells 
depicted inclusions containing RBs of normal morphology and several developing EBs (Figure 
3.5A).  Alternatively, chlamydiae in HSV-2UV co-infected cells exhibited the same swollen, 
abnormally shaped RBs that were observed in cells co-infected with replication-competent virus 
(Figure 3.5, B and C). Additionally, co-infection with HSV-2UV  decreased production of 
infectious EBs similarly to that observed with replication-competent HSV-2 (Figure 3.5D).   
Total cellular DNA was isolated immediately following (To) and at 20 h (T20) post-HSV-
2 infection from singly-and co-infected cells from triplicate experiments and the accumulation of 
human, chlamydial, and HSV-2 DNA was determined by PCR. In each experiment, a six log 
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dilution series of known DNA template controls was used to generate amplification standard 
curves. Experimental samples were only quantified if they fell within the linear range of the 
PCR. Template negative samples were also included in every experiment; amplification in 
template-negative samples was never observed. Accumulation of host cell DNA as ascertained 
by human GAPDH amplification was similar in all samples (data not shown). Chlamydial 16S 
rRNA was only amplified in those samples infected with C. trachomatis. Likewise, HSV-2 gG 
DNA was amplified only in virus-infected samples (data not shown). Both chlamydial and HSV-
2 genomic DNA was normalized to host cell DNA after quantification.  The amount of HSV-2 
DNA increased from T0 to T20 in all the samples infected with replication-competent HSV-2 
(Figure 3.5E). However, the amount of HSV-2 DNA did not increase from T0 to T20 in those 
samples infected with HSV-2UV, indicating that there was no viral DNA replication during the 
infection (Figure 3.5E). It is important to note that the quantity of cell-associated HSV DNA at 
T0 is similar in HSV-2- and HSV-2UV -infected cultures (Figure 3.5E), demonstrating that UV 
exposure does not inhibit virus/host cell attachment.  Therefore, HSV-2UV viral particles were 
capable of attaching to the host cells but were unable to productively replicate. These data 
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Figure 3.5: Co-infection with HSV-2UV induces chlamydial persistence.  Cultures of HeLa cells 
were C. trachomatis-infected followed by infection with replication-competent HSV-2 at 10 
MOI or an equal amount of HSV-2UV.  Cells were harvested for TEM (panels A, B, and C), C. 
trachomatis titer analyses (Panel D) and total DNA isolation (panel E) at 0 or 20 h post-HSV 
infection. HSV-2 viral stocks were UV-inactivated by exposure to 2.5 J/cm2 UV irradiation at 
4oC; plaque assays demonstrate that HSV-2UV stocks contain no replication-competent virions 
(data not shown).  EBs on electron micrographs are indicated by black arrows; RBs by white 
arrows.  EB titers are expressed as IFU/ml sample ± SEM; n=3. Asterisks (*) indicate titers that 
are significantly different (by t-test) compared to those from C. trachomatis singly-infected cells 
(p<0.05). The data shown are representative of three independent experiments.  
 
Co-infection in the presence of cyclohexamide or with HSV-2UV does not alter accumulation of 
chlamydial DNA.   
Chlamydiae in a persistent state remain viable and continue to replicate their DNA 
although they do not divide (Gerard et al., 2001). Therefore, the amount of chlamydial DNA 
should not differ between persistent and normal chlamydial infections.  To ensure that 
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chlamydiae remain viable and that replication of chlamydial DNA is not halted by co-infection, 
HeLa cells were co-infected with HSV-2/C. trachomatis and the cells were harvested at both T0 
and T20 for PCR analyses. The quantity of chlamydial DNA amplified at T20 is significantly 
higher than that at T0, demonstrating that continued accumulation of chlamydial DNA occurred 
during HSV-2 co-infection (Figure 3.6A). These data show that both the analysis method is able 
to detect an increase in chlamydial DNA and that the chlamydiae remain viable.  
 Chlamydial DNA accumulation at T20 was also measured in co-infected cultures 
performed in the presence of cyclohexamide or with HSV-2UV.  PCR analyses demonstrated that 
there were similar amounts of chlamydial DNA in the singly and co-infected cells despite 
cyclohexamide exposure or HSV-2UV infection (Figure 3.6B). HSV-2 genome accumulation was 
also similar in HSV-2 singly and co-infected cells as previously observed (Deka et al., 2006). As 
expected, levels of HSV-2 DNA in co-infected cells exposed to cyclohexamide or infected with 
HSV-2UV were significantly decreased compared those in diluent-exposed/HSV-2 co-infected 
cells (data not shown). These results demonstrate that the chlamydiae within co-infected cells 
continue to accumulate genomic DNA in the presence of cyclohexamide or replication 






















































































































































Figure 3.6: Co-infection does not alter accumulation of chlamydial DNA. Total DNA was 
purified and subjected to PCR analyses using host genome (GAPDH), and chlamydial genome 
(16S rRNA gene) specific DNA oligonucleotides. Amplimers were electrophoresed and 
quantified as described. The data in panel A were quantified after conversion from Macintosh to 
Personal Computer format where as the data in panel B were quantified using the Macintosh 
format, thus causing differences in the intensity scales. Chlamydial DNA quantities were 
normalized to host DNA as ascertained by PCR with human GAPDH- specific primers (data not 
shown).  These data are representative of three independent experiments and are averages of 
three biological replicates. The average integrated intensity for each amplimer was plotted ± 
SEM. A. HeLa cells were co-infected with HSV-2/C. trachomatis. Total cellular DNA was 
collected at 0 (T0) and 20 (T20) h post-HSV-2 infection. B. HeLa cells were C. trachomatis 
infected, or co-infected with HSV-2, HSV-2UV, or HSV-2 in the presence of cyclohexamide. 
Total cellular DNA was collected at 20 h post-HSV infection.   
 
Discussion 
Chlamydiae that have deviated from the normal developmental cycle and exist in a 
viable, yet non-cultivable state are described as being persistent. Studies of chlamydial 
persistence have revealed several mechanisms by which developing chlamydiae are stimulated to 
enter this state. The most thoroughly investigated models of persistence include amino acid and 
iron deprivation, INF-γ exposure, and β-lactam antibiotic exposure (Gerard et al., 2001; Darville, 
2000; Raulston, 1997; Beatty et al., 1994a). In general, it seems that when chlamydiae are 
presented with an environmental factor that is unfavorable for their growth, they respond by 
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entering persistence.  Previous data from our laboratory indicate that viral co-infection also 
stimulates the formation of persistent chlamydiae as evidenced by abnormal RB morphology, 
and decreased chlamydial titer during co-infection (Deka et al., 2006).  In this study, we have 
further characterized HSV-2 co-infection-induced persistence. In particular, we have 
demonstrated that this phenomenon is not dependent on a specific host cell type or HSV strain. 
Additionally, our data indicate that productive viral replication is not required for the induction 
of chlamydial persistence.   
HSV-2/C. trachomatis co-infection has the potential to elicit several unfavorable 
environmental conditions for chlamydial growth, including amino acid deprivation and induction 
of IFN- γ.  One of the most obvious potential mechanisms for co-infection-induced persistence is 
that the virus simply exhausts cellular amino acids to synthesize viral proteins, thereby, 
depriving the chlamydiae of nutrients. UV-inactivation of HSV-2 prevents viral DNA replication 
and viral protein synthesis (Moxley, 2002).  Consequently, HSV-2UV would not be expected to 
deprive chlamydiae of amino acids by using them to manufacture viral proteins. Cyclohexamide 
also strongly inhibits HSV protein synthesis and enhances C. trachomatis development by 
inhibiting host cell protein synthesis (Ripa KT, 1977). However, cyclohexamide exposure during 
co-infection also did not prevent chlamydial persistence.  Therefore, it does not appear that HSV-
2 co-infection-induced chlamydial persistence is based upon simple amino acid deprivation.  
A second possible mechanism for co-infection-induced persistence is that HSV-2 
infection stimulates IFN-γ synthesis/release that, in turn, up-regulates indoleamine 2, 3-
dioxygenase and depletes cellular tryptophan. Without this source of tryptophan, chlamydiae 
would be expected to enter a persistent state (Hogan et al., 2004; Beatty et al., 1994b). However, 
chlamydiae exhibit characteristics of persistence within co-infected HEC-1B cells.  Previous 
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studies have demonstrated that chlamydiae do not respond to IFN-γ exposure in HEC-1B cells 
(Wyrick and Knight, 2004; Kane and Byrne, 1998).  Therefore, it is unlikely that IFN-γ-induced 
IDO activity is responsible for co-infection-induced persistence.  
In our studies, the reduction in C. trachomatis infectivity due to HSV co-infection was 
dose dependant. Despite the fact that HSV infection at 1 or 0.1 MOI does not productively infect 
all chlamydiae-infected host cells, chlamydial infectivity in these cultures was significantly 
reduced. These experiments might suggest the involvement of a factor secreted from HSV-
infected cells. However, HSV produces 50-200 defective viral particles for every replication-
competent virion (Roizman, 2001). Given the results obtained with UV-inactivated virions and 
cyclohexamide exposed co-infected cells, a more likely explanation is that defective virions in 
the HSV-2 inocula can alter chlamydial development in a manner similar to replication-
competent virions. 
Several studies have demonstrated that while UV-irradiation of HSV prevents productive 
replication, it does not inhibit virion associated functions such as attachment and entry 
(Sanfilippo and Blaho, 2006; Moxley, 2002). Plaque assays and PCR from co-infection 
experiments confirm these observations. Interestingly, co-infection with UV inactivated, 
replication incompetent HSV-2 alters chlamydial development similarly to that observed during 
co-infections with replication-competent virus. Likewise, cyclohexamide exposure decreases 
HSV-2 productive replication >95% but does not abrogate HSV-2-induced C. trachomatis 
persistence. These data indicate that productive HSV-2 replication is not required to stimulate 
chlamydial persistence. Rather, these results suggest that an early event in the viral replication 
cycle, most likely host cell attachment and entry is sufficient to force chlamydiae into a 
persistent state.  
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Both cyclohexamide exposure and UV-inactivation strongly inhibit de novo HSV protein 
synthesis, particularly those of the delayed-early and late kinetic classes. Although a small 
amount of immediate-early viral protein synthesis occurs in both cases, the magnitude is 
considerably diminished, particularly in the case of UV-inactivated virus. In contrast, viral 
attachment and entry are unaffected (Sanfilippo and Blaho, 2006; Sanfilippo, 2004; Moxley, 
2002; Vasquez, 1979; Swanstrom et al., 1975). However, co-infection with HSV-2UV induced 
chlamydial persistence, suggesting that de novo viral protein synthesis is not required.  Data 
obtained from cyclohexamide exposure experiments also support this interpretation. These 
experimental results suggest that chlamydial persistence in co-infected cells is induced by: 1) a 
virus/host cell binding event, 2) introduction of a virion associated protein into the host cell or, 
less likely, 3) expression of a viral immediately-early transcript. 
During viral attachment and entry, HSV binds to one of several co-receptors using the 
viral gD envelope glycoprotein (Spear, 2004). These co-receptors include herpes viral entry 
mediator (HVEM), Nectin-1, Nectin-2, and 3-O-Sulfated Heparan Sulfate (Spear, 2004). HVEM 
is a member of the tumor necrosis factor receptor family (Mauri et al., 1998). When complexed 
to its natural ligand, LIGHT, HVEM has been shown to stimulate cellular transduction pathways 
involved in the activation of T-cells (Granger and Rickert, 2003; Hsu et al., 1997). Nectin-1 and 
nectin-2 are members  of the Immunoglobulin superfamily and are involved in the formation of 
cell junctional complexes (Cocchi et al., 1998). When stimulated, nectins interact with cell 
signaling molecules, Cdc42 and Rac small G proteins, through their cytoplasmic tails to 
coordinate cytoskeletal rearrangements (Nakanishi and Takai, 2004).  Given these observations, 
it is feasible that stimulation of viral co-receptors by attachment of HSV-2 could transmit a 
cellular signal that has downstream effects on developing chlamydiae.   
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 HSV has also been shown to trigger cellular defense mechanisms by interacting with toll-
like receptors (TLR). TLR-2 is host cell surface exposed and appears to recognize herpes virion 
envelope glycoproteins.  For example, the gB envelope glycoprotein of human cytomegalovirus, 
a betaherpesvirus, provides sufficient stimulus to activate anti-viral responses through TLR-2 
(Compton et al., 2003).  Infection with varicella zoster virus, HSV-1, and HSV-2 can all 
stimulate IL-6 production in culture; this induction is TLR-2 dependant and does not require 
productive viral replication (Aravalli, 2005; Kurt-Jones, 2005; Wang, 2005).  TLR-2 knockout 
mice challenged with HSV-1 exhibit reduced production of inflammatory cytokines and 
diminished neuropathogenesis when compared to wildtype control animals, suggesting that 
HSV-mediated stimulation of the inflammatory response through TLR-2 occurs in vivo as well 
(Kurt-Jones et al., 2004).  Additionally, the intracellular toll-like receptor, TLR-9, is stimulated 
by unmethylated CpG motifs commonly found in HSV genomic DNA (Pyles, 2002). Although 
not definitive, these studies suggest the possibility that HSV-mediated stimulation of TLR-linked 
anti-viral or anti-chlamydial cascades could affect developing chlamydiae within co-infected 
cells.  
Another possibility is that viral transport within the cell, activity of a virion-associated 
protein or nuclear entry of viral DNA is responsible for inducing chlamydial persistence. After 
fusion with the cellular membrane, viral capsids interact with the molecular motor dynein and 
are transported along microtubules to the nucleus where capsids dock with nuclear pore 
complexes and translocation of the viral genome occurs (Ojala, 2000). Upon viral entry, active 
viral tegument proteins are released into the cytoplasm. One such protein, VP22, functions as a 
microtubule associated protein and induces reorganization of microtubules in the host cell 
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cytoplasm (Elliott, 1998), suggesting the possibility that HSV co-infection might alter or inhibit 
vesicular transport to the developing inclusion. However, inclusion size analyses revealed that 
chlamydial inclusions in co-infected cells are actually larger than those in C. trachomatis singly-
infected cells (Deka et al., 2006). These data suggest that viral-induced changes in host cell 
trafficking diminish neither vesicular transport to nor development of the inclusion.  Another 
virion protein, the HSV-2 virion host shut off protein (VHS), immediately suppresses host 
transcription by inducing degradation of host mRNAs (Roizman, 2001; Kwong, 1989).  VP16 is 
a virion protein that is transported to the nucleus and is involved in activation of both viral and 
host gene transcription (Roizman, 2001). Thus, it is also possible that the activity of one or more 
virion-associated proteins such as VHS and VP22 could either activate a cellular anti-chlamydial 
response or disrupt a cellular pathway that is required for normal chlamydial development, 
leading to persistence.  As stated above, another intriguing possibility is that viral nuclear entry 
or other viral nuclear functions that occur prior to immediate-early gene expression might alter 
chlamydial development in co-infected cells. Unfortunately, the limited information available 
regarding host nuclear functions required for normal chlamydial development makes it difficult 
to speculate upon which virus/host nuclear interactions might be required for this effect.  
Previous studies have confirmed the important role that chlamydia/host cell interactions 
play in the proper development of infectious chlamydial progeny. When these crucial host cell 
interactions are disrupted, chlamydiae often survive by becoming persistent (Gerard et al., 2001; 
Darville, 2000; Raulston, 1997; Beatty et al., 1994a).  Additionally, it appears that the host has 
evolved  “anti-chlamydial” pathways such as the IFN-γ/IDO system that when stimulated 
interfere with chlamydial development. The developing chlamydiae may then respond by 
becoming persistent (Hogan et al., 2004).  This study suggests that attachment and entry of HSV-
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2 may: 1) disrupt host cellular function, such that chlamydiae cannot complete the developmental 
cycle and/or 2) trigger a novel host anti-chlamydial pathway that restricts chlamydial 
development. Examination of the cellular pathways that are stimulated by HSV-2 attachment and 
entry during co-infection will further illuminate the mechanisms that C. trachomatis uses to exist 




Chlamydia, HSV-2, and host cells.  
A human urogenital isolate of C. trachomatis E/UW-5/CX was originally obtained from 
S.P. Wang and C. C Kuo (University of Washington, Seattle, WA).  The same standardized 
inoculum of C. trachomatis serovar E elementary bodies, propagated in McCoy cells, was used 
for all experiments (Wyrick, 1996). Herpes simplex virus type 2 strain 333 and HSV-1 strain 
KOS stocks were obtained from Mary K. Howett and Udayasankar Kumaraguru. Viral stocks 
were prepared in monolayers of Vero cells (African green monkey kidney cells ATCC#CCL-81) 
using standard techniques (Duff and Rapp, 1971). 
 
Co-infection experimental design.   
HeLa cells, a cervical adenocarcinoma epithelial cell line (ATCC #CCL2), or HEC-1B 
cells, an endometrial epithelial cell line (ATCC#HTB-113), were used for all infection 
experiments. In each experiment the appropriate host cells were divided into four groups, 1 x 106 
cells per 60 mm culture dish for mock infection, chlamydial infection, HSV infection, and both 
C. trachomatis and HSV double infection. In some experiments, HEC-1B or HeLa cells were 
polarized on 3.0 micron, Collagen IV coated chamber inserts (Biocoat 4544, Becton Dickinson) 
as previously described (Wyrick, 1989). The results obtained from co-infection in polarized host 
cells were identical to those obtained using non-polarized cells. Host cells were infected with a 
dilution of crude EB stock (200 µl) calculated to infect >80% of the cells. For most experiments 
the cells were infected with HSV-2, HSV-1, or an amount of replication incompetent HSV-2 
(HSV-2uv) equivalent to a multiplicity of infection (MOI) of 10 PFU/cell. In some experiments, 
HSV-2 infections were also conducted at 1 or 0.1 MOI. Mock-infected cells were treated 
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similarly except they were exposed to 200 µl of either 2SPG (0.2 M sucrose, 6mM NaH2PO4, 
15mM Na2HPO4, 5mM L-glutamine, pH 7.2; mock C. trachomatis-infected) or growth medium 
(mock viral infection). 
 
Cyclohexamide exposure during co-infection.  
In a selected group of co-infections, the infected host cells were exposed to 
cyclohexamide. Monolayers of HeLa cells were either mock or chlamydiae-infected. Twenty-
three hours post-chlamydial infection, 1µg/ml cyclohexamide or an equivalent volume of ddH2O 
(diluent exposed controls) was added to the growth medium.  Cells were incubated at 37oC for 
another hour, at which time they were either mock or HSV-2-infected. The viral inoculum also 
contained 1 µg/ml cyclohexamide or diluent (ddH2O). Following HSV-2 infection the cells were 
refed with medium again containing either 1 µg/ml cyclohexamide or ddH2O. The cells 




tion of replication incompetent HSV-2 (HSV-2UV).   
A  UV Crosslinker (Spectroline Microprocessor Controlled UV-Crosslinker Spectrolink
XL1500, Spectronics Corporation, New York) was used to generate stocks of UV-inactivated, 
replication incompetent HSV-2. Stock HSV-2 was thawed and 200 µl was aliquoted into each 
well of a 24 well plate. The plates were placed on a 4ºC heat sink during UV exposure to preven
heat inactivation of the samples. HSV-2 inactivation was assayed by performing plaque assa






HSV-2. A UV dose of 2.5 J/cm2 was found to be sufficient to completely inactivate 109 PFU of 
HSV-2. 
 
Purification of HSV-2 and mock-infected crude stocks.  
Viral purification was performed as described previously with the following 
modifications (Sathananthan, 1997). Duplicate flasks of Vero cells were either mock or HSV-2-
infected. The cells were monitored and collected when the virally infected cells began to exhibit 
signs of viral cytopathic effect. Each stock (mock and HSV-2-infected) was split into duplicate 
aliquots. The stocks were frozen/thawed to lyse the cells and centrifuged for 10 min (1000xg, a
4 C) to remove large cellular debris. The supernatant from one aliquot of the mock and HSV-2 
stocks was subaliquoted and stored at -80 C. The supernatant from the second aliquot of each 
stock was centrifuged again for 1 hr at 18,000 rpm (39,2000xg) in a Beckman JA-20 rotor. After 
centrifugation, the supernatants were removed and the pellets were resuspended overnight in 4ml 
growth medium without agitation.  The purified mock and HSV-2 stocks were subaliquo
t 
ted and 
stored at -80oC. Plaque assays were performed to determine the titer of each stock and to ensure 
 mock and purified mock stocks were free of contaminating HSV-2. 
o 
o
that both the crude
 
Luminex assay.    
Aliquots of crude, mock crude, pure, and mock pure HSV-2 stocks were examined for the 
cytokines IFN-γ, IFN-α, TNF-α, and IL-6 using the BioSource Multiplex Bead Immunoas
(BioSource International, Camarillo, CA) according to the manufacturer’s instructions.
were UV-irradiated as previously described before the assay was performed such that no 
infectious virion
say 
  Samples 
s were present in the samples.   A Luminex 100 instrument (Luminex 
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Corporation, Austin, TX) was used to measure the quantity of each cytokine bound to antibody 
coupled beads.  
 
Fluorescent and transmission electron microscopy.   
Fluorescence analyses were performed as described previously (Deka et al., 2006) exc
FITC-conjugated monoclonal antibodies generated against C. trachomatis MOMP (Pathfinder 
Chlamydia trachomatis monoclonal antibody 30702, BioRad) were used to stain chlamydial 
inclusions.  Duplicate samples of infected HeLa and HEC-1B cells were processed at 20 h post-
HSV infection for high contrast tran
ept 
smission electron microscopy as described (Wyrick, 1994).  
Counterstained gold thin sections were examined using a Tecnai 10 (FEI) transmission electron 
microscope operating at 60-80 kV. 
 
Chlamydial titrations by subpassage.  
Chlamydial titrations were performed as previously described (Deka et al., 2006) ex
that Pathfinder anti-chlamydial stain was used to stain chlamydial inclusions formed from 
subpassaged EBs. Inclusions present 
cept 
on triplicate HeLa cell monolayers were counted and 
veraged. The number of inclusion forming units (IFU) in the undiluted inoculum was then 




DNA isolation.  
Infected HeLa cells were collected at 0 h (T ) and/or 20 h (T ) post-HSV infection in 
200 µl medium and lysed by freeze/thaw. Total DNA from the resulting cell lysates was iso
using the QIAmp DNA Blood Mini Kit 
0 20
lated 
(Qiagen) according to the manufacture’s instructions.  
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Total DNA preparations were quantified using optical density (OD) at 260 and 280 nm; all 
had OD260/280 ratios > 1.9.   
 
samples 
 PCR.   
PCR was performed using purified total cellular DNA as template.  Experimental 
template DNAs were used at dilutions ranging from 1/10 to 1/1000 (in ddH O) such th
reaction was in the linear amplification range. PCR was performed using identical conditions to 
those previously described (Deka et al., 2006). Published primer sets included HSV-2 
Glycoprotein G (Filen et al., 2004) as well as chlamydial 16S rRNA and human glyceraldehyde-
3-phosphate dehydrogenase (Deka et al., 2006).  After PCR, all reactions were electrophoresed 
on 1.5% agaro
2 at each 
se/TBE gels stained with Ethidium Bromide.  A BioRad Chemi Doc XRS Image 
Capture System with Quantity One V4.5.0 software (BioRad) was used to visualize and quantify 
amplimers.   
 
HSV plaque assay.  
At various times post-HSV infection, culture supernatants were centrifuged at 400
for 5 min and 4 C to remove cell debris. Plaque assays were carried out on the resulting 
supernatants as described (Duff and Rapp, 1971).  Quadruplicate, infected cu
0 X g 
ltures were 
cubated for 72 h at 37oC, fixed, stained, and counted. Average plaque counts from each set of 




plates were used to ca
Statistical analyses.  
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Statistical analyses were perfor Excel. Comparison of means was 
done by
med using Microsoft 
 using a 2-sample t-test for independent samples.  P values of ≤ 0.05 were considered 
significant. 
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   Several inducers of chlamydial persistence have been described including Interferon-γ 
(IFN-γ), IFN-α, IFN-β, and tumor necrosis factor-α (TNF-α) exposure and iron, amino acid, or 
glucose deprivation.  A tissue culture model of C. trachomatis/Herpes simplex virus type-2 
(HSV-2) co-infection indicates that viral co-infection stimulates the formation of persistent 
chlamydiae. This study was designed to ascertain whether co-infection-induced persistence is 
mediated by a previously characterized mechanism. Luminex assays indicate that IFN-γ, IFN-α, 
and TNF-α are not released from co-infected cells. Semi-quantitative RT-PCR studies 
demonstrate that IFN-β, IFN-γ, indoleamine 2, 3-dioxygenase, lymphotoxin-α, and inducible 
nitric oxide synthase are not expressed during co-infection. These data indicate that viral-induced 
persistence is not stimulated by any persistence-associated cytokine.  Supplementation of co-
infected cells with excess amino acids, iron-saturated holotransferrin, glucose, or a combination 
of amino acids + iron does not restore chlamydial infectivity, demonstrating that HSV-2-induced 
persistence is not mediated by depletion of these nutrients.  Finally, inclusions within co-infected 
cells continue to enlarge and incorporate C6-NBD-ceramide, indicating that HSV-2 co-infection 
does not inhibit vesicular transport to the developing inclusion. Collectively these data 
demonstrate that co-infection-induced persistence is not mediated by any currently characterized 
persistence inducer or anti-chlamydial pathway. Previous studies indicate that HSV-2 attachment 
and/or entry into the host cell is sufficient for stimulating chlamydial persistence, suggesting that 





 Herpes Simplex Virus Types 1 and 2 (HSV-1 and HSV-2) are enveloped DNA viruses of 
the viral family, Herpesviridae. HSV-2 is the primary cause of genital herpes infection, causing 
200,000-500,000 new infections annually. HSV-2 infection usually occurs on the mucous 
membranes and skin surrounding the genitals, causing a characteristic lesion. After primary 
infection, HSV-2 can establish a life-long latent infection in the neurons of the sacral ganglia that 
is reactivated, on average, five times each year.  Although most genital HSV infections are 
clinically mild, HSV-2 can cause serious diseases including keratitis and meningitis (Roizman, 
2001). 
 Herpes simplex viruses begin their infection of epithelial cells by binding to the host cell 
receptor, heparan sulfate. After this initial binding, viral envelope glycoproteins interact with one 
of four known co-receptors (herpes viral entry mediator [HVEM], Nectin-1, 2, and 3-O-sulfated 
heparan sulfate), facilitating viral entry (Spear, 2004). Following fusion of the viral envelope 
with the host cell, viral tegument proteins are released into the cytoplasm and the capsid is 
transported to the nucleus, where viral genome replication occurs. The viral genome is 
transcribed and viral proteins are synthesized using host cell machinery.  New virions are then 
assembled and exit the host cell (Roizman, 2001). 
 Chlamydia trachomatis is a Gram-negative, obligate intracellular bacterium that is 
responsible for 4 million sexually transmitted infections each year in the US (Butler, 1997; 
Weinstock et al., 2004). Genital chlamydial infections are often chronic and asymptomatic, 
leading to severe complications including pelvic inflammatory disease, ectopic pregnancy, and 
infertility (Darville, 2000). In vivo and in culture, chlamydiae carry out a characteristic biphasic 
developmental cycle.  Extracellularly, chlamydiae exist as infectious elementary bodies (EBs). 
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EBs attach to and enter a host cell where they differentiate within an inclusion into non-
infectious reticulate bodies (RBs). The infectious cycle spans 30-72 hours (depending upon the 
chlamydial species/serovar). Near the end of the cycle, RBs develop back into EBs and are 
released from the infected host cell. When developing chlamydiae are exposed to certain adverse 
environmental factors (such as interferon-γ [IFN-γ] or penicillin G) or are deprived of nutrients 
(such as amino acids, iron, or glucose), they deviate from the normal developmental cycle into a 
state termed persistence (Hogan et al., 2004). Once in the persistent state, RBs continue to grow 
but do not divide, resulting in the formation of enlarged, abnormally shaped RBs. Though they 
remain viable and continue genomic DNA replication and rRNA synthesis, persistent chlamydiae 
are no longer infectious. Interestingly, persistent chlamydiae can reenter the normal 
developmental cycle and recover infectivity if the environmental stressor is removed. For 
example, nutrient deprived, persistent chlamydiae resume development into infectious EBs if the 
appropriate nutrients are replenished (Harper et al., 2000; Matsushima et al., 1999; Raulston, 
1997). 
 Several host cell pathways have evolved to limit the spread of chlamydial infections. In 
human cells, IFN-γ exposure increases host cell indoleamine 2, 3-dioxygenase (IDO) expression, 
leading to depletion of host cellular tryptophan. Without this essential amino acid, developing 
chlamydiae enter into persistence and cease productive replication (Beatty et al., 1994). In 
murine cells, IFN-γ exposure increases synthesis/activity of the p47 GTPase, Iigp1. Iigp1 inhibits 
chlamydial development by restricting vesicular trafficking to developing inclusions (Nelson, 
2005). IFN-α, IFN-β, and tumor necrosis factor-α (TNF-α) interfere with chlamydial 
development by induction of IDO, induction of inducible nitric oxide synthase (iNOS), and/or  
restriction of intracellular iron stores (Hogan et al., 2004; Matsushima et al., 1999). When iNOS 
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is up-regulated, the host cell produces nitric oxide (NO) that kills developing chlamydiae. 
Although these pathways are intended to eliminate the bacterial infection, chlamydiae are often 
able to survive the onslaught of the host cell’s arsenal by entering into a persistent state until 
conditions become favorable for their continued development.  
 Several studies have shown that C. trachomatis and HSV-2 co-infections occur in vivo 
(Paavonen et al., 1985; Tait et al., 1985).  In vitro models of HSV-2/C. trachomatis co-infections 
have indicated that HSV-2 co-infection alters chlamydial development; however, previous 
studies did not examine the co-infection process in detail (Chiarini et al., 1996; Pontefract et al., 
1989; Superti et al., 2001). Data from a tissue culture model of C. trachomatis and HSV-2 co-
infection established in our laboratory indicate that during C. trachomatis serovar E and HSV-2 
co-infection HSV attachment and or entry transmits a signal that interrupts the normal 
chlamydial developmental cycle and induces persistence (Deka et al, 2007). These, and other 
data, have lead us to hypothesize that HSV attachment to and/or entry activates a novel anti-
chlamydial defense pathway in mucosal epithelial cells.  
 
Methods 
Chlamydia, HSV-2, and host cells.  
A human urogenital isolate of C. trachomatis E/UW-5/CX was originally obtained from 
S.P. Wang and C. C Kuo (University of Washington, Seattle, WA).  The same standardized 
inoculum of C. trachomatis serovar E, propagated in McCoy cells, was used for all experiments 
(Wyrick et al., 1996). Herpes simplex virus type 2 strain 333 and HSV-1 strain KOS stocks were 
obtained from Mary K. Howett and Udayasankar Kumaraguru, respectively. Viral stocks were 
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prepared in monolayers of Vero cells (African green monkey kidney cells ATCC#CCL-81) as 
described (Duff & Rapp, 1971). 
 
Co-infection experimental design and nutrient supplementation.   
HeLa cells, a human cervical adenocarcinoma epithelial cell line (ATCC #CCL2), or 
HEC-1B cells, a human endometrial epithelial cell line (ATCC No. HTB-113), were used for all 
infection experiments. In each experiment, the appropriate host cells were divided into four 
groups for mock infection, chlamydial infection, HSV infection, and C. trachomatis/HSV double 
infection. Host cells were incubated with a dilution of crude EB stock calculated to infect >80% 
of the cells. Following an hour of adsorption, monolayers were refed with Minimal Essential 
Medium (MEM; Gibco) and incubated at 35 °C for either 4 or 24 h. Cultures were then infected 
with either HSV-2 or HSV-1 at a multiplicity of infection (MOI) of 10 PFU/cell. Mock-infected 
HeLa or HEC-1B cells were treated similarly except they were exposed to either 2SPG (0.2 M 
sucrose, 6mM NaH2PO4, 15mM Na2HPO4, 5mM L-glutamine, pH 7.2; mock C. trachomatis
infection) or growth medium (mock viral infection). In most experiments, monolayers were refed 
with MEM following HSV adsorption. For nutrient supplementation studies, cultures were either 
refed with MEM or MEM supplemented with excess essential and non-essential amino acids 
(Gibco), iron saturated holotransferrin (hTF; Sigma), glucose or a combination of amino acids 
and hTF as described in the legend to Supplementary Fig. 4.3. 
 
 
Luminex assay.    
Aliquots of culture supernatants were examined for IFN-γ, IFN-α, TNF-α, Granulocyte-
macrophage colony-stimulating factor (GM-CSF), and interleukin-6 (IL-6) using the BioSource 
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Multiplex Bead Immunoassay (BioSource International) according to the manufacturer’s 
instructions (Deka et al, 2007).   
 
RNA and DNA isolation.   
Total RNA and DNA were isolated simultaneously from experimental samples using the 
RNeasy Mini (Qiagen) and QIAmp DNA Blood Mini (Qiagen) kits as described (Deka et al., 
2006). Total RNA and DNA preparations were quantified using optical density (OD) at 260 and 
280 nm; all samples had OD260/280 ratios >1.9.   
 
 Reverse transcription, PCR and RT-PCR.  
 Reverse transcription of total RNA, PCR, and RT-PCR was performed using identical 
conditions to those previously described (Deka et al., 2006). PCR was performed using purified 
total cellular DNA or cDNA as a template.  Control and experimental template DNAs were 
diluted from 1/10 to 1/1000 (in ddH2O) and synthetic control DNA targets diluted from 10 to 0.1 
pg ml-1, insuring that each reaction was quantified in the linear amplification range. Published 
primer sets included chlamydial 16S rRNA, human glyceraldehyde-3-phosphate dehydrogenase 
and IDO (Deka et al., 2006; Nelson, 2005).  We designed specific primer sets and, in some 
cases, synthetic DNA targets for chlamydial trpA, human 18S rRNA, ifn-β, inf-γ, lymphotoxin-α, 
and inos (see Supplementary table 4-1 for sequences). All synthetic DNA targets and primer sets 
were designed using Ensembl and Vector NTI Advance V10 (Invitrogen). After PCR, all 
reactions were electrophoresed and quantified as described (Deka et al., 2006). 
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Griess reaction.   
Aliquots of select culture supernatants (50 µl) were examined for nitrite using the Griess 
Reagent System (Promega) according to the manufacturer’s instructions.  
 
Fluorescent  microscopy and image analysis.   
Fluorescence analyses were performed as described previously (Deka et al., 2006) except 
FITC-conjugated monoclonal antibodies generated against C. trachomatis major outer membrane 
protein (Pathfinder Chlamydia trachomatis monoclonal MOMP antibody #30702, BioRad) were 
used to stain chlamydial inclusions.  Images were captured using a Zeiss Axiovert S100 
microscope and Axiocam camera. Measurement of inclusion sizes was performed as described 
by Deka et al. (2006) except that selected photomicrographs were converted to grayscale using 
Adobe Photoshope V5.0. The relative area of each inclusion was determined using Dymension II 
Imaging Software V2.06 (SynGene).  
 
Cer6-NBD-ceramide labeling.  
HeLa cells were plated in 24 well plates (1.5x105 cells/well), and mock, singly, or co-
infected as described above.  At 16.5 h post-HSV-2 infection, cells were stained with 200 ug ml-1 
BSA pre-conjugated C6-NBD-ceramide stain (Molecular Probes) for 30 min at 4 °C. The stain 
was then back-extracted for 3 h at 37 °C until 20 post-HSV-2 infection (Alzhanov et al., 2007; 
Hackstadt et al., 1995). Cells were mounted with GelMount (Fisher) and examined by 
fluorescence microscopy using FITC filters. Images were captured as described above with a 4 s 




Chlamydial titrations by subpassage.  
Chlamydial titrations were performed as previously described (Deka et al., 2006) using 
Pathfinder anti-chlamydial stain (BioRad) to stain chlamydial inclusions formed from 
subpassaged EBs. The number of inclusion forming units (IFU) in the undiluted inoculum was 
then derived from triplicate counts and expressed as IFU ml-1. 
 
Spectro ferritin ELISA.  
Intracellular ferritin in cell lysates collected from mock-, chlamydiae-singly-infected +/- 
50 uM Desferal and C. trachomatis/HSV-2 co-infected cells was measured using the Spectro 
Ferritin ELISA kit (Ramco) as described in the legend to Supplementary Fig. 4.3. Addition of the 
iron chelating agent Desferal (Sigma) to chlamydiae-infected cultures was used as a positive 
control for iron depletion (Raulston, 1997). 
 
Statistical analyses.  
Statistical analyses were performed using Microsoft Excel. Comparison of means was 
done by using a 2-sample t-test for independent samples.  P values of ≤ 0.05 were considered 
significant.  All plotted values are averages of either eight or nine biological replicates divided 
between 3 individual experiments ± SEM.  
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Results and Discussion 
C. trachomatis/HSV co-infected cells do not produce cytokines known to alter chlamydial 
development.  
Cytokine exposure, in particular IFN-γ, is one of the most extensively studied 
mechanisms of inducing chlamydial persistence. However, other cytokines can also negatively 
affect C. trachomatis development. TNF-α, IL-1α and IL-1β can synergize with IFN-γ, lowering 
the concentration at which IFN-γ exposure affects developing chlamydiae (Carlin & Weller, 
1995; Shemer-Avni et al., 1988; Summersgill et al., 1995). Lymphotoxin-α (LT-α), TNF-α, and 
IFN- α/β exposure can also up-regulate iNOS expression and cellular NO production, inhibiting 
chlamydial development (Devitt et al., 1996; Matsushima et al., 1999).  Cycloheximide exposure 
experiments (Deka, 2007) suggest that HSV-induced persistence occurs in the absence of de 
novo host protein synthesis.  However, the observation that cycloheximide exposure did not 
completely abrogate host protein synthesis (Deka et al, 2007) made it important to confirm that 
“anti-chlamydial” cytokines were not released from co-infected cells. HSV-infected, human 
corneal epithelial cells produce IFN-β, as well as the cytokines TNF-α, interleukin-8 (IL-8), and 
IL-6 (Li et al, 2005). However, co-infected epithelial cells may produce cytokines that are not 
elicited by infection with either pathogen alone (or by other commonly used experimental 
stimuli, such as cytokine exposure). Therefore, production of all cytokines known to elicit an 
anti-chlamydial response was examined in triplicate mock, singly, or co-infected cultures as 
described in the methods. Twenty h post-viral infection, supernatants were collected and assayed 
for IFN-γ, IFN-α, TNF-α, GM-CSF, IL-1α/β and IL-6. IFN-γ, IFN-α, TNF-α, and GM-CSF were 
not detected in HeLa supernatants, regardless of infection status. IL-1α (11.1-13.4 pg ml-1), IL-
1β (34.7-46.9 pg ml-1), and IL-8 (1.7-3.6 pg ml-1) were detected, but at similar levels in C. 
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trachomatis singly-infected and co-infected HeLa cultures, indicating that they were unlikely to 
be involved in HSV-2-induced persistence. As expected, IL-6 was strongly induced by HSV-2 
infection and was increased in HSV singly and co-infected HeLa cultures compared to that in 
mock and C. trachomatis singly-infected cultures (Fig. 4.1a). However, in duplicate singly and 
co-infected HEC-1B cultures, similar quantities of IL-6 were detected in all experimental 
samples (Fig. 4.1b). Because HSV-induced persistence also occurs in HEC-1B cells, it is 
unlikely that IL-6 production stimulates HSV-induced persistence (Deka et al, 2007).  Co-
infection experiments using HSV-1 yielded similar results (data not shown). 
 Expression of IFN-γ, IFN-β, and LT- α mRNAs during co-infection was measured by 
semi-quantitative RT-PCR.  As shown in Fig. 4.1(c), ifn-γ, ifn-β, and lt-α were not expressed in 
mock, singly, or co-infected cells. Amplification of diluted synthetic DNA targets specific to the 
ifn-γ, ifn-β, and lt-α genes demonstrated that PCR reactions were sensitive and specific. Human 
18S rRNA targets were also amplified to ensure that the cDNAs were not degraded 
(Supplementary Fig. 4.1b). Amplification of a dilution series of control HeLa cell genomic DNA 
ensured that all 18S rRNA amplification reactions were quantified within the linear range of the 
PCR (Deka et al., 2006). All template negative (Fig. 4.1c) and RT(-) (data not shown) samples 
were negative, as expected.  Finally, all amplimers were the expected size and sequence (data not 
shown).  Taken together, these data indicate that HSV/C. trachomatis co-infection does not 






























































































































Figure 4.1: C. trachomatis/HSV co-infected cells do not produce cytokines known to alter 
chlamydial development. Concentration of IL-6 present in culture supernatants from mock-, 
singly- and co-infected HeLa (a) and HEC-1B (b) cells, as determined by Luminex assays. 
Cytokine concentrations are expressed as pg ml-1 ± SEM; n=3. Asterisks (*) indicate cytokine 
concentrations that are significantly different (by t-test) compared to those from C. trachomatis 
singly-infected cells (p<0.05). c. Total cellular RNA was subjected to semi-quantitative RT-PCR 
using primers specific to human ifn-β, ifn-γ and lt-α. A dilution series of synthetic DNA targets 
was amplified for each gene as a positive control. N=8. 
 
C. trachomatis/HSV-2 co-infected cells do not produce iNOS. 
The iNOS/NO pathway is another an important component of the anti-chlamydial 
defense (Devitt et al., 1996; Matsushima et al., 1999).  Although iNOS activity is not stimulated 
by either IFN-γ or chlamydial infection in cultured human epithelial cells (Roshick et al., 2006), 
the possibility that the additional stimulus provided by viral co-infection might activate 
iNOS/NO production in human cells is untested and should be evaluated. Therefore, C. 
trachomatis/HSV-2 co-infected cells were examined for iNOS mRNA up-regulation by semi-
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quantitative RT-PCR and for nitrite accumulation in supernatants using the Griess reaction. 
Neither iNOS mRNA nor nitrite was detected in any of experimental cell cultures 
(Supplementary Fig. 4.1a and data not shown), confirming that HSV-2-induced chlamydial 
persistence is not mediated by iNOS induction or NO production.  
 
Inclusions within co-infected cells continue to enlarge and incorporate C6-NBD-ceramide.    
In murine cells, IFN-γ exposure activates the p47 GTPase, Iigp1 that halts C. trachomatis 
development by interrupting sphingomyelin transport and vesicular trafficking to the inclusion. If 
C. trachomatis-infected murine cells are exposed to IFN-γ early in the developmental cycle, 
inclusions remain small (Nelson et al, 2005). Recent studies indicate that Iigp1 is up-regulated in 
HSV-1-infected murine cells at 3 hpi (Pasieka et al., 2006). Although a human Iigp1 homologue 
has not been identified, it is possible that HSV/host cell interaction activates human p47 
GTPases that function similarly. Therefore, C. trachomatis-infected HeLa cells were co-infected 
with HSV-2 at either 4 or 24 h post-chlamydial infection. Replicate cultures were harvested 
either immediately after HSV adsorption or 20 h post-HSV-2 infection. Monolayers were fixed, 
immunostained with anti-MOMP antibodies, and photographed and relative inclusion size was 
determined (Deka et al., 2006). Average inclusion size was similarly increased in both singly and 
co-infected cells over the course of the experiment when HSV-2 was added 4 h post-chlamydial 
infection (Fig. 4.2a). In cells co-infected with HSV-2 at 24 h post-C. trachomatis infection, the 
starting inclusion size was identical in both cultures. However, inclusions in co-infected cells 
were significantly larger than those in singly-infected controls after the 20 h HSV-2 infection 
period, as previously reported (Deka et al., 2006). Additional cultures were infected as described 
above, labeled with BSA-conjugated, C6-NBD-ceramide stain, and visualized by fluorescence 
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microscopy (Alzhanov et al., 2007; Hackstadt et al., 1995). No obvious difference was observed 
in the intensity or distribution of ceramide staining between chlamydial inclusions in singly and 
co-infected cells at either time interval tested (Fig. 4.2b and data not shown). Although it is 
possible that vesicular trafficking to the inclusion is subtly altered by HSV infection, these data 
demonstrate that neither gross vesicular trafficking nor sphingomyelin transport to the inclusion 
are disrupted by viral co-infection. 
 
Figure 4.2: Inclusions within co-infected cells continue to enlarge and incorporate C6-NBD-
ceramide. a. Cultures of mock-, singly- and co-infected HeLa cells were harvested immediately 
after HSV adsorption or 20 h later, fixed, subjected to IFA, and photographed at 320X. Relative 
inclusion size from 25 random fields was determined. Values are averages of triplicate 
determinations. Asterisks (*) indicate values that are significantly different (by t-test) compared 
to those from C. trachomatis singly-infected cells immediately post-HSV adsorption or a 
significant difference (**) between C. trachomatis singly-infected and co-infected cells at 20 h 
post-HSV infection (p<0.05)  b. Cells were C. trachomatis-infected, HSV-2 co-infected at 24 h 
post-chlamydial infection and C6-NBD-ceramide stained, as described. Cells were photographed 




 HSV-2 induction of chlamydial persistence is not mediated by IDO activity or global nutrient 
deficiencies.  
 Degradation of the essential amino acid tryptophan by the host enzyme IDO strongly 
induces chlamydial persistence (Hogan et al., 2004). In response to tryptophan deprivation, 
chlamydiae up-regulate expression of the tryptophan synthase gene, trpA (Belland et al., 2003). 
To determine whether or not our HeLa cell clone can express IDO, mock- and C. trachomatis-
infected HeLa monolayers were exposed to IFN-γ (50 U ml-1) for 48 h followed by RNA 
isolation. Expression of ido and trpA mRNA in IFN-γ-exposed control cultures was then 
evaluated by semi-quantitative RT-PCR. IDO expression was significantly increased in both 
mock- (data not shown) and C. trachomatis-infected HeLa cells in response to IFN-γ, compared 
to that in unexposed cells (Supplementary Fig. 4.2a). A significant increase in trpA expression 
was also observed in C. trachomatis-infected cells following IFN-γ exposure versus unexposed, 
chlamydiae-infected cultures (data not shown). 
To determine if co-infection similarly elevates ido or trpA levels, total RNA was isolated 
from triplicate sets of mock, singly, or co-infected HeLa cells and subjected to reverse 
transcription and semi-quantitative RT-PCR with primers specific for the human ido and 
chlamydial trpA genes. Again, amplification of a dilution series of cDNA from C. trachomatis-
infected, IFN-γ exposed HeLa cells indicated that the IDO RT-PCR was specific and sensitive. 
IDO mRNA was not detected in any of the experimental samples tested, regardless of infection 
status (Supplementary Fig. 4.2b). Various dilutions of chlamydial genomic DNA were amplified 
to ensure that all trpA amplification reactions were quantified within the linear range of the PCR 
(data not shown). Additionally, chlamydial genome copy number in each sample was determined 
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by amplification of the chlamydial 16S rRNA gene (data not shown). All trpA RT-PCR values 
were normalized to the chlamydial genome copy number (Deka et al., 2006). In contrast to trpA 
expression during IFN-γ exposure, no statistical difference in trpA expression was observed 
between C. trachomatis singly-infected and co-infected samples (Supplementary Fig. 4.2c). 
These data confirm that C. trachomatis/HSV-2 co-infected cells are not deprived of tryptophan 
by the action of IDO.  
 Global deprivation of amino acids and other nutrients, especially iron and glucose, can 
also cause developing chlamydiae to enter persistence (Harper et al., 2000; Raulston, 1997). To 
investigate the possibility that HSV-2 co-infection induces chlamydial persistence by limiting 
iron availability, we first determined whether co-infected cells were iron-deprived. Intracellular 
ferritin levels can be used as an indirect measure of host intracellular iron levels (Dill & 
Raulston, 2007). As a positive control for iron depletion, duplicate C. trachomatis-infected HeLa 
cultures were exposed to the iron chelating agent, Desferal, following chlamydial infection. 
Intracellular ferritin levels were not significantly reduced in chlamydiae singly-infected or co-
infected cells, compared to that in mock-infected controls (Supplementary Fig. 4.3a), indicating 
that co-infected cells were not iron-deprived. In contrast, Desferal exposure significantly reduced 
intracellular ferritin levels, as expected (Supplementary Fig. 4.3a). 
 During HSV-2 replication, cellular amino acids are depleted through the synthesis of 
viral proteins (Roizman, 2001). While it is possible that co-infection induces persistence by 
depriving the chlamydiae of amino acids, it remains unlikely, given previous data, that UV-
inactivated, replication-incompetent HSV-2 stimulates chlamydial persistence (Deka et al, 2007). 
However, several incoming HSV virion proteins such as the virion host shut off protein (VHS) 
produce significant host cellular physiologic alterations in the absence of viral replication 
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(Roizman, 2001). Thus, the possibility that viral infection induces nutrient depravation via an 
indirect pathway cannot be excluded. Notably, supplementation of nutrient-starved chlamydiae 
with amino acids, iron, or glucose reverses the negative effect of the nutrient deficiency (Hogan 
et al., 2004; Raulston, 1997).  Additionally, the anti-chlamydial effect stimulated by IFN-α can 
only be completely reversed by addition of both excess amino acids and iron (Devitt et al., 
1996). Based upon this information, we performed co-infection supplementation studies with 
excess amino acids, iron, glucose, or a combination of amino acids + iron. Immediately 
following HSV-2 infection, mock, singly, or co-infected cells were refed with MEM or MEM 
supplemented with a 5x concentration of both essential and non-essential amino acids, 6 mg ml-1 
iron-saturated holotransferrin (hTF), 450 mg ml-1 glucose, or a combination of 5X amino acids + 
6 mg ml-1 hTF. This concentration of hTF has been previously shown to rescue chlamydial 
infectivity in iron-deprived, infected epithelial cells (Raulston, 1997). Twenty hours after HSV-2 
infection, the monolayers were collected and processed for chlamydial titration. The titer of 
infectious EBs was significantly reduced in epithelial cells co-infected with HSV-2 compared to 
that from cultures singly-infected with C. trachomatis (Supplementary Fig. 4.3b). 
Supplementation of co-infected host cells with hTF did not rescue chlamydial infectivity 
(Supplementary Fig. 4.3b), indicating that supplementation with excess iron was not able to 
restore production of infectious chlamydial progeny during co-infection. Similar results were 
obtained with excess amino acids, glucose (Supplementary Fig. 4.3c), and a combination of 
amino acids + iron supplementation (data not shown).  These data demonstrate that co-infection-
induced chlamydial persistence is not mediated by limitation of amino acids, iron, glucose, or the 
combination of amino acids + iron within the host cell. Because the anti-chlamydial effect of 
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IFN-α is mediated by restriction of both tryptophan and iron, these results support previous data 
indicating that co-infection does not induce persistence through an IFN-α-dependent mechanism. 
 Collectively, these data demonstrate that co-infection-induced persistence is not mediated 
by: i) any known anti-chlamydial cytokine; ii) activation of iNOS or IDO; iii) inhibition of 
vesicular trafficking or sphingomyelin transport to the inclusion or; iv) amino acid, iron, or 
glucose deprivation. The reduction in chlamydial infectivity stimulated by HSV-2 co-infection is 
of smaller magnitude than that observed in other models of persistence (Beatty et al., 1994; 
Pantoja et al., 2001). Additionally, the negative effects of HSV-2 co-infection on chlamydial 
development are observed when the stimulus is added at 24h post-C. trachomatis infection, 
where as IFN-γ must be added to chlamydiae-infected cultures either before infection or very 
early during the developmental cycle for maximal effect (Nelson et al., 2005). Taken together, 
these observations support the hypothesis that HSV-2 co-infection induces C. trachomatis 
persistence through an undescribed and, therefore, novel mechanism.  
 Previously, we reported that both cycloheximide-exposure during co-infection with 
replication-competent HSV-2 and co-infection with UV-inactivated HSV-2 can stimulate 
chlamydial persistence, indicating that early events during HSV-2 infection are sufficient for this 
effect (Deka, 2007). During the host cell entry process, HSV binds to one of several co-
receptors: HVEM, Nectin-1, Nectin-2, or 3-O-sulfated heparin sulfate (Spear, 2004). Previous 
studies have demonstrated that each of these co-receptors can alter cellular signaling pathways 
when bound to their natural ligands (Granger & Rickert, 2003; Hsu et al., 1997; Mauri et al., 
1998; Nakanishi & Takai, 2004).  Therefore, HSV-2 attachment to the host cell during co-
infection could alter cellular signaling and activate a novel host anti-chlamydial response, 
leading to persistence. Another possibility is that HSV stimulates Toll-like receptors, initiating 
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such an anti-chlamydial pathway (Aravalli, 2005; Compton et al., 2003; Kurt-Jones, 2005; Pyles, 
2002; Wang et al., 2005). Conversely, there is the potential that viral tegument proteins, released 
into the cell during entry, could stimulate chlamydial persistence by altering the host 
cytoskeleton, degrading host mRNAs or altering host gene transcription (Elliott & O'Hare, 1998; 
Kwong & Frenkel, 1989; Roizman, 2001). Investigations of anti-chlamydial host cell responses 
have provided valuable information regarding C. trachomatis biology, pathogenesis, and its 
interactions with the host cell. Illumination of the mechanism behind HSV-2-induced persistence 
will allow us to evaluate the contribution of this novel anti-chlamydial response to C. 
trachomatis pathogenesis and host defense. 
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Supplementary Table 4.1: Semi-quantitative RT-PCR Primer and Synthetic 





















































132 Forward -5’ccttgtgcttgaggtggcca Reverse -5’acctcaagcagcatgttggc 105 
trpA N/A N/A Forward -5’atgtattggctatctaaccgctgg  Reverse -5’gggacttcttgattaaaagctcgg 234 
18S rRNA N/A N/A Forward - 5’cggacacggacaggattga Reverse - 5’gcatgccagagtctcgttcg 119 






















































Supplementary Figure 4.1: C. trachomatis/HSV co-infected cells do not produce nitric oxide 
synthase. Total cellular RNA from mock-, C. trachomatis and HSV-2 singly- and co-infected 
HeLa cells was used for semi-quantitative RT-PCR with primers specific to human inos (a) and 
18S rRNA (b). A dilution series of synthetic DNA targets or host genomic DNA served as an 




































































































































































Supplementary Figure 4.2: HSV-2 co-infection does not stimulate ido or trpA expression.  C. 
trachomatis-infected HeLa cultures were either exposed to diluent (-IFN-γ) or 50U ml-1 of IFN-γ 
(+IFN-γ) beginning immediately after infection. Total RNA was isolated at 48 h PI as described 
and subjected to RT-PCR using primers specific for human ido (a). Total cellular RNA was 
isolated from mock-, C. trachomatis and HSV-2 singly- and co-infected HeLa cultures for semi-
quantitative RT-PCR using primers specific to human ido (b) and chlamydial trpA (c). A dilution 
series of synthetic DNA targets (ido) or chlamydial genomic DNA (trpA) served as an 
amplification control for each gene. Chlamydial trpA and human ido amplimers were quantified 
as described and normalized to chlamydial (trpA) or host (ido) genome copy number (data not 





Supplementary Figure 4.3: HSV-2 induction of chlamydial persistence is not mediated by 
nutrient deprivation.  a. Cultures of HeLa cells were mock-, C. trachomatis singly-infected +/- 
Desferal or co-infected. Protein concentrations were standardized using the MicroBCA kit 
(Pierce) prior to analysis by ELISA. Ferritin concentration is expressed as ng ml-1 sample ± 
SEM; n=3. Asterisks (*) indicate ferritin concentrations that are significantly different (by t-test) 
compared to mock-infected cells (p<0.05).  b and c.  Cultures of mock-, C. trachomatis and 
HSV-2 singly- and co-infected HeLa cells were refed with either MEM (controls) or MEM + 
6mg ml-1 hTF, 5x (1.4 mM) essential and non-essential amino acids or 450mg ml-1 glucose 
following HSV-2 adsorption and harvested for EB titration at 20 h post-HSV-2 infection. EB 
titers are expressed as IFU/ml sample ± SEM; n=3. Asterisks (*) indicate titers that are 
significantly different (by t-test) compared to those from C. trachomatis singly-infected cells 
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When presented with certain unfavorable environmental conditions, C. trachomatis 
reticulate bodies (RBs) enter into a viable, yet non-cultivable state called persistence. Several 
models of chlamydial persistence have been described, including IFN-γ, IFN-α, IFN-β, and TNF- 
α-exposure and nutrient deprivation. Previously, we established an in vitro co-infection model of 
two common sexually transmitted pathogens, C. trachomatis and Herpes Simplex Virus-2. Data 
from this model indicate that: i) viral co-infection stimulates the formation of persistent 
chlamydiae and ii) productive HSV replication is not required for persistence induction. Other 
data indicate that co-infection-induced persistence is not mediated by any currently characterized 
anti-chlamydial pathway or persistence inducer. The present study demonstrates that co-
incubation of fixed, HSV-2-infected inducer cells with viable, C. trachomatis-infected responder 
cells suppresses production of infectious chlamydial progeny and stimulates the formation of 
swollen, aberrantly shaped RBs. Though chlamydial infectivity is initially suppressed, infectivity 
recovered within 44hr during long-term co-infection with UV-inactivated HSV-2, demonstrating 
that HSV-induced persistence is reversible. Pre-incubation of viral particles with gD specific 
neutralizing antibody prevents co-infection-induced persistence, suggesting that HSV gD 
interaction with host cell surface receptors provides the necessary stimulus to alter C. 
trachomatis development. Finally, exposure of C. trachomatis infected cells to a soluble, 
recombinant HSV-2 gD:Fc fusion protein decreases production of infectious EBs to a similar 
degree observed in co-infected cultures. Thus, we conclude that interaction of HSV gD with the 
host cell surface triggers a novel host anti-chlamydial response that restricts chlamydial 




      Herpes simplex virus type 2 (HSV-2) and Chlamydia trachomatis are two of the 
leading sexually transmitted disease agents in the United States (Weinstock et al., 2004; Butler, 
1997). Several studies have shown that C. trachomatis and HSV-2 co-infections occur in vivo 
(Paavonen et al., 1985; Tait et al., 1985). In one study, examination of cervical biopsy samples 
indicated that approximately 10% of women were positive for C. trachomatis, HSV and HPV 
(Finan et al., 2006). In vitro models of HSV-2/C. trachomatis co-infections have indicated that 
HSV-2 co-infection alters chlamydial development; however, the mechanism by which this 
occurred was not defined (Superti et al., 2001; Chiarini et al., 1996; Pontefract et al., 1989).   
Herpes Simplex Virus Types 1 and 2 (HSV-1 and HSV-2) are enveloped DNA viruses of 
the viral family Herpesviridae. HSV-2 is the primary cause of genital herpes infection, causing 
200,000-500,000 new infections annually. Although predominantly associated with oral 
infections, HSV-1 is a common agent of genital herpes infections as well (Whitley, 2001).  
Primary genital herpes infections usually occur on genital mucous membranes or the surrounding 
skin, causing a characteristic vesicular lesion. After primary infection of epithelial cells, HSV 
infects nearby sensory nerve endings and establishes latent infection in the sacral ganglia. Latent 
infections can be reactivated by numerous stimuli such as emotional or physical stress, fever, 
tissue damage, and immune suppression. Upon reactivation, virions are transported by infected 
neurons to the site of primary infection where they re-infect the epithelial cells in that area. Skin 
lesions often occur during recurrent infections; however, virions can also be shed in the absence 
of noticeable symptoms (Whitley, 2001; Mertz et al., 1992). On average, reactivations occur at 
least five times each year (Corey et al., 1983). Most genital HSV infections are not severe; 
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however, HSV-2 infection can causes keratitis, meningitis, and disseminated neonatal HSV 
infection (Roizman, 2001).  
Infection of a host cell by HSV is initiated by a series of interactions between envelope 
glycoproteins and the host cell surface. First, glycoproteins B (gB) and gC bind to heparan 
sulfate. Second, the viral gD binds one of several host co-receptors (Spear, 2004). Once gD and 
the appropriate co-receptor interact, the viral gH/L complex mediates fusion of the viral envelope 
and the host cell plasma membrane. Once the viral capsid enters the host cell, viral tegument 
proteins are released. Viral transcription and genome replication occur in the nucleus and viral 
proteins are synthesized using host cell machinery. New virions are assembled in the nucleus bud 
through viral glycoprotein-enriched areas of the nuclear envelope and exit the host cell through 
vesicular transport (Roizman, 2001). 
All chlamydiae are Gram-negative obligate intracellular bacteria and share a unique 
biphasic developmental cycle. Extracellularly, chlamydiae exist as small (0.3µm), infectious, 
metabolically inert forms of the bacteria termed elementary bodies (EBs).  EBs attach to host 
cells and enter via receptor mediated endocytosis (Abdelrahman and Belland, 2005; Wyrick, 
2000). Once inside the host cell, chlamydiae containing vesicles escape lysosomal fusion and are 
transported to the perinuclear region. Here the EB differentiate within a modified vacuole called 
an inclusion into larger (1µm), non-infectious reticulate bodies (RBs).  Reticulate bodies are 
metabolically active and will undergo 8-12 rounds of replication. Following replication, RBs 
condense to form EBs, which are released and can infect new host cells (Wyrick, 2000). C. 
trachomatis serovars D-K represent the world’s most reported sexually transmitted disease 
agents causing urethritis or cervicitis. Approximately 85-90% of chlamydial infections are 
asymptomatic and chronic, resulting in endometritis, salpingitis, and pelvic inflammatory 
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disease. The damage sustained by the host response to C. trachomatis infections promotes the 
development of more severe disease sequelae including ectopic pregnancy, infertility, and 
reactive arthritis (Peipert, 2003).  
In addition to growth in the normal developmental cycle, chlamydiae have evolved a 
mechanism to sustain life during adverse conditions (Harper et al., 2000). When developing 
chlamydiae are exposed to certain environmental insults, they deviate from the normal 
developmental cycle into a state called persistence (Hogan et al., 2004). Persistence is 
traditionally defined as a viable but non-cultivable form of chlamydiae (Beatty et al., 1994). 
Persistent chlamydial forms appear as swollen, diffuse, and aberrantly shaped RBs upon 
examination by transmission electron microscopy (TEM). While in the persistent state, RBs 
continue to grow and replicate chromosomes but fail to divide, resulting in the persistent 
morphology. The abnormal RBs do not differentiate into EBs; thus, causing a decrease in 
progeny EB infectivity (Beatty et al., 1994; Beatty et al., 1993; Byrne et al., 1986; Johnson and 
Hobson, 1977; Matsumoto and Manire, 1970). Evidence from several studies strongly suggests 
that chlamydiae do enter the persistent state in vivo (Gerard et al., 2002; Bragina et al., 2001; 
Gerard et al., 2001; Dean et al., 2000; Fortenberry et al., 1999; Nanagara et al., 1995; Patton et 
al., 1994). Several models of persistence have been examined in culture, including: antibiotic 
exposure, monocyte infection, nutritional deficiencies, and cytokine (IFN-γ) exposure (Gerard et 
al., 2001; Darville et al., 2000; Raulston, 1997; Beatty et al., 1994) 
 Characterization of a tissue-culture model of HSV and C. trachomatis co-infection 
indicates that co-infection stimulates chlamydiae to become persistent as evidenced by: i) 
decreased production of infectious EBs; ii) abnormal RB morphology; and iii) continued 
accumulation of chlamydial chromosomes and the expression of chlamydial 16S rRNA primary 
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transcripts (Deka et al., 2006). In addition, co-infection-induced persistence is not mediated by 
any previously characterized anti-chlamydial pathway or persistence inducer (Vanover et al., 
2008). In this study we will present data that suggest that interaction of the viral glycoprotein gD 
with host co-receptors activates a novel anti-chlamydial defense pathway in mucosal epithelial 
cells resulting in development of chlamydial persistence. 
 
Results 
Chlamydial infectivity recovers following long-term co-infection with UV-inactivated HSV-2 
(HSV-2UV)  
Under constant stimulus, persistent chlamydiae can be sustained in culture for long 
periods of time (Byrne et al., 1989; Matsumoto and Manire, 1970). Additionally, chlamydiae 
recover infectivity following removal of the persistence inducer. For example, when Penicillin G 
is removed from the culture medium, RBs resume normal development and production of 
infectious progeny is restored (Matsumoto and Manire, 1970). Replacement of deficient/depleted 
nutrients also allows recovery of chlamydial infectivity (Harper et al., 2000; Raulston, 1997; 
Coles et al., 1993). Finally, IFN-γ-induced persistence is also reversible with the addition of 
exogenous tryptophan to the culture medium (Belland et al., 2003; Beatty et al., 1994). Previous 
data indicate that co-infection with UV-inactivated HSV-2 (HSV-2UV) induces persistence (Deka 
et al., 2007). HSV-2 UV is both replication incompetent and nonlethal to infected cells (Moxley et 
al., 2002). This property of HSV-2UV was exploited to study the long-term effects of co-infection 
on C. trachomatis serovar E development. 
 Triplicate HeLa cell monolayers were either mock, singly, or co-infected with C. 
trachomatis and HSV-2UV. Cultures were refed with fresh medium containing 1µg/ml 
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cyclohexamide (Cx) following HSV-2UV infection and every 48hpi thereafter. Cyclohexamide 
was added to the medium to prevent cell overgrowth and does not interfere with HSV-induced 
persistence (Deka et al., 2007).  Replicate samples were harvested at 20h (Day1), 68h (Day 3), 
and 140h (Day 6) post-HSV-2UV infection and processed for total DNA isolation and chlamydial 
titration as described in the Experimental Procedures. HSV and chlamydial genome 
accumulation was determined by semi-quantitative PCR; human GAPDH was amplified as an 
internal control (Deka et al., 2006). Dilution series of HSV-2, chlamydial, and HeLa cell DNA 
were amplified as positive controls to insure that results were quantified within the linear range 
of the PCR (Deka et al., 2006). HSV DNA was not amplified in any of the HSV-infected 
samples (Fig. 5.1A), indicating that viral replication was inhibited during co-infection with HSV-
2UV. Plaques assays also indicated that no viral replication occurred during the course of the co-
infection with HSV-2UV (data not shown). Also, the amount of chlamydial DNA in chlamydia 
singly-infected and co-infected cultures was equivalent (Fig. 5.1A). However, the amount of 
infectious EBs produced in the co-infected cultures on Day 1 was significantly lower than that in 
the C. trachomatis singly-infected cultures (Fig. 5.1B) as previously observed (Deka et al., 
2007). In contrast, EB production in HSV-2UV/C. trachomatis samples collected on Days 3 and 6 
was not significantly different from those in chlamydia singly-infected samples. These data 
indicate that chlamydiae can recover infectivity if incubated for more than 24h following a single 

































































































Figure 5.1: Chlamydial infectivity recovers during long-term co-infection with UV-inactivated 
HSV-2 (HSV-2UV).  Hela cell monolayers were either mock, singly or co-infected with C. 
trachomatis and an amount of HSV-2UV equivalent to 10 MOI replication competent HSV-2. 
Replicate samples were harvested at 20h (Day1), 68h (Day 3), and 140h (Day 6) post-HSV-2UV  
infection and processed for DNA isolation (Panel A) and chlamydial titration (Panel B). A. Total 
DNA was used to determine relative HSV (HSV G2), chlamydial (Ct 16S rRNA gene) and host 
(GAPDH) genome accumulation in co-infected cells by PCR. A dilution series of purified HSV-
2, C. trachomatis or HeLa DNA was amplified to insure that results were quantified within the 
linear range of the PCR (not shown). Results shown are representative of three biological 
replicates. B. Cells were harvested for EB titration analyses. EB titers are expressed as IFU/ml 
sample ± SEM; n=3. Asterisks (*) indicate titers that are significantly different (by t-test) 





HSV-2-induced chlamydial persistence may be triggered by interaction of viral glycoproteins 
with host cell surface receptors. 
Co-infection with either HSV-2UV or with replication-competent HSV-2 in the presence 
of cyclohexamide triggers chlamydial persistence, indicating that productive viral replication is 
not required for this phenomenon (Deka et al., 2007). To determine whether viral 
glycoprotein/host receptor interactions alone induce persistence we performed co-incubation 
studies. These experiments are based on the observation that molecules present on the surface of 
fixed cells can interact with molecules on the surface of live responder cells causing signal 
transduction pathways to be activated (Savage et al., 1991). HeLa cell monolayers were either 
mock- or HSV-2- infected for 20h; at which time HSV envelope glycoproteins are expressed on 
the infected host cell surface (Roizman, 2001 and Fig. 5.2A). These monolayers were 
paraformaldehyde fixed using conditions which preserve protein structures on the host cell 
surface (Savage et al., 1991) but inactivate all infectious virions present in these cultures. These 
fixed cells were used as either mock (MI) or HSV-infected (HI) inducer cells in subsequent co-
incubation experiments. To confirm the presence of viral glycoproteins on the surface of  fixed 
inducer cells, replicate MI and HI cultures were immunostained with α-HSV glycoprotein 
antibodies + AlexFlor 488 conjugated secondary antibody. As an irrelevant antibody control, 
cells were also immunostained with α-Salmonella Common Antigen (α-Sal; Millipore). 
Immunofluorescent photomicrographs demonstrate that HSV gB, gC, gD, and gH are all present 
on the surface of the paraformaldehyde fixed HI (Fig. 5.2A). In contrast, no glycoprotein staining 
was observed on the surface of MI (Fig 5.2A), nor was staining observed in HI and MI cultures 
stained with secondary antibody alone (data not shown).  
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Duplicate viable HeLa cell monolayers were either mock (not shown) or chlamydiae-
infected. At 24hpi viable mock or chlamydiae-infected responder cells were overlayed with MI 
or HI cells at a ratio of 5 fixed inducer cells/1 viable responder cell. The cells were co-incubated 
for 20h (Day 1) and then harvested for EB titration analysis or transmission electron microscopy 
(TEM). C. trachomatis singly-infected and co-infected HeLa cultures were also prepared as 
positive controls. Replicate co-incubated cultures were also harvested at 44h (Day 2), 68h (Day 
3), and 140h (Day 6) and processed for chlamydial titration. As expected, HSV-2 co-infection 
significantly reduced infectious EB production compared to that from singly-infected cells (Fig. 
5.2B). Co-incubation of fixed, HI cells with viable C. trachomatis-infected responder cells for 
20h similarly reduced chlamydial infectivity (Fig. 5.2B). However, EB production in HI co-
incubated samples recovered by Day 2 (44h) and was no longer significantly different from MI 
co-incubated samples by Day 3 (Fig. 5.2B). Electron microscopic studies (Fig. 5.2C) indicate 
that RB within C. trachomatis-infected responder cells co-incubated with HI cells for 20h 
became swollen and misshapen, typical of persistent chlamydiae (Fig. 5.2C, gray arrow). 
Conversely, co-incubation of MI cells with chlamydiae-infected responder cells did not alter the 
morphology of developing RB (Fig. 5.2C, White arrow) or prevent EB development (Fig. 5.2C, 
Black arrow). Importantly, both viral plaque assays and viral DNA PCR studies indicate that: i) 
no viable HSV was present and ii) no HSV replication occurred in co-incubated cultures (data 
not shown). These data suggest that interaction between HSV-2 virion glycoproteins and their 
cognate host cell receptors is sufficient to stimulate chlamydial persistence and confirm that 
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Figure 5.2: Co-Incubation of HSV-2-infected fixed inducer cells with C. trachomatis-infected 
responder cells.  A. Mock (MI) or HSV-2-infected (HI) inducer cells were paraformaldehyde 
fixed and immunostained with α-Sal, α-gB, α-gC α-gD, or α-gH NuAb + AlexFlor 488 
conjugated secondary antibody. Photomicrographs are 320X magnification. B. MI or HI inducer 
cells were co-incubated with mock or chlamydiae-infected responder cells for 20h (Day 1), 44h 
(Day 2), 68h (Day 3), and 140h (Day 6) and then harvested for EB titration analysis. C. 
trachomatis singly-infected and co-infected HeLa cultures were prepared as positive controls. 
Asterisks (*) indicate titers that are significantly different (by t-test) compared to those from 
either C. trachomatis singly-infected cultures (for Ct/HSV controls) or C. trachomatis + mock 
inducer cultures (for HI+Ct samples) (p<0.05). C. Co-incubated cultures were harvested at 20h, 
fixed with glutaraldehyde-paraformaldehyde and processed for TEM. Sections were examined 




 Neutralization of virions with HSV glycoprotein D specific antibody prior to co-infection 
prevents induction of chlamydial persistence. 
HSV attachment studies have demonstrated that interaction of gD or gH with neutralizing 
antibodies (NuAbs) inhibits viral entry and replication. In contrast, anti-gC NuAbs have no effect 
on HSV entry or infectivity (Parry et al., 2005; Fuller et al., 1989; Fuller and Spear, 1987). 
Based upon this information, antibody neutralization of individual HSV glycoproteins during C. 
trachomatis/HSV co-infection was used to determine which glycoprotein(s) are required for 
altering chlamydial development during co-infection. A strain of HSV-1 expressing the β-
galactosidase gene (HSV-1/β-gal) was used in these experiments so that viral entry into the host 
cell could be examined.  For each replicate sample, α-gB, α-gC, or α-gD NuAb was added to 
HSV-1/β-gal before infection. An equal quantity of α-Sal or α-Human Papilloma Virus 18 (α-
HPV: OEM Concepts) was used as irrelevant Ab controls. HSV host cell entry is not affected by 
α-HPV (data not shown) or by α-Sal (Fuller and Spear, 1987). In duplicate experiments, spin 
concentrated α-gH hybridoma supernatant was used to neutralize gH. To control for effects 
caused by concentration of serum components in the α-gH hybridoma supernatant, concentrated 
medium+10% serum (cMEM) and medium+10% serum+α-HPV (cMEM/α-HPV) were used as 
negative controls. In these experiments, HeLa cell monolayers were co-infected with C. 
trachomatis and neutralized HSV-1/ β-gal. Replicate cultures were processed for β-gal assays 
(Fig. 5.3A), chlamydial titration (Fig. 5.3B) and plaque assay analyses (data not shown). As 
expected, β-galactosidase activity was present in the HSV-1/β-gal infected monolayers as well as 
in cells infected with cMEM, cMEM/α-HPV, α-Sal, α-gB, or α-gC neutralized HSV-1/β-gal (Fig. 
5.3A). Only α-gD and α-gH inhibited HSV-1/β-gal entry into the host cells, as evidenced by the 
lack of β-galactosidase activity (Fig. 5.3A). Chlamydial titer analyses indicate that co-infection 
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with non-neutralized HSV-1/β-gal or α-Sal cMEM, cMEM/α-HPV, α-gB α-gC, and α-gH Ab 
neutralized virus, significantly decreased infectious EB production compared to C. trachomatis 
singly-infected samples (Fig. 5.3B and C). Notably, chlamydial titer was not decreased when 
cells were co-infected with α-gD neutralized HSV-1/β-gal virus (Fig. 5.4B). Plaque assays 
indicated that viral replication and release was decreased by > 90% when HSV-1/β-gal was 
neutralized with α-gD or α-gH  NuAbs (data not shown). Anti-Sal, cMEM, cMEM/α-HPV, α-gB, 
or α-gC had no effect on virion replication and release (data not shown). These data indicate that 
HSV gD/host co-receptor interaction is required, and is likely sufficient, for induction of co-
































































































Figure 5.3: Co-infection of C. trachomatis with antibody neutralized HSV-1/β-gal. A. Cultures 
of Hela cells were either mock, singly or co-infected with C. trachomatis and HSV-1/ β-gal or 
HSV-1/ β-gal neutralized by α-Sal, α-gB, α-gC, α-gD or α-gH NuAbs, cMEM or cMEM/α-HPV, 
incubated for 6h and assayed for β-galactosidase activity.  Monolayers in 24 well tissue plates 
were photographed with an Epson Perfection 3200 Photo Scanner. Replicate cultures of Hela 
cells were either mock, singly, or co-infected with C. trachomatis and HSV-1/ β-gal or HSV-1/ 
β-gal neutralized by α-Sal, α-gB, α-gC, α-gD (Panel B) or α-gH NuAbs, cMEM or cMEM/α-
HPV (Panel C) and processed for chlamydial titration. EB titers are expressed as IFU/ml sample 
± SEM; n=3. Asterisks (*) indicate titers that are significantly different (by t-test) compared to 





HSV gD/host cell co-receptor interaction is sufficient to stimulate chlamydial persistence. 
 Because gD was implicated as the major virion component necessary for stimulating 
HSV-induced persistence, the effects of soluble, recombinant HSV-2 gD protein on chlamydial 
infectivity were examined. Plasmids expressing a soluble HSV-2 gD/rabbit IgG Fc (gD:Fc) 
fusion protein and the vector control (Blk:Fc) were obtained from Dr. Patricia Spear (Yoon et al., 
2003). The gD:Fc expression plasmid was constructed such that the transmembrane portion of 
gD was replaced with the Fc portion of rabbit IgG, which allows the fusion protein to be secreted 
from expressing cells and purified by protein A chromatography. The Blk:Fc control plasmid 
expresses only rabbit IgG Fc (Yoon et al., 2003). Culture supernatants from stable CHO cell 
lines containing each plasmid were collected and secreted gD:Fc fusion proteins were purified 
and quantified as described in the Experimental Procedures. Binding of purified gD:Fc to HeLa 
cells was confirmed by immunofluorescent staining with Texas Red conjugated α-Rabbit IgG Fc 
antibodies (Figure 5.4A).  
Many cell surface receptors must aggregate to initiate signal transduction. For example, 
Nectin molecules must dimerize before initiating associated cell signaling cascades (Ogita and 
Takai, 2006). If the same is true for the gD initiated signaling pathway responsible for 
persistence induction, then signaling (and chlamydial persistence induction) would require 
multimerization of the gD:Fc protein. Such ligand clustering can be achieved by adding anti-
rabbit IgG (Fig. 5.4B, right). Replicate C. trachomatis singly-infected samples were incubated 
with α-Rabbit IgG, gD:Fc, Blk:Fc, mixtures of α-Rabbit IgG + gD:Fc (αIgG/gD:Fc) or 
αIgG/Blk:Fc at 1:4 αIgG:fusion protein ratios for 1h. Samples were then refed with culture 
medium, harvested at 20h post-fusion protein exposure, and processed for chlamydial titration. 
As a positive control, HeLa cell monolayers were co-infected with C. trachomatis and HSV-2 
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(Fig. 5.4C; Ct/HSV). As expected, chlamydial infectivity was decreased by HSV-2 co-infection. 
No significant difference in EB production was observed when chlamydiae-infected samples 
were exposed to αIgG, gD:Fc, or Blk:Fc alone or to the αIgG/Blk:Fc negative control (Fig. 
5.4C). However, when chlamydiae-infected cells were exposed to αIgG/gD:Fc, EB production 
was significantly decreased compared to the C. trachomatis singly-infected control. Data from 
preliminary experiments indicated chlamydial infectivity was reduced in a dose dependent 
manner; lower αIgG to fusion protein ratios (1:4 and 1:8), which would be expected to produce 
maximal ligand cross-linking, have the greatest effect on chlamydial infectivity (data not shown). 
In duplicate experiments, C. trachomatis singly-infected samples were incubated with 
αIgG/gD:Fc or αIgG/gD:Fc that had been previously incubated with α-gD NuAbs (αIgG/gD:Fc + 
αgD). Chlamydial titer analyses demonstrated that neutralization with gD specific antibody 
prevented the decrease in EB production observed when chlamydiae-infected cells were exposed 
to αIgG/gD:Fc (Fig. 5.4D). Overall, these data indicate that: i) HSV-2 gD interaction with host 
cell surface receptors is sufficient to induce chlamydial persistence and ii) ligand (and likely 
receptor) clustering is required for the inhibitory effect (Fig. 5.4B).  
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 Figure 5.4: Interaction of HSV-2 gD:Fc fusion proteins with C. trachomatis infected cultures 
decreases chlamydial infectivity.  A. HeLa cell cultures were immunostained with 1xPBS 
(Mock), Blk:Fc or gD:Fc +/- Texas Red conjugated α-Rabbit IgG Fc antibodies. Cells were 
photographed at 320x magnification. B. Model for activation of signaling from HSV co-
receptors by antibody/ligand cross-linking and receptor clustering. Because many cell surface 
receptors must aggregate to initiate signal transduction, HSV gD may require multimerization to 
initiate chlamydial persistence. Clustering of gD:Fc can be achieved by adding α-IgG FcAb.  C. 
Replicate C. trachomatis singly-infected samples were incubated with α-IgG, gD:Fc, Blk:Fc or 
mixtures of α-IgG + gD:Fc (αIgG/gD:Fc) or αIgG/Blk:Fc at a 1:4 ratio and harvested for 
chlamydial EB titration. As a positive control, Hela cultures were co-infected with both C. 
trachomatis and HSV-2 (Ct/HSV). D. C. trachomatis singly-infected samples were incubated 
with αIgG/gD:Fc or αIgG/gD:Fc neutralized with α-gD NuAbs (αIgG/gD:Fc + αgD) and 
harvested for EB titer analysis at 20h post-fusion protein exposure. Asterisks (*) indicate titers 







The studies presented here further characterize HSV-2 co-infection-induced, C. 
trachomatis serovar E persistence. The results demonstrate that chlamydiae can recover 
infectivity after undergoing HSV-induced persistence. However, co-infection-induced 
persistence was not prolonged following HSV-2UV infection or co-incubation of chlamydiae-
infected responder cells with HI. These results most likely reflect the fact that chlamydial 
recovery was examined following a single stimulation event. In contrast, other models 
demonstrate that persistent chlamydiae were maintained for several days as long as the 
exogenous persistence inducer was regularly added to the culture medium (Byrne et al., 1989).   
Co-incubation of fixed, HSV-infected inducer cells with viable C. trachomatis-infected 
responder cells reduces production of infectious chlamydiae, suggesting that interaction between 
HSV-2 glycoproteins and their associated host cell receptors is sufficient to stimulate chlamydial 
persistence. Viral attachment to the host cell is a dynamic and active process that stimulates 
cellular signaling cascades. For example, TLR-2 is host cell surface exposed and appears to 
recognize the herpes virion protein, gB. This interaction stimulates TLR-linked anti-viral 
cascades in host cells (Aravalli et al., 2007; Kurt-Jones et al., 2005; Compton et al., 2003). 
Likewise, human cytomegalovirus gB provides sufficient stimulus to activate anti-viral 
responses through TLR-2 (Compton et al., 2003).  Infection with varicella zoster virus, HSV-1, 
and HSV-2 can all stimulate IL-6 production in culture; this induction is TLR-2 dependant and 
does not require productive viral replication (Aravalli et al., 2005; Kurt-Jones et al., 2005; Wang 
et al., 2005).  However, neutralization of gB, gC, or gH was not able to circumvent the decrease 
in infectious chlamydial progeny caused by HSV co-infection. In addition, recombinant gD:Fc 
fusion protein induces persistence. Finally, IFN-β is one of the first genes activated by HSV-
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induced TLR signaling (Schneider et al., 2004). Previously we demonstrated that IFN-β mRNA 
is not expressed in HSV-2/C. trachomatis co-infected cells (Vanover et al., 2008). Therefore, 
HSV gB/TLR receptor interaction is unlikely to be the mechanism behind co-infection-induced 
chlamydial persistence.     
 Antibody neutralization experiments indicated that the viral gD, but not gC, gB, or gH/L, 
was required for stimulation of co-infection-induced persistence. Addition of clustered, soluble 
gD:Fc fusion proteins to chlamydiae-infected cells also decreased infectivity. Taken together 
these data indicate that HSV-2 gD interaction with host cell surface receptors is sufficient to 
stimulate developing chlamydiae to enter persistence. The primary role of gD during viral 
attachment is to bind to at least one of several co-receptors, herpes viral entry mediator (HVEM), 
Nectin-1, Nectin-2, or 3-O-Sulfated Heparan Sulfate, present on the surface of the host cell 
(Spear, 2004).   
HVEM is a member of the tumor necrosis factor receptor family (Mauri et al., 1998). 
When complexed to its natural ligand, LIGHT, HVEM interacts with TNF-associated factors that 
trigger NF-κB signaling pathways. Activation of these cascades by HVEM has been shown to be 
involved in the activation of T-cells (Granger and Rickert, 2003; Hsu et al., 1997). HVEM is 
primarily expressed on T and B lymphocytes, epithelial cells, and fibroblasts and can be used by 
both HSV-1 and HSV-2 for entry into the host cell (Kwon et al., 2006; Spear, 2004; Hsu et al., 
1997; Marsters et al., 1997; Montgomery et al., 1996). Nectin-1 and Nectin-2 are members of the 
Immunoglobulin superfamily and are involved in the formation of cell junctional complexes 
(Cocchi et al., 1998). When stimulated, nectins activate cell signaling molecules Cdc42 and Rac 
small G proteins via c-Scr that leads to reorganization of the actin cytoskeleton and formation of 
cell-cell adherens junctions (Nakanishi and Takai, 2004; Shimizu and Takai, 2003). Activation 
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of Cdc42 via Nectin also leads to changes in gene expression by triggering the c-JunN-terminal 
kinase (JNK) pathway (Nakanishi and Takai, 2004). Nectin-activated pathways are involved in 
important cellular events such as apoptosis and cell growth regulation (Sakisaka and Takai, 
2004; Lin, 2003; Johnson and Lapadat, 2002). Both Nectin 1 and 2 are expressed on epithelial 
and neuronal cells (Spear, 2004). However, Nectin-2 is primarily a co-receptor for HSV-2, 
whereas, Nectin-1 is used with equal efficiency by both HSV-1 and HSV-2. Lastly, 3-O-sulfated 
heparan sulfate is expressed on numerous cell types, although it is only used as a co-receptor by 
HSV-1 (Shukla et al., 1999). 
Interestingly, gD/co-receptor interaction has been shown to trigger several signaling 
cascades associated with HVEM and Nectin-1/2. UV-inactivated HSV-1 and HSV-2 can 
stimulate cytokine production in human cells, specifically TNF-α production from IFN-γ primed 
macrophages and IL-15 production from monocytes (Ahmad et al., 2007; Paludan, 2001). Both 
HSV-1 gD and UV-inactivated virions can stimulate NF-κB activity at 1-3 hpi (Teresa Sciortino 
et al., 2007; Amici et al., 2006). Activation of Rac1 and Cdc42 has been shown early during 
HSV-1 infection of MDCK canine kidney cells (Hoppe et al., 2006). HSV attachment/entry also 
stimulates calcium-signaling pathways leading to intracellular calcium uptake (Cheshenko et al., 
2003). Given these observations, it is feasible that stimulation of viral co-receptors by attachment 
of HSV-2 could transmit a cellular signal that has downstream effects on developing chlamydiae.   
These observations lead to the following question. If gD/co-receptor interaction initiates a 
signal resulting in persistence, which co-receptor is involved? Several lines of evidence point to 
the involvement of Nectin-1 in co-infection-induced persistence. First, both HSV-1 and HSV-2 
induce chlamydial persistence. Because both HVEM and Nectin-1 serve equally well as co-
receptors for the two types of HSV, both of these receptors are candidates for initiating this 
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response. However, Montgomery et al. demonstrated that anti-HVEM serum only had marginal 
effects on the entry of HSV-1 into HeLa cells, suggesting that HVEM is probably not the 
principle receptor for HSV entry into HeLa cells (Montgomery et al., 1996).  Secondly, exposure 
to non-clustered, soluble gD:Fc fusion proteins had little effect on chlamydial infectivity. In 
contrast, IgG-preclustered gD:Fc significantly reduced chlamydial infectivity. Interestingly, 
aggregation of Nectin molecules by ligand clustering is also required for initiation of cell 
signaling cascades (Ogita and Takai, 2006). We hypothesize that preclustering of gD:Fc fusion 
proteins increases receptor multimerization and, thus, increases the efficiency of downstream cell 
signaling. Collectively, the observations that: i) both HSV-1 and HSV-2 induce persistence and 
use Nectin-1 and HVEM as co-receptors, ii) HVEM is not considered the primary HSV co-
receptor in HeLa cells, and iii) clustering of gD receptors is required for the gD:Fc fusion protein 
stimulated effects on chlamydial infectivity argues that HSV gD interaction with Nectin-1 is the 
most likely candidate for stimulation of co-infection-induced persistence.  
However, caution must be exerted when eliminating potential mechanisms for co-
infection-induced C. trachomatis persistence. HVEM encoding cDNA was originally isolated 
from a HeLa cell library (Montgomery et al., 1996). Although HVEM may not be the major co-
receptor present on HeLa cells, it is possible that interaction between gD and the small amount of 
HVEM present provides adequate signal transduction to halt chlamydial development. Though 
Nectin-2 does not efficiently mediate HSV-1 entry, the low affinity of HSV-1 gD for Nectin -2 
could be sufficient to stimulate anti-chlamydial signaling pathways. HSV-2 can also enter 
Chinese hamster ovary (CHO) cells by an unknown receptor (Spear, 2004). Thus, there is a 
chance that gD interaction with an unknown HSV co-receptor could trigger chlamydial 
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persistence. Finally, gD interaction with multiple co-receptors could activate several host 
pathways that work together to negatively affect developing chlamydiae. 
Investigations of the underlying mechanisms that drive developing chlamydiae to enter 
persistence have provided valuable information about the biology and pathogenesis of this 
fascinating organism (Nelson et al., 2005; Fehlner-Gardiner et al., 2002). HVEM, Nectin-1, and 
Nectin-2 all have endogenous, natural ligands (Nakanishi and Takai, 2004; Granger and Rickert, 
2003; Shimizu and Takai, 2003; Hsu et al., 1997). This observation raises the question of 
whether natural stimulation of these receptors could also negatively affect chlamydial 
development. If so, this novel host pathway could be involved in limiting the spread of 
chlamydiae in host epithelial cells, much like the well characterized IFN-γ-induced anti-
chlamydial response. Thus, investigations of the pathways that are activated by HSV co-
receptors and how these cascades interact with developing chlamydiae have the potential to 






Chlamydia, HSV, and host cells.  
A human urogenital isolate of C. trachomatis E/UW-5/CX was originally obtained from 
S.P. Wang and C. C Kuo (University of Washington, Seattle, WA).  The same standardized 
inoculum of C. trachomatis serovar E, propagated in McCoy cells, was used for all experiments 
(Wyrick et al., 1996). Herpes simplex virus type 2 strain 333 and HSV-1/β-gal (originally 
denoted as HSV-1 strain tk-12; Montgomery et al., 1996) stocks were obtained from Mary K. 
Howett (Drexel Unversity) and Patricia Spear (Northwestern University) respectively. Viral 
stocks were prepared in monolayers of Vero cells (African green monkey kidney cells 
ATCC#CCL-81) as described (Duff & Rapp, 1971). Chinese Hampster Ovary-K1 cells (CHO-
K1 ATCC#CCL-61) were obtained from Russell Hayman (James H. Quillen College of 
Medicine). 
 
Co-infection experimental design. 
Co-infections were performed as previously described with the following exceptions 
(Deka et al., 2006). HeLa cells, a human cervical adenocarcinoma epithelial cell line (ATCC 
#CCL2), were used for all infection experiments. In most experiments, host cells were divided 
into four groups for mock-infection, chlamydial-infection, HSV-infection, and C. 
trachomatis/HSV-co-infection. First, HeLa cell monolayers were incubated with a dilution of 
crude EB stock calculated to infect >80% of the cells. Following an hour of adsorption, 
monolayers were refed with Minimal Essential Medium (MEM; Gibco) and incubated at 35 °C 
for 24h. Cultures were then infected with HSV-2, HSV-2UV, HSV-1/β-gal, or neutralized HSV-
1/β-gal at a multiplicity of infection (MOI) of 10 PFU/cell. In certain studies, HSV infection was 
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replaced with exposure to various recombinant fusion proteins for 1h at 35oC. Mock-infected 
HeLa cells were treated similarly except they were exposed to either 2SPG (0.2 M sucrose, 6mM 
NaH2PO4, 15mM Na2HPO4, 5mM L-glutamine, pH 7.2; mock C. trachomatis infection) or 
growth medium (mock viral infection). Monolayers were refed with MEM following HSV 
adsorption. For long-term studies, cultures were refed with culture medium containing 1µg/ml 
cyclohexamide. 
 
Generation of replication incompetent HSV-2 (HSV-2UV).   
A  UV Crosslinker (Spectroline Microprocessor Controlled UV-Crosslinker Spectrolinker 
XL1500, Spectronics Corporation, New York) was used to generate stocks of UV-inactivated, 
replication incompetent HSV-2 as previously described (Deka et al., 2007).  Plaque assays 
analyses confirmed HSV-2 inactivation (data not shown) and were performed as described 
previously (Deka et al., 2007). 
 
Co-incubation experiments. 
Co-incubation experiments were performed as described previously with modifications 
(Savage et al., 1991). HeLa cell monolayers were either mock or HSV-2-infected, incubated at  
37oC for 20h, and fixed for 15min at 37oC in a 1% paraformaldehyde, 2% FBS, 1x PBS solution. 
Monolayers were washed extensively and “refed” with MEM so that the fixative could leach out 
of the cells overnight. The inducer cells were then washed, scraped into 5ml culture medium, and 
counted with a hemocytometer. The fixed mock (MI) or HSV-infected (HI) inducer cells were 
overlayed onto viable mock or chlamydiae-infected responder cell cultures at a ratio of 5 fixed 
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inducer cells/1 viable responder cell. The cells were co-incubated at 35°C in normal growth 
medium for 20, 44, 68, or 120h before being harvested.  
 
Antibody neutralization of HSV glycoproteins. 
Neutralizing antibodies to HSV gD (III-174), gB (II 105-1.6), and gC (II529-1) were all 
kind gifts from Patricia Spear (Northwestern University; Fuller and Spear, 1987).  For each 
sample 4µl of culture medium, α-Sal (Millipore, MAB746), α-gB, α-gC, or α-gD NuAb was 
added to 100ul of HSV-1/β-gal (10MOI). All inocula were incubated for 1h at 37oC prior to 
infection of mock- or chlamydiae-infected HeLa monolayers (Fuller and Spear, 1987). Plaque 
assay analyses demonstrate that 4 µl of α-gD NuAb sufficiently eliminated productive HSV 
replication (data not shown). The α-gH (LP11) mouse hybridoma supernatant was a kind gift 
from Helena Browne (University of Cambridge; Parry et al., 2005). Amicon Ultra Centrifugal 
Filter Devices were used to concentrate 10ml of α-gH hybridoma supernatant, MEM+10%FBS, 
and MEM+10%FBS + 40µl α-HPV Ab (OEM Concepts, M2-V56) to 1ml. Maximal 
neutralization of 10MOI HSV-1/ β-gal required 25 µl of concentrated α-gH NuAbs (data not 
shown). In control samples, 25 µl of cMEM or cMEM/α-HPV was added to the viral inocula.  
 
Preparation of HSV-2 gD:Fc fusion proteins. 
Plasmids expressing a soluble HSV-2 gD/rabbit IgG Fc (gD:Fc) fusion protein and the 
vector control (Blk:Fc) were obtained from Patricia Spear (Yoon et al., 2003).  The plasmids 
were propagated in XL1 Blue competent Escherichia coli under Ampicillin (50 µg/ml) selection. 
Plasmid DNA was harvested using the PureLink HiPure Plasmid DNA Purification Kit 
(Invitrogen) and the identity of each plasmid was confirmed by restriction enzyme disgest (data 
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not shown). The plasmids were transfected into CHO-K1 cells using Lipofectamine 2000 
Reagent (Invitrogen) according to the manufacture’s recommendations. Stable, plasmid 
containing cell populations were isolated under geneticin selection (250 µg/ml G418).  After 
drug selection, culture supernatants were collected and secreted gD:Fc fusion proteins were 
purified using PROSEPA Montage Affinity Purification Spin Columns (Millipore) and 
concentrated with Amicon Ultra-15 centrifugal filters according to the manufacture’s 
instructions.  
 
Quantification and preclustering of HSV-2 gD:Fc fusion proteins. 
Purified HSV-2 gD:Fc as well as Blk:Fc fusion proteins were separated on on Nu-PAGE 
4-12% Bis-Tris gels (Invitrogen) and visualized with Sypro Ruby stain (Pierce). The amount of 
each fusion protein was estimated by comparison to a known quantity of protein standards 
(Broad Range Standards, Pierce). Gels were visualized using a BioRad Chemi Doc XRS Image 
Capture System.  Proteins were quantified on the image analysis system using Quantity One 
V4.5.0 software (BioRad). Ten microliters of each fusion protein was mixed with Mouse-anti-
Rabbit IgG (Jackson Immuno) at various antibody:fusion protein molar ratios and incubated for 
1h at RT. Preclustering of gD:Fc fusion proteins with α-IgG was based upon the protocol 
published by Ogita and Takai (2006). 
 
Chlamydial titrations by subpassage.  
Chlamydial titrations were performed as previously described (Deka et al., 2006) using 
Pathfinder anti-chlamydial stain (BioRad) to stain chlamydial inclusions formed from 
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subpassaged EBs. The number of inclusion forming units (IFU) in the undiluted inoculum was 
then derived from triplicate counts and expressed as IFU/ml. 
 
DNA isolation and PCR.  
Total DNA  was isolated from cells as described previously (Deka et al., 2006). Total 
DNA preparations were quantified using optical density (OD) at 260 and 280 nm; all samples 
had OD260/280 ratios > 1.9.  Following DNA isolation, the human GAPDH, chlamydial 
16SrRNA, and HSV-2 glycoprotein G2 genes were amplified by PCR as previously described 
(Deka et al., 2006).  After PCR, all reactions were electrophoresed on 1.5% agarose/TBE gels.  
Gels were stained with EtBr and visualized using a BioRad Chemi Doc XRS Image Capture 
System.  Amplimers were quantified on the image analysis system using Quantity One V4.5.0 
software (BioRad).  
 
β-galactosidase assay.  
Β-galactosidase activity was assayed essentially as described (Montgomery et al., 1996). 
Briefly, HeLa cells were infected with HSV-1/β-gal or antibody neutralized HSV-1/β-gal for 6h, 
washed with 1x PBS, fixed with a 2% formaldehyde/0.2% glutaraldehyde PBS solution for 
10min at RT. Following fixation the cells were washed and permeablized in a 2mM 
MgCl2/0.01% deoxycholate/ 0.02% NP40 solution for 10min at RT. The cells were stained with 
0.5 mg/ml X-Gal in PBS for 1hr at 37oC. Images were captured using an Epson Perfection 3200 





Fluorescent microscopy, tranmission electron microscopy and image analysis.   
Fluorescence analyses were performed as described previously (Deka et al., 2007). HSV 
gD:Fc fusion proteins bound to HeLa cells were stained using a 1:200 dilution of Texas red-
conjugated donkey-anti-rabbit IgG (Jackson Immuno). The same fixation conditions used to 
prepare inducer cells in co-incubation experiments were used to visualize HSV glycoproteins on 
the surface of HeLa cells. Because the cells were not permeablized, only the surface 
glycoproteins are detected in this assay. Following fixation, cells were washed 3x with 1xPBS, 
blocked with 15%FBS in PBS for 45min at RT, and stained for 1h with 1:50 dilution of mouse-
α-gB, α-gC, α-gD, or α-gH mAbs followed by staining for 1h with 1:1000 dilution of Alexa fluor 
donkey-anti-mouse IgG (Invitrogen). Images were captured using a Zeiss Axiovert S100 
microscope and Axiocam camera.  Duplicate samples of chlamydiae-infected cultures co-
incubated with MI or HI were processed at 20 h post-co-incubation for high contrast 
transmission electron microscopy as described (Wyrick, 1994).  Counterstained gold thin 
sections were examined using a Tecnai 10 (FEI) transmission electron microscope operating at 
60-80 kV. 
 
Statistical analyses.  
Statistical analyses were performed using Microsoft Excel. Comparison of means was 
done by using a 2-sample t-test for independent samples.  P values of ≤ 0.05 were considered 
significant.  All plotted values are averages of either eight or nine biological replicates divided 
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Investigations of the underlying mechanisms that drive developing chlamydiae to enter 
persistence have provided valuable information about the biology and pathogenesis of this 
fascinating organism. Notably, studies have revealed that the mechanism of IFN-γ mediated 
immune control of chlamydial infection is different in mice and humans. In murine cells, IFN-γ 
exposure inhibits chlamydial development by restricting vesicular trafficking to developing 
inclusions whereas in human cells IFN-γ-exposure indirectly deprives chlamydiae of trypophan 
(Nelson, 2005; Beatty, 1994d).  Related studies involving IFN-γ-induced persistence have also 
revealed the genetic basis of differences in cell tropism between the ocular and genital serovars 
of C. trachomatis. Genital serovars contain a functional tryptophan synthase gene that allows 
them to use exogenous indole (presumably acquired from the local bacterial flora of the genital 
tract) to recover from IFN-γ stimulated degradation of host tryptophan. Ocular serovars do not 
recover from IFN-γ persistence using indole (Fehlner-Gardiner et al., 2002).  
Characterization of a tissue-culture model of HSV and C. trachomatis co-infection 
indicates that co-infection stimulates chlamydiae to become persistent. This conclusion is 
evidenced by numerous observations during C. trachomatis/HSV co-infection: i) a decrease in 
the production of infectious EBs, ii) abnormal RB morphology, iii) increased accumulation of 
chlamydial Hsp60, iv) decreased accumulation of MOMP, v) continued accumulation of 
chlamydial chromosomes, and vi) constant expression of chlamydial 16S rRNA primary 
transcripts, indicating that chlamydiae remain viable although they are less infectious (Deka et 
al., 2006). Co-infection-induced persistence is neither cell type specific nor viral strain specific 
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because it occurs in both HeLa and HEC-1B cell lines and is stimulated by both HSV-1 and 
HSV-2 (Deka et al., 2007). Co-infection-induced persistence is also not limited to C. 
trachomatis. Unpublished data from our laboratory demonstrate that C. muridarum also enters 
persistence following HSV-2 co-infection (data not shown). Additionally, co-infection with 
either UV-inactivated, replication-incompetent virus or with replication-competent HSV-2 in the 
presence of cyclohexamide triggers chlamydial persistence, indicating that productive viral 
replication is not required for this phenomenon (Deka et al., 2007). Finally, investigation of 
chlamydial titer following long-term exposure to HSV-2UV indicates that chlamydiae recover 
infectivity from HSV-induced persistence in a manner similar to other tissue culture persistence 
models.  
Because there are several characterized models of chlamydial persistence, we wanted to 
determine whether any of these mechanisms were activated by co-infection-induced persistence. 
Cytokines known to be involved in persistence induction were either not detected (IFN-γ, IFN-α, 
and TNF-α) or were detected in similar amounts (IL-1α, IL-1β, IL-8) in supernatants from C. 
trachomatis singly-infected and co-infected cultures. Additional data demonstrate that IFN-γ, 
IFN-β, IDO, LT- α, and iNOS mRNAs are not expressed during co-infection. Furthermore, 
previous studies have demonstrated that chlamydiae do not respond to IFN-γ exposure in HEC-
1B cells (Wyrick and Knight, 2004; Kane and Byrne, 1998).  However, developing chlamydiae 
exhibit characteristics of persistence within co-infected HEC-1B cells. Collectively these data 
eliminate cytokine activity as the inducer of persistence during co-infection. Moreover, 
supplementation of co-infected cells with excess amino acids, iron, glucose, or a combination of 
amino acids and iron does not restore chlamydial infectivity during co-infection, supporting the 
conclusion that virally-induced persistence is not mediated by the activities of cytokines. These 
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data also indicate that a global depletion of nutrients is not responsible for co-infection-induced 
persistence. Lastly, inclusions within co-infected cells continue to enlarge and incorporate C6-
NBD-ceramide, indicating that HSV-2 co-infection does not inhibit vesicular transport to the 
developing inclusion. The degree of reduction in chlamydial infectivity stimulated by HSV-2 co-
infection is lower than that observed in other models of persistence (Pantoja et al., 2001; Beatty 
et al., 1994d), suggesting that a unique mechanism could be involved. To observe the negative 
effects of cytokine exposure on chlamydial development, IFN-γ must be added to chlamydiae-
infected cultures either before or very early during infection (Nelson et al., 2005). On the 
contrary, harmful effects on chlamydial development are observed with HSV-2 co-infection 
when the stimulus is added at 24h post-C. trachomatis infection (Deka et al., 2007). Overall, 
these observations demonstrate that HSV-2 co-infection-induced chlamydial persistence is not 
mediated by any known persistence inducer or anti-chlamydial pathway (Vanover et al., 2008).  
As mentioned above, productive viral replication is not required for co-infection-induced 
persistence, indicating that events during HSV-2 attachment and/or entry are sufficient for this 
effect (Deka, 2007). Co-incubation of fixed, HSV-infected inducer cells with viable C. 
trachomatis-infected responder cells suggests that the events of HSV attachment, specifically 
interaction between HSV-2 virion glycoproteins and their cognate host cell receptors, is 
sufficient to stimulate chlamydial persistence. The initial stages of viral invasion are dynamic 
and active; thus, there are several possible avenues for stimulating persistence during virion 
attachment to the host cell. HSV attachment to the host cell involves co-receptors that naturally 
function as cell signaling molecules (Nakanishi and Takai, 2004; Granger and Rickert, 2003; 
Cocchi et al., 1998; Hsu et al., 1997).  It is feasible that HSV attachment to co-receptors during 
co-infection could activate persistence by stimulating cell signaling pathways that have anti-
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chlamydial effects. HSV also triggers anti-viral pathways via Toll-like receptors, thus, raising the 
possibility that stimulation of  anti-viral cellular functions during co-infection could have a 
negative effect on chlamydial development (Aravalli, 2005; Kurt-Jones, 2005; Wang et al., 2005; 
Compton T., 2003; Pyles, 2002).  
Several studies indicate that HSV gB is the major glycoprotein responsible for 
stimulation of TLR-linked anti-viral cascades in host cells (Aravalli et al., 2007; Kurt-Jones et 
al., 2005; Compton et al., 2003). Notably, in our studies, neutralization of gB was not able to 
restore chlamydial infectivity during co-infection. Antibody neutralization of individual HSV 
glycoproteins indicates that only gD interaction with co-receptors on the surface of host cells is 
required for stimulation of chlamydial persistence. Addition of clustered, soluble gD:Fc fusion 
proteins to chlamydiae-infected cells decreased production of in infectious EB progeny, thus 
confirming the conclusion that HSV-2 gD interaction with host cell surface receptors can 
stimulate developing chlamydiae to enter persistence. Therefore, HSV interaction with TLR 
receptors is not likely the mechanism behind co-infection-induced chlamydial persistence. 
The HSV envelope glycoprotein gD binds to one of several co-receptors that mediate 
entry of the virus into the host cell (Spear, 2004). These co-receptors include herpes viral entry 
mediator (HVEM), Nectin-1, Nectin-2, and 3-O-Sulfated Heparan Sulfate (Spear, 2004). HVEM 
is a member of the tumor necrosis factor receptor family (Mauri et al., 1998). When complexed 
to its natural ligand, LIGHT, HVEM interacts with TNF-associated factors that trigger NF-κB 
signaling pathways. Activation of these cascades by HVEM has been shown to be involved in 
the activation of T-cells (Granger and Rickert, 2003; Hsu et al., 1997). Nectin-1 and Nectin-2 are 
members of the Immunoglobulin superfamily and are involved in the formation of cell junctional 
complexes (Cocchi et al., 1998). When stimulated, nectins activate cell signaling molecules, 
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Cdc42 and Rac small G proteins, via c-Src that leads to reorganization of the actin cytoskeleton 
and formation of cell-cell adherens junctions. Epithelial cell polarity is based upon the 
maintenance of tight cell-cell junctions. Nectin stimulated, Cdc42 signaling activates 
downstream effectors that aid in the formation of tight junctions (Nakanishi and Takai, 2004; 
Shimizu and Takai, 2003). Activation of Cdc42 via nectin also leads to changes in gene 
expression by triggering the c-JunN-terminal kinase (JNK) pathway (Nakanishi and Takai, 
2004). This pathway is involved in important cellular events such as apoptosis and cell growth 
(Sakisaka and Takai, 2004; Lin, 2003; Johnson and Lapadat, 2002).  
Interaction of HSV-1 and HSV-2 virions or glycoproteins with host cells also triggers 
some of the same cell signaling cascades that are associated with HVEM and Nectin 1/2. UV-
inactivated HSV-1 and HSV-2 can stimulate cytokine production in human cells, specifically 
TNF-α production from IFN-γ primed macrophages and IL-15 production from monocytes 
(Ahmad et al., 2007; Paludan, 2001). Both HSV-1 gD and UV-inactivated virions can stimulate 
NF-κB activity from 1-3hpi (Teresa Sciortino et al., 2007; Amici et al., 2006). Activation of 
Rac1 and Cdc42 has been shown at 15 to 30 minutes following HSV-1 infection of MDCK 
canine kidney cells (Hoppe et al., 2006). HSV attachment/entry also stimulates calcium-signally 
pathways leading to intracellular calcium uptake (Cheshenko et al., 2003). Conversely, HSV 
infection causes downregulation of the JAK/STAT signaling pathway by causing host cells to 
express SOCS3, suppressor of cytokine signaling 3 (Yokota et al., 2005). 
Given these observations, it is feasible that stimulation of viral co-receptors by 
attachment of HSV-2 could transmit a cellular signal that has downstream effects on developing 
chlamydiae.  While our studies demonstrate that the viral ligand involved in co-infection-induced 
persistence is gD, we are left with the question of which co-receptor is involved? As explained 
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below, preliminary data from our laboratory, as well as observations from other investigators, 
suggest that Nectin-1 has the most potential for triggering co-infection-induced persistence.  
Because HSV-1 and HSV-2 are capable of inducing chlamydial persistence and both 
HVEM and Nectin-1 serve equally as co-receptors for the two types of HSV, these receptors are 
both strong candidates for triggering co-infection-induced persistence. Although HVEM cDNA 
was originally isolated from a HeLa cell library (Montgomery et al., 1996) studies have shown 
that HVEM is probably not the principle receptor for HSV entry into HeLa cells. Montgomery 
et. al. (1996) demonstrated that anti-HVEM serum only had marginal effects on the entry of 
HSV-1 into HeLa cells. Additionally, both RT-PCR and western blot analyses demonstrate that 
HVEM is not expressed in our HeLa and HEC-1B cell line clones (data not shown).  
Additional studies in our laboratory demonstrate that Nectin-1 is degraded in C. 
trachomatis infected HeLa cells at 36hpi (Sun et al., 2008). In our experimental model of co-
infection-induced persistence, HSV infection/soluble gD exposure is performed at 24h after C. 
trachomatis infection before Nectin-1 degradation occurs. Western blot analysis of HeLa cells 
demonstrate that C. muridarum also degrades Nectin-1 and that significant degradation is 
observed by 24hpi (Sun et al., 2008). Co-infection of C. muridarum infected HeLa cells with 
HSV-2 causes a decrease in chlamydial infectivity as well. However, HSV infection of C. 
muridarum infected cells must be performed by 12h post-chlamydia infection for maximal 
effects on chlamydial infectivity to be observed. No significant decrease in EB production was 
seen when HSV was added to C. muridarum infected cells at 24hpi (data not shown). These data 




Additionally, non-clustered, soluble gD:Fc fusion proteins had little to no effect on 
chlamydial infectivity. Exposure to gD:Fc fusion proteins decreased chlamydial infectivity only 
when the viral ligands were preclustered with anti-rabbit IgG. Many cell surface receptors must 
aggregate to initiate signal transduction; in fact, nectin molecules must dimerize before initiating 
cell signaling cascades (Ogita and Takai, 2006). We theorize that preclustering of gD:Fc fusion 
proteins increases receptor aggregation and thus, increases the efficiency of downstream cell 
signaling. Collectively, the observations that: i) both HSV-1 and HSV-2 induce persistence and 
use Nectin-1 and HVEM as co-receptors; ii) HVEM is not detected in our cell lines; iii) co-
infection-induced persistence is not stimulated following Nectin-1 degradation in C. muridarum-
infected cells;  and iv) clustering of gD receptors is required for the gD:Fc fusion protein 
stimulated effects on chlamydial infectivity, suggest that HSV gD interaction with Nectin-1 is 
the most likely candidate for stimulation of co-infection-induced persistence.  
However, without further experimental examination, we must be cautious in eliminating 
possible mechanisms for co-infection-induced persistence. Although our analyses indicate that 
HVEM is not present in our system, it is possible that only very small amounts of the protein, 
which are below our detection level, are required for stimulation of persistence. Nectin-2, along 
with Nectin-1, is expressed in our HeLa and HEC-1B cell lines (data not shown). Although 
Nectin-2 does not mediate HSV-1 entry, it is possible that HSV-1 gD has sufficient affinity for 
Nectin -2 to stimulate anti-chlamydial signaling pathways. HSV can also enter Chinese hamster 
ovary cells by an unknown low-affinity receptor (Spear, 2004). Thus, there is a chance that gD 
interaction with an unidentified HSV co-receptor is responsible for triggering chlamydial 
persistence. Finally, we cannot ignore the possibility that gD interaction with multiple co-
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receptors could activate several host pathways that work together to negatively affect developing 
chlamydiae.  
Induction of chlamydial persistence by HSV-2 co-infection has significant implications 
for pathogenesis. Release of chlamydial LPS from persistently-infected cells has been associated 
with membrane blebs similar to those observed in inclusions from C. trachomatis/HSV co-
infected cultures (Wyrick et al., 1999; Wyrick et al., 1994; Karimi et al., 1989). Although 
chlamydial LPS is less potent than that of other Gram-negative bacteria, it still has the capacity 
to enhance the host inflammatory response (Ingalls et al., 1995). We have also demonstrated that 
Hsp60 is increased in co-infected cells. Chlamydial Hsp60 shares 48% identity with human 
Hsp60 and thus, increased accumulation of chlamydial Hsp60 during prolonged persistent 
infection has the potential to induce auto-immunity to human Hsp60 (Yi et al., 1997; Viale et al., 
1994). We would predict that co-infection would increase inflammation and tissue damage by 
causing an increase in chlamydial LPS release or Hsp60-induced autoimmunity (Figure 6.1A). 
Because complications of chlamydial infection are thought to be due, at least in part, to release of 
inflammatory mediators from infected cells, any stimulus that increases release of these 
compounds might enhance disease pathology. The probability of this scenario is further 
enhanced by studies that suggest that virions are shed continuously even in the absence of 
lesions, making it is possible that viral-induced persistence could be stimulated in vivo when 
symptomatic viral reactivation is not obvious (Mertz et al., 1992). Furthermore, it is estimated 
that 50-200 defective virions are released for every replication competent virion produced 
(Roizman, 2001). Because only gD interaction with the host cell is required for persistence 
induction, attachment of defective virions to C. trachomatis infected cells could stimulate 
persistence. Because persistent chlamydiae have been shown to be able to withstand 
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bacteriacidal concentrations of antibiotics, they could potentially exist within the co-infected host 
for prolonged periods of time perpetuating even more tissue damage and severe disease 
manifestations (Wyrick and Knight, 2004).  
 
Figure 6.1: Possible roles for gD co-receptor signaling in the development of persistent 





Given that HSV co-receptors have natural ligands, it is tempting to speculate that 
interaction between these molecules and their endogenous ligands could also trigger anti-
chlamydial pathways causing persistence in the absence of co-infection. In fact, one HVEM 
ligand, LT-α, has been demonstrated to restrict C. pneumoniae development (Matsushima et al., 
1999). Another intriguing possibility is that chlamydiae could use nectin-induced signaling to 
synchronize their development with the differentiation of the host cell, much like Human 
Papilloma Virus (HPV). During HPV infection, viral genomic replication occurs in 
undifferentiated basal epithelial cells; however, infectious virions are not produced from these 
immature cells. As the infected cells divide, the viral DNA is distributed to both daughter cells. 
One daughter cell will remain undifferentiated, serving as a reservoir for new epithelial cells and 
for viral genomic material. The other daughter cell will differentiate and move to the surface of 
the epithelium where infectious virions will be produced and released from the maturing cell 
(Longworth and Laimins, 2004). In this manner, HPV establishes both a productive, 
disseminating infection in the mature epithelial cells, as well as a reservoir of infection in the 
undifferentiated basal cells. C. suis has been shown to persistently infect immature, glandular 
epithelial cells while establishing a normal development cycle in differentiated lumenal epithelial 
cells (Guseva et al., 2003). Because nectin-induced signaling is essential for the formation of 
new adherence junctions and polarity of epithelial cells (Nakanishi and Takai, 2004; Shimizu and 
Takai, 2003), it is feasible the nectin signaling events could be important in the replenishment of 
mature lumenal epithelial cells from the glands of the genital tract. Therefore, nectin-activated 
signal transduction might play a role in regulating chlamydial development in glandular versus 
lumenal epithelial cells and allow for both productive and chronic chlamydial infections to be 
established (Figure 6.1B).  
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In the absence of a genetic system, studies of chlamydial persistence have provided 
valuable information regarding chlamydial biology and chlamydiae/host cell interactions. Data 
from the investigation of HSV/C. trachomatis co-infection have potentially uncovered yet 
another host-derived anti-chlamydial pathway. Examination of the cellular pathways that are 
activated by HSV co-receptor stimulation during co-infection has the potential to reveal new and 
fascinating aspects of the relationship that C. trachomatis builds with the host cell and the 
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